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Allogeneic stem cell transplantation
Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for various 
malignant and non-malignant hematological diseases1. The goal of alloSCT is to replace 
the recipient hematopoietic cells with hematopoietic cells derived from stem cells from a 
human-leukocyte-antigen (HLA) matched donor. Immune suppressive conditioning of the 
recipient prior to the alloSCT is necessary to allow engraftment of the donor stem cells. 
This conditioning leads to a period of profound pancytopenia prior to engraftment of donor 
hematopoietic cells. The duration of this pre-engraftment period is correlated with the 
occurrence of infectious complications2. Conventional myeloablative conditioning (MAC) 
regimens aim to fully eradicate the hematopoietic cells of the recipient. Reduced intensity 
conditioning (RIC) regimens aim to allow engraftment of donor hematopoietic cells without 
full elimination of recipient derived hematopoietic stem cells. RIC regimens are less toxic, but 
additional immune suppression is necessary to allow engraftment of donor hematopoietic 
cells leading to additional immune deficiency3, 4. The mere ablation of recipient hematopoietic 
cells by chemotherapy and/or irradiation in the conditioning regimen is not sufficient to 
prevent disease relapse after transplantation, as demonstrated by the high risk of disease 
relapse after autologous stem cell transplantation in acute leukemia. Long-term control of 
the disease can be achieved by donor derived alloreactive T cells. These alloreactive T cells 
can eradicate residual malignant cells by inducing a graft versus leukemia (GVL) response 
when the immune response is directed against the hematopoietic cells of the patient5, 6. 
However, when alloreactive T cells also target non-hematopoietic cells in the tissues and 
organs of the patient, potentially fatal graft versus host disease (GVHD) can occur. GVL is 
part of a spectrum of GVHD, as illustrated by the increased risk of disease relapse in the 
absence of GVHD in alloSCT using stem cells from an HLA identical syngeneic twin7. 
Prevention of GVHD
GVHD can be prevented or reduced by long-term immune suppression or by depleting 
donor T cells from the graft (T cell depletion, TCD)8-10. In non-TCD alloSCT, recipients are 
treated with long-term immune suppression, which may be tapered in the months or years 
after alloSCT. Immune suppression is not selective and suppresses not only alloreactive 
immune responses causing GVHD, but also potentially beneficial immune responses causing 
GVL or immune responses needed for protection against infectious diseases. In TCD alloSCT 
strategies, donor T cells are depleted from the stem cell graft or depleted in-vivo by infusion 
of T cell specific antibodies (e.g. ATG, alemtuzumab). Various methods are used to deplete 
T cells from the graft such as CD34+ selection or the use of lymphocyte-depleting antibodies 
such as alemtuzumab (anti CD52)11, 12. TCD strategies are effective in preventing GVHD and 
long-term post-transplant immune suppression is generally not required. The absence of 
immune suppression makes TCD alloSCT suitable as a platform for cellular therapy such as 
donor lymphocyte infusion (DLI) or adoptive cell transfer (ACT) of selected or manipulated 
T cell populations. Postponed application of DLI  several months after TCD alloSCT to induce 
10 CHAPTER 1
a GVL effect is associated with an acceptable risk of GVHD13-15. In ACT strategies, in-vitro 
selected T cell populations are adoptively transferred to restore (anti-viral) immunity. By 
selecting specific T cells with a defined antigen specificity (e.g. targeting viral epitopes), the 
risk for inducing GVHD is lower compared to unmodified DLI containing T cells of unknown 
specificity16, 17. 
Inherently to the effect of TCD on the prevention of GVHD, a period of profound and 
prolonged T cell deficiency follows TCD. During this period patients are at risk for developing 
infectious complications, especially for reactivations of endogenous herpes viruses. 
Herpes virus reactivations after alloSCT
Infections with herpes viruses are common in the general population. These infections 
usually occur during childhood and the clinical symptoms are often mild or even absent. The 
infection is controlled by virus-specific memory T cells, which develop following a primary 
immune response. Although virus-specific T cells control these viruses, herpes viruses are 
not completely cleared and lead to latent infections in their hosts. This latency results in an 
equilibrium between these viruses and the virus-specific T cells. The most common herpes 
viruses complicating alloSCT are cytomegalovirus (CMV), Epstein-Barr virus (EBV) and varicella 
zoster virus (VZV)18-20. These viruses share the ability for lifelong persistence and reactivation 
when T cell immunity fades. T cell immunity is provided by CD4+ and CD8+ T cells, where 
CD4+ T cells regulate immune responses and CD8+ T cells eliminate the pathogens. CD4+ T 
cells recognize peptides presented in HLA class II molecules, that are primarily expressed by 
antigen presenting cells (APCs), whereas CD8+ T cells recognize peptides presented in HLA 
class I molecules that are ubiquitous expressed on all human tissues. Professional APCs are 
required for the induction of a primary T cell response leading to a rapid increase of effector 
T cells and the formation of memory T cells that can react directly upon re-encounter 
with the pathogen. In CMV and EBV infections, repeated stimulation of memory T cells by 
reactivation of the virus can result in frequencies of up to 40% of these virus-specific T cells 
within the T cell compartment in peripheral blood in immune competent individual21, 22. 
VZV resides in an immune privileged site and does not reactivate as often as CMV and EBV. 
VZV-specific memory T cells are therefore not stimulated repeatedly leading to decreasing 
frequencies of circulating VZV-specific memory T cells in time23.  
In the period of profound and prolonged T cell deficiency after (TCD) alloSCT the equilibrium 
between the T cells and the virus is lost and control of reactivation of CMV and EBV 
infection is impaired. The impaired control may lead to potentially fatal CMV disease in 
case of CMV reactivation or Post Transplantation Lymphoproliferative Disease (PTLD) after 
EBV reactivation, caused by uncontrolled proliferation of EBV infected B cells. The decline 
in VZV-specific memory T cells is accelerated by the conditioning and/or TCD leading to an 
increased risk for reactivation of VZV leading to herpes zoster. Uncontrolled herpes zoster 





Cytomegalovirus, a double stranded DNA virus, can infect a broad range of cell types upon 
primary infection. Primary infection is followed by a lifelong persistence with monocytes 
and vascular endothelial cells as important sites for latency24. The clinical course of CMV 
infection in immune competent individuals is generally asymptomatic or mild and self-
limiting with the exemption of congenital neurological disease by maternal transfer of 
the virus in primary CMV infection during pregnancy. In immune competent individuals 
CMV reactivation is controlled by CMV-specific memory T cells. In immune compromised 
patients, lack of CMV-specific T cells and consequential absence of immune control of CMV 
reactivation can lead to potentially fatal CMV disease, such as CMV pneumonitis, CMV colitis 
or CMV encephalitis following CMV infection or reactivation25. Reactivation of endogenous 
CMV is the most frequently occurring herpes virus reactivation following alloSCT with an 
incidence of 80% in CMV seropositive recipients19. Approximately 60% of alloSCT recipients 
are seropositive for CMV and are therefore at risk for endogenous reactivation of latent 
CMV virus26. CMV infection of a CMV seronegative recipient via a stem cell graft from a CMV 
seropositive donor occurs, but less frequently because endothelial cells and monocytes, the 
most important sites for CMV latency and persistence, are not an elementary components 
of the stem cell graft27. CD8+ T cells can be analyzed and monitored using artificial HLA 
class I constructs loaded with a specific antigen. These constructs consist of multiple HLA 
molecules (tetramers or pentamers depending on the number of HLA molecules used) 
combined with a fluorescent label, allowing direct detection using flow cytometry. For CMV 
several HLA constructs have been developed and studies have demonstrated that presence 
of CMV-specific tetramer+ CD8+ T cells is directly related with control of CMV reactivation28, 29. 
Epstein-Barr Virus
Epstein-Barr Virus (EBV) is a herpes virus, which infects more than 90% of the population. 
After primary infection, which may lead to the clinical syndrome of infectious mononucleosis, 
the virus latently resides in the B cell population30. Infectious mononucleosis is caused by a 
massive expansion of EBV specific T cells upon recognition of an EBV antigen presented in HLA 
molecules with the goal to control the EBV infection. After alloSCT, reactivation of EBV may 
occur in the absence of sufficient EBV specific T cell immunity. With failing T cell control, EBV 
infected B cells can expand massively leading to potentially fatal PTLD. Although the incidence 
of EBV associated PTLD is low following alloSCT (4%)31, the risk correlates with the level of 
TCD. TCD strategies deleting only T cells, the risk increases because B cells, the principle site 
for EBV latency are not depleted. In TCD strategies using depleting antibodies targeting both 
T and B cells, such as alemtuzumab, the risk is not increased32. Analogous to CMV, also or EBV 
several HLA constructs have been developed and studies have also demonstrated increased 
control of EBV reactivation by EBV specific tetramer+ CD8+ T cells28, 29, 33, 34.
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Varicella zoster virus
Varicella zoster virus (VZV) is a herpes virus, which infects about 95% of the population. The 
primary infection with VZV leads to the clinical entity of varicella (chickenpox). After the 
primary infection VZV resides latently in neurons and reactivation leads to herpes zoster 
(shingles). Similar to CMV, cellular immunity is essential for preventing reactivation of VZV. 
After alloSCT, reactivation of the virus causes considerable morbidity and is potentially fatal 
in disseminated reactivation18. Most frequent complications are post-herpetic neuralgia 
and peripheral neuropathy. In contrast to CMV little is known about VZV-specific CD8+ T cell 
immunity because validated VZV-derived immunodominant peptides for HLA class I are 
lacking35. Previous studies demonstrated VZV-specific memory CD4+ T cells but VZV-specific 
CD8+ T cells were only detectable after in-vitro expansion. The inability to directly detect 
VZV-specific CD8+ T cells directly ex-vivo may be due to the low frequencies of VZV-specific 
CD8+ T cells or to the low sensitivity of the screening methods used to detect CD8+ T 
cells36-38. Identification of a VZV derived immunodominant peptide and the construction of 
VZV-specific peptide-HLA complexes is important to ex vivo analyze the role of CD8+ T cells 
in the immune responses to VZV infection and reactivation after alloSCT. 
Prevention of CMV disease by antiviral medication
In order to prevent CMV disease, a period of profound T cell deficiency after (TCD) alloSCT 
must be bridged to allow CMV-specific T cell immunity to restore and prevent CMV 
disease. Bridging this period is possible using antiviral medication. Ganciclovir is a synthetic 
nucleoside that inhibits DNA viruses, such as herpes viruses and especially CMV, by 
inhibiting viral DNA polymerase and viral DNA elongation. Ganciclovir is the golden standard 
for treating CMV disease but has considerable side effects, the most important being bone 
marrow suppression39. Furthermore ganciclovir has poor bioavailability, which precludes 
oral administration and often necessitates hospitalization for intravenous treatment40. 
Prophylactic use of ganciclovir to prevent CMV disease is therefore not feasible. However, 
because high viral loads precede the development of CMV disease when patients are still 
asymptomatic, prevention of CMV disease is possible by pre-emptive administration of 
ganciclovir40, 41. In a pre-emptive treatment strategy, antiviral therapy is initiated when the 
viral load is above a predetermined threshold. CMV viral load can be detected and monitored 
by using quantitative PCR42. Valganciclovir is an orally administered pre-drug of ganciclovir 
and suitable for pre-emptive outpatient clinical treatment to prevent CMV disease43-45. 
However, similar to ganciclovir, prolonged usage of valganciclovir is not appropriate for 
long-term prevention of CMV disease due to adverse effects and possible development of 
resistance46.
CMV-specific T cell reconstitution 
Restoration of immune control by reconstitution of CMV-specific T cells is required for long-
term control of viral replication and prevention of CMV disease28, 29, 47, 48. Reconstitution of 
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CMV-specific T cells can be the result of expansion of recipient memory T cells that survived 
the conditioning regimen prior to alloSCT or donor memory T cells transferred with the 
graft. Various factors can influence CMV-specific T cell reconstitution. Immune suppression 
for prevention of GVHD after transplantation with an unrelated or partially matched donor 
or treatment of GVHD can impair T cell reconstitution. CMV-specific T cell reconstitution 
may also be impaired by more intensive conditioning regimens prior to alloSCT due to more 
profound eradication of residual recipient T cell immunity. 
Following transplantation with a CMV seronegative donor, the CMV-specific T cells 
reconstituting after alloSCT are expected to be of recipient origin, because a primary 
immune response by donor T cells is not likely to occur shortly after alloSCT. Residual 
CMV-specific T cells of the recipient can be eradicated by alloreactive donor T cells when an 
immune response is induced after alloSCT and/or  Donor Lymphocyte Infusion (DLI), leaving 
the patient at risk for developing CMV disease. In these patients, development of a primary 
donor derived CMV-specific T cell response from donor origin would be essential to prevent 
CMV disease. For a primary CMV-specific immune response, naive T cells recognizing CMV 
antigens are required. Naive T cells need thymic education, and because the function of the 
thymus is impaired in (adult) alloSCT patients49, a primary donor derived CMV-specific T cell 
response is not expected shortly after alloSCT. 
Following transplantation with a CMV seropositive donor, CMV-specific T cells can be 
of recipient and/or donor origin, possibly at the same time leading to a state of mixed 
CMV-specific T cell chimerism. CMV-specific T cell reconstitution can originate from donor 
memory T cells transferred with the graft from CMV seropositive donors. Manipulation of 
the graft by TCD may abrogate this transfer of CMV-specific T cells and increase the risk of 
developing CMV disease. Eradication of recipient lymphopoietic cells in patients with mixed 
CMV-specific T cell chimerism by an alloreactive donor T cell response is not expected to be 
harmful as protection by donor CMV-specific T cells is still present or transferred with the 
DLI. 
Despite pre-emptive antiviral medication, persistent CMV reactivation or CMV disease can 
occur when CMV-specific T cell reconstitution is not sufficient. Adoptive transfer of donor 
T cells may be an elegant strategy to enhance T cell reconstitution after alloSCT. However, 
although this approach may be effective in reconstituting antiviral T cell immunity, it 
may induce potentially fatal GVHD. To enhance CMV-specific T cell reconstitution and to 
minimize the risk of inducing GVHD, donor derived CMV-specific T cells can be transferred 
to the recipient after alloSCT (CMV-specific adoptive cell transfer (ACT)) 50-52. CMV-specific 
ACT can be used either as a prophylactic or pre-emptive treatment to prevent CMV disease 
or as treatment for overt CMV disease. Adoptive transfer of T cells is most effective in the 
absence of immune suppression, as is in general the case in TCD alloSCT. However, the use of 
adoptive transfer is not commonplace, as questions regarding safety and efficacy still need 
answering. 
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Aim of the thesis
Profound T cell deficiency can lead to reactivation of endogenous herpes viruses after TCD 
alloSCT. Inadequate control of these viruses by virus-specific T cells can lead to significant 
complications. Long-term immunity depends on virus-specific T cell reconstitution. In case 
of CMV reactivation, antiviral medication can bridge the period of T cell deficiency, at the 
expense of potential toxic side effects. The aim of this thesis is to evaluate several options 
for preventing CMV disease after T cell depleted  (TCD) allogeneic stem cell transplantation 
(alloSCT). These options include a choice in conditioning regimen and in donor prior 
to alloSCT, pharmacological intervention following alloSCT and adoptive cell transfer in 
treatment of refractory CMV reactivation or CMV disease.
In chapter 2 we aimed to determine the efficacy and safety of oral valganciclovir compared 
to intravenous ganciclovir to prevent CMV disease after TCD alloSCT in a pre-emptive 
outpatient strategy. Ganciclovir is associated with hematological toxicity and intravenous 
administration necessitates hospital admission. Oral valganciclovir is considered to be less 
toxic compared to intravenous ganciclovir and does not necessitate hospital admission. 
Efficacy and safety of valganciclovir was already demonstrated in other high-risk populations 
such as renal- and heart-transplant patients.  In this chapter we evaluated the use of oral 
valganciclovir in preventing CMV disease in 107 consecutive patients following TCD alloSCT.
Reduced intensity conditioning (RIC) relatively spares residual recipient hematopoietic cells 
compared to conventional myeloablative conditioning (MAC). Therefore, reconstitution of 
CMV-specific T cells may be improved after RIC by sparing residual recipient CMV-specific 
T cell immunity. In chapter 3 our aim was to determine whether the incidence and severity 
of CMV reactivation was affected by the intensity of the conditioning regimen. To determine 
whether a less toxic conditioning regimen would lead to differences in incidence of CMV 
reactivation and disease, we compared the frequency and severity of CMV reactivation and 
the incidence of CMV disease in 107 consecutive patients following RIC or MAC TCD alloSCT.
Transplantation with a CMV seropositive donor implies that the donor graft may confer 
donor derived CMV-specific T cells in contrast to the graft from a CMV negative donor. 
CMV-specific T cells may be transferred with the graft from CMV seropositive donors 
and provide protection for CMV disease, but profound TCD can eradicate this transfer of 
CMV-specific T cells. In chapter 4 our aim was to determine the effect of donor CMV serostatus 
on the incidence of CMV disease and T cell reconstitution after TCD alloSCT. We analyzed 
the incidence of CMV disease after TCD alloSCT in CMV positive recipients transplanted 
with either a CMV seropositive or seronegative donor. Furthermore we investigated if and 
when a primary donor derived CMV-specific T cell response could be detected following 
TCD alloSCT. Demonstrating CMV-specific T cells of donor origin after transplantation with a 
CMV seronegative donor who lacks CMV-specific memory T cells would be illustrative of the 
induction of a primary CMV specific T cell response. Therefore, we determined the origin of 
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CMV-specific T cells in CMV seropositive recipients transplanted with a CMV seronegative 
donor. 
The risk for potentially fatal CMV disease increases if pre-emptive treatment fails to 
control CMV reactivation and rapid reconstitution of CMV-specific T cells is then pivotal 
for preventing CMV disease. Adoptive transfer of CMV-specific T cells may be a treatment 
option in patients failing preemptive anti-viral treatment, although routine application of 
adoptive cellular immunotherapy is hampered by questions regarding safety and efficacy. 
Therefore, in chapter 5 we aimed to analyze the safety and efficacy of adoptive transfer 
of CMV pp65-specific CD8+ T cell lines to restore CMV-specific T cell immunity in patients 
with persistent CMV reactivation failing anti-viral therapy. CMV-specific T cells from donor 
or patient were isolated using an IFNg-based isolation technique, cultured for 1–2 weeks to 
generate CMV-specific T cell lines, which were transferred to patients with refractory CMV 
reactivation. Adverse events, clinical effects and CMV-specific T cell reconstitution were 
monitored to assess the safety and efficacy of adoptive transfer of CMV-specific T cells. 
In contrast to CMV-specific CD8+ T cell reconstitution little is known about VZV-specific CD8+ 
T cell reconstitution. Identification of VZV-derived immunodominant peptides binding in 
HLA class I and development of VZV-specific peptide-HLA complexes could facilitate analysis 
of VZV-specific T cell reconstitution. In chapter 6 we searched for immunogenic antigens 
for VZV to develop VZV-specific pentamers using a new pentamer-based epitope discovery 
method. This method has the potential to quickly assess whether part of a protein can be 
immunogenic by determining the binding affinity with the HLA molecule. Development of 
VZV-specific peptide-HLA complexes is important to ex vivo analyze VZV-specific CD8+ T cell 
reconstitution and the immune response to VZV infection, reactivation, and possibly VZV 
vaccination. 
In chapter 7 we summarized and reviewed recent studies on prevalence and treatment 
of CMV disease after alloSCT in the era of pre-emptive antiviral treatment. We reviewed 
literature on the influence of Graft versus Host Disease, unrelated or HLA mismatched 
donors and TCD on the prevalence of CMV disease. We reviewed studies on the influence of 
donor CMV status on CMV-specific T cell reconstitution and CMV disease. Recent studies on 
the safety and efficacy of adoptive transfer of donor CMV-specific T cells for the prevention 
and treatment of CMV disease following alloSCT are discussed, including studies on adoptive 
transfer of third-party CMV-specific T cells as a possible alternative when donor T cells are 
not available.  
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Oral valganciclovir as pre-emptive therapy has similar efficacy on 
cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic 
stem cell transplantation recipients
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The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive 
treatment of cytomegalovirus (CMV) in T cell depleted allogeneic stem cell transplant 
(alloSCT) recipients. A therapeutic guideline was developed to allow the safe application 
of valganciclovir in alloSCT recipients requiring CMV therapy. In total, 107 consecutive 
transplant recipients were evaluated. Cytomegalovirus DNA load in plasma was monitored 
longitudinally; details on antiviral therapy and treatment responses were analyzed 
retrospectively. Fifty-seven CMV treatment episodes were recorded in 34 patients: 20 with 
valganciclovir (900 mg twice-daily) and 37 with ganciclovir (5 mg/kg twice-daily). Median 
CMV DNA load reduction was 0.079 and 0.069 log
10
copies/ml/ day in the ganciclovir and 
valganciclovir group, respectively. Good response on CMV DNA load (reduction below 3.0 
log
10 copies/ml) was observed in 75.7% of ganciclovir and 80.0% of valganciclovir treatment 
episodes. Severe adverse effects were not observed and CMV-related disease did not 
occur. However, the percentage of patients receiving erythrocyte transfusion was higher 
in the group of patients receiving ganciclovir as compared to valganciclovir (41 versus 20%, 
P=0.116). In conclusion, pre-emptive treatment with valganciclovir and ganciclovir, led to 
similar reduction of CMV DNA load. Oral valganciclovir is an attractive and safe alternative 
for pre-emptive CMV treatment in T cell depleted allo- SCT recipients. 
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Introduction 
In myeloablative (MA) allogeneic stem cell transplant (alloSCT) recipients, cytomegalovirus 
(CMV) infection contributes significantly to morbidity and mortality.1 Primary infection 
results in a lifelong persistence of the virus with reactivation and potentially fatal disease 
when immunity fails. Cytomegalovirus seropositivity in a patient before transplantation is 
associated with the highest risk of CMV disease.2 Furthermore, graft-versus-host disease 
(GVHD) and T cell depletion (TCD) of the transplant are important contributing factors.3 
Current strategies for the prevention of CMV disease aim at preventing end-organ disease 
by using ganciclovir or valganciclovir prophylaxis4,5 or ganciclovir pre-emptive therapy, 
initiated upon early detection of CMV infection by antigenemia or CMV DNA in plasma.5,6 
The relative merits of both strategies have been debated extensively in the literature.7,8 
The major drawback limiting the use of oral ganciclovir is its poor bioavailability, which 
precludes therapeutic use by oral administration.6 This has now changed with the 
introduction of valganciclovir, which is an orally administered prodrug of ganciclovir with 
good bioavailability. Previous pharmacokinetic studies showed similar drug exposure to 
ganciclovir after a single oral dose of 900 mg valganciclovir as compared to an intravenous 
dose of 5mg/kg ganciclovir.9–11 Recently, oral valganciclovir and intravenous ganciclovir were 
shown to have similar efficacy in pre-emptive CMV treatment in solid organ transplant 
recipients.1 2 – 1 4 As a consequence, the prevention of CMV disease in high-risk renal, renal–
pancreas and heart transplant patients was added as another indication to the original 
approval of valganciclovir for the treatment of CMV retinitis in AIDS patients. So far, no data 
are available on the efficacy of 900 mg valganciclovir twice daily as compared to intravenous 
5 mg/kg ganciclovir twice daily in the pre-emptive therapy of CMV infection in stem cell 
transplant recipients and therefore valganciclovir is not licensed for use in alloSCT patients. 
A comparison with intravenous ganciclovir in alloSCT patients is warranted, as hematological 
toxicity is a common side effect of ganciclovir and of particular significance in this population. 
In this observational prospective study, we compared the efficacy and safety of CMV DNA 
load-guided pre-emptive therapy with valganciclovir to ganciclovir intravenously in alloSCT 
recipients. 
Patients and methods 
Patients 
All consecutive patients undergoing MA and reduced-intensity allogeneic stem cell 
transplantation at the Leiden University Medical Center between January 2001 and 
December 2004 were included in this analysis. All patients at risk for CMV infection (i.e. 
CMV seropositivity in either the recipient (R+), the donor (D+) or both (D+R+)) were routinely 
monitored by CMV DNA load detection in plasma. Data were available on demographic 
characteristics, underlying diseases, donor and recipient CMV serostatus, occurrence 
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of GVHD and treatment (i.e. initiation, duration, type and dosage of drugs used) and the 
ganciclovir formulation (i.e. valganciclovir or ganciclovir), CMV DNA load measurements and 
general laboratory parameters. 
Transplantation 
T cell depleted transplantation was performed either according to a reduced-intensity 
conditioning (RIC) protocol or a conventional MA regimen as described previously.15,16 The 
RIC regimen consisted of fludarabine (30 mg/m2 , intravenously, days -10 to -6), busulphan 
(3.2 mg/kg, intravenously, days -6 and -5) and ATG (10 mg/kg/day intravenously, days -4 
to -1), for both sibling and matched unrelated donor (MUD) grafts. The MA conditioning 
regimen consisted of cyclophosphamide (60 mg/kg/day intravenously for 2 consecutive 
days) followed by single dose of total body irradiation (TBI, 9 Gy, day -1) in patients receiving 
sibling donor grafts. Recipients of MUD grafts, in the MA regimen, received additional 
Campath- 1G or -1H (days -8 and -4) and cyclosporine (3mg/kg intravenously, starting on 
day -1) and TBI (6 Gy, days -8 and -7). The stem cell product was infused on day 0. In all 
conditioning regimens, TCD of the graft was performed by in vitro incubation of the graft 
with Campath-1H (20 mg). Assessment of acute and chronic GVHD was performed using 
the Glucksberg and Shulman criteria.17,18 In the absence of GVHD or graft failure, patients 
received donor lymphocyte infusion (DLI) after RIC transplantation or in mixed chimerism 
or relapsed disease after MA transplantation. Donor lymphocyte infusion was administered 
at least 6 months following transplantation. Donor lymphocyte infusion was not used as a 
therapeutic modality for CMV infection. 
Cytomegalovirus monitoring and treatment 
CMV DNA load was measured at weekly intervals for at least 180 days following transplantation, 
until death occurred or beyond day 180 until CMV DNA became undetectable. The real-
time quantitative PCR for detection of CMV DNA in plasma was performed according to 
the method described previously.19 Cytomegalovirus DNA load-guided pre-emptive therapy 
was initiated according to a guideline as described previously.13 In short, any symptomatic 
CMV infection would be treated with intravenous 5 mg/kg ganciclovir twice daily. In case 
of a first reactivation or a significant viraemia (CMV DNA load >104 copies/ml, or CMV load 
>103 copies/ml and more than 1.0 log
10 increase as compared to preceding measurement) 
without clinical symptoms of CMV disease, either 900 mg valganciclovir twice daily or 
intravenous 5 mg/kg ganciclovir twice daily was administered for 2 weeks. Until 2003 
intravenous ganciclovir was used as primary pre-emptive treatment. From 2003 onwards, 
as soon as it became available for clinical use, valganciclovir was used as preferred primary 
treatment of outpatients, only limited to approval by the patients’ medical insurance. When 
such approval was not granted, or if hospital admission was indicated for other reasons, 
intravenous ganciclovir was administered. Ganciclovir and valganciclovir dosages were 
adjusted to renal function as described previously.20 During (val)ganciclovir treatment, CMV 
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DNA load and hematological parameters were monitored at least weekly; G-CSF prophylaxis 
was not routinely used. Donor lymphocyte infusion was not used as a therapeutic modality 
for CMV infection. 
End points and statistical analysis 
The effect of CMV treatment on CMV DNA load in plasma, following a full course of either 
ganciclovir or valganciclovir, was defined as good response (CMV DNA load reduction of 
more than 0.5 log
10 and to a level below 3.0 log10 copies/ml), moderate response (reduction 
of CMV DNA load of more than 0.5 log
10
, but not to a level below 3.0 log
10 copies/ml) and 
no response (equal DNA load (i.e. reduction of less than 0.5 log
10
) or an increase). The levels 
of 3.0 log
10 and 0.5 log10 were chosen as reference values based on a previous report on 
pre-emptive CMV treatment in SCT recipients.19 In addition, absolute reduction in number 
of CMV DNA copies/ml was calculated to compensate for differences in baseline CMV load 
before treatment. To avoid bias owing to possible differences in CMV reduction rate in first 
episodes as compared to subsequent episodes, the effect of antiviral medication in first 
and subsequent episodes was analyzed separately. Cytomegalovirus load reduction per day 
was calculated by dividing the difference in pre- and post-treatment CMV DNA load by the 
number of treatment days. 
Hematological toxicity was assessed by comparing the number of erythrocyte and 
thrombocyte transfusion units administered during and following antiviral treatment and 
by comparing leucocyte ratios (calculated by dividing the leucocyte count before treatment 
by the count at the end of treatment). Criteria for erythrocyte and thrombocyte transfusion 
were hemoglobin concentration below 6.0 mmol/l and platelet count below 10 x 1010/l, 
respectively. Definitions of CMV infection, CMV disease and CMV detection in blood were 
consistent with internationally accepted criteria.21 
All statistical analyses were performed using SPSS version 12.0.1. Differences in the 
distribution of categorical data were tested using χ2 test. For comparison of the antiviral 
effect between the two treatments (i.e. ganciclovir or valganciclovir) and comparison of 
baseline non-categorical data we used Mann–Whitney U-test. Paired observations (e.g., 
pre-treatment versus post treatment measurements) were analyzed non-parametrically 
using the Wilcoxon signed ranks test for paired observations. 
Results 
A total of 107 patients were included in this study. The demographic and disease 
characteristics for both CMV treatment groups are shown in Table 1. Distribution of 
the characteristics across the two groups was similar. Briefly, 48 patients received a 
transplantation following an RIC protocol, whereas 59 patients received their transplants 
following an MA conditioning regimen. With regard to donor and recipient CMV serostatus, 
40 D+R+ (37.4%), eight D+R- (7.5%), 30 D-R+ (28.0%) and 29 D-R- (27.1%) combinations were 
observed. The D-R- patients were excluded from further analysis, as they are not considered 
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to be at risk for CMV infection. The median follow-up period following transplantation was 
200 days (range: 30–611). During the follow-up period, CMV DNA load became detectable 
in 42 out of 78 (54%) patients at risk for CMV infection, resulting in 57 CMV treatment 
episodes with either ganciclovir or valganciclovir in 34 patients. The incidence of GVHD and 
the percentage of patients treated for GVHD were similar in the two CMV treatment groups. 
In none of the patients DLI was administered during treatment episodes. 
The CMV treatment results are shown in Table 2. Intravenous ganciclovir was used in 37 
episodes. A good response was observed in 28 episodes (76%). A moderate response was 
observed in five episodes (14%) occurring in four separate patients. One of these patients 
died as a result of extensive GVHD without signs of CMV disease. The remaining three 
patients reached a good response following a second course of intravenous ganciclovir. In 
four ganciclovir treatment episodes (11%), occurring in four individual patients, no response 
on CMV load was observed. In three of these four non-responding patients, CMV DNA 
load decreased below undetectable levels within 2 weeks after cessation of ganciclovir. In 
the remaining patient, CMV DNA load increased from 3.5 to 4.8 log
10 copies/ml, despite 
4 weeks of ganciclovir treatment, and subsequently foscarnet was administered, resulting 
in a CMV DNA load below detectable levels within 14 days of treatment. Treatment with 
valganciclovir was administered in 20 of the 57 episodes, resulting in a good response in 
16 out of these 20 episodes (80%). Moderate response was observed in three out of these 
20 episodes (15%) occurring in three individual patients. One of these patients died as a 
result of extensive GVHD without signs of CMV disease, and the remaining two patients 
showed a good response following a second course of valganciclovir. In one out of the 20 
valganciclovir treatment episodes (5%), no response on CMV DNA load was observed; this 
patient showed a good response upon a second course of valganciclovir. 
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Table 1. Characteristics of the study population in both treatment groups. In total, 57 CMV treatment 
episodes were observed in 34 patients. No statistically significant differences were observed 
between the two treatment groups. Systemic treatment of GVHD consisted of oral prednisone, 
intravenous methylprednisolone and/or oral cyclosporine. (CLL: chronic lymphocytic leukemia; CML: 
chronic myelogenous leukemia; MM: multiple myeloma; NHL: non-Hodgkin lymphoma).
Parameter ValGCV GCV
Treatment episodes, n  20 37
Number of patients, n  14 26
Median age in years (range)  51 (41-62) 50 (24-62)
Male gender, n (%)  9 (64) 17 (65)
Type of conditioning, n (%)
Reduced intensity 6 (40) 14 (54)
Myeloablative 8 (60) 12 (46)
Type of donor, n (%)
Related 11 (80) 20 (76)
Unrelated 3 (20) 6 (24)
Underlying disease, n (%)
Acute leukemia 5 (38) 9 (35)
CML 2 (14) 3 (12)
CLL 1 (7) 1 (4)
MM 1 (7) 6 (23)
NHL 4 (29) 1 (4)
Other 1 (7) 6 (23)
GvHD, n (%)
No GVHD 10 (70) 19 (73)
Grade I/II 4 (25) 6 (24)
Grade III/IV 1 (5) 1 (3)
Treatment 3 (20) 5 (19)
CMV serostatus, n (%)
D+R- 0 (0) 1 (3)
D+R+ 7 (50) 13 (51)
D-R+ 7 (50) 12 (46)
Median duration of treatment  
in days (range) 14 (7-36) 14 (7-28)
Hematological parameters at start  
of treatment 
[Median values (range)]
Hemoglobin (mmol/L) 7.3 (5.1-8.3) 6.9 (4.5-10.6)
Leucocyte count 






Table 2. Characteristics of 57 CMV treatment episodes in 34 patients and response on CMV DNA load 
according to treatment group (valGCV: valganciclovir; GCV: ganciclovir). No statistically significant 
differences were observed between the two treatment groups.
Parameter valGCV (n = 20) GCV (n = 37)
First treatment episodes, n (%) 8 (40) 26 (70)
Subsequent treatment episodes, n (%) 12 (60) 11 (30)
Response on CMV DNA load
Good response, n (%) 16 (80) 28 (76)
Moderate response, 
n (%) 3 (15) 5 (14)
No response, n (%) 1 (5) 4 (11) 
Erythrocyte transfusion, n (%) 4 (20) 15 (41)
Thrombocyte transfusion, n (%) 3 (15) 5 (14)
Leucocyte ratio* (median, range between parenthesis) 1.6 (0.6-27.1) 1.2 (0.2-11.0)
Leucocyte count x109/l (median, range 
between parenthesis)
Pre-treatment 5.0 (1.9-8.0) 3.1 (0.7-11.5)
Post-treatment 3.6 (0.1-9.7) 3.0 (0.4-8.6) 
*Calculated by dividing leucocyte count before treatment by the count and the end of treatment.
The effect of anti-CMV treatment with ganciclovir and valganciclovir was further assessed by 
comparing the CMV DNA load at the start and at the completion of the treatment episode. 
When first treatment episodes as well as all subsequent episodes were evaluated, CMV DNA 
load at start of therapy in the ganciclovir and the valganciclovir group was similar (median 
4.3 (range: 3.3–6.2) and 4.2 log10 copies/ml (range: 3.1–5.7), P>0.4, respectively, Figure 
1b). The kinetics of CMV DNA following treatment with ganciclovir and valganciclovir for 
individual patients are shown in Figure 1a. A median reduction of 1.20 and 1.10 log10 DNA 
copies/ml was reached in the ganciclovir- (n = 37) and the valganciclovir- (n = 20) treated 
patients, respectively (P<0.0001 for both groups). No difference in the magnitude of CMV 
DNA load reduction/treatment day was observed between the ganciclovir and valganciclovir 
groups (median 0.0786 (range: -0.0464–0.767) and 0.0690 log10 copies/ml/day (range: 
0.0182–0.171), P>0.8, respectively; Figure 1b). Cytomegalovirus treatment episodes 
were further subdivided into 34 first episodes (26 ganciclovir, eight valganciclovir) and 23 
subsequent episodes (11 ganciclovir, 12 valganciclovir) (Figure 2a). Cytomegalovirus DNA 
load at start of therapy, according to treatment episode, was similar in the ganciclovir and 
valganciclovir groups (median 4.4 (range: 3.3–5.6) versus 4.1 log10 copies/ml (range: 3.1–
5.1) in first episodes, P>0.3, respectively and 4.3 (range: 3.5–5.7) versus 4.3 log10 copies/ ml 
(range: 3.5–5.7) in subsequent episodes, P>0.7, respectively). The magnitude of CMV load 
reduction/ treatment day in first treatment episodes was similar for the ganciclovir and 
valganciclovir group (median 0.0941 (range: 0.000–0.767) and 0.0833 log10 copies/ml/day 
(range: 0.0381–0.171), P>0.6, respectively, Figure 2b). For subsequent episodes, the same 
ORAL VALGANCICLOVIR AS PRE-EMPTIVE THERAPY 29
2
result was obtained (median 0.0786 (range: -0.0464–0.260) and 0.0685 log10 copies/ml/ day 
(range: 0.0182–0.150), P>0.4, for ganciclovir and valganciclovir, respectively; Figure 2b). 
Erythrocyte transfusions were administered in 15 out of the 37 (41%) ganciclovir treatment 
episodes (median number of units: 2, range 2–6 units) as compared to four out of the 20 
(20%) (median number of units: 2, range 2–6 units) of the valganciclovir treatment episodes 
(P = 0.116). The percentage of patients receiving thrombocyte transfusions was similar in 
the ganciclovir- and valganciclovir- treated groups (15.0 and 13.5%, P40.8, respectively). 
Furthermore, the leucocyte ratio was not significantly different between ganciclovir and 
valganciclovir treatment episodes (median 1.16 and 1.55, P > 0.1, respectively). 
No signs of CMV disease and no severe adverse reaction (NCI grade 3–4) of (val)ganciclovir 
treatment were observed.
Figure 1.
In panel A, the course of CMV DNA load before and after treatment with valganciclovir or ganciclovir for individual 
patients is shown (all treatment episodes). 
In panel B, the CMV DNA load reduction per treatment day with valganciclovir (ValGCV) and intravenous ganciclovir 
(GCV) is shown (all treatment episodes). The box plots display the median, the 25th and 75th percentiles (box), and 
the smallest and largest values (whiskers).
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Figure 2.
In panel A, the courses of CMV DNA load before and after treatment with valganciclovir or ganciclovir for individual 
patients are shown. First (upper panel) and subsequent (lower panel) treatment episodes are plotted separately. 
In panel B, the CMV DNA load reduction per day during treatment with valganciclovir (ValGCV) and intravenous 
ganciclovir (GCV). First (left box plots) and subsequent (right box plots) episodes are shown separately. The box 
plots display the median, the 25th and 75th percentiles (box), and the smallest and largest values (whiskers). No 
significant differences are present.
Discussion 
This study demonstrates that pre-emptive treatments with oral valganciclovir and 
intravenous ganciclovir are equally effective in reducing CMV DNA load in allogeneic stem 
cell recipients. Pre-emptive treatment of CMV viraemia episodes in allogeneic stem cell 
recipients with either valganciclovir or ganciclovir led to a similar median CMV DNA load 
reduction in plasma of approximately 0.1 log
10 
copies/ml/day, which is in accordance with 
our previous report on renal and renal/pancreas transplant recipients.13 
Although initially no response was seen upon treatment with intravenous ganciclovir in 
four patients, CMV DNA load spontaneously declined in three of these whereas in only one 
patient a switch to foscarnet was made. Furthermore, in four other patients (five treatment 
ORAL VALGANCICLOVIR AS PRE-EMPTIVE THERAPY 31
2
episodes), treatment with intravenous ganciclovir for 14 days did not reduce the CMV 
DNA load below the level of 3.0 log
10 copies/ml and a subsequent course was needed to 
further reduce CMV DNA load. Similarly, in four patients treated with valganciclovir, either 
a subsequent course or a switch to foscarnet was needed to reduce CMV DNA load beyond 
detectable levels. Reasons for these failures are not clear and this study was not designed to 
identify factors associated with antiviral treatment failure. Therefore, further investigation 
with regard to these treatment failures is warranted. 
As soon as valganciclovir became available in our institution in 2003, it was used as preferred 
primary treatment of asymptomatic patients, only limited to approval by the patient’s 
medical insurance. In case such an approval was not granted or in case of co-morbidity 
leading to hospitalization, intravenous ganciclovir was administered. Patient selection might 
therefore have occurred, as co-morbidity was more likely to be present in admitted patients 
treated with ganciclovir. However, we do not expect that this possible bias has influenced our 
results to such an extent that the conclusions drawn might be incorrect. The baseline CMV 
loads in the ganciclovir- and valganciclovir-treated groups were similar, indicating similar 
CMV activity. Furthermore, the magnitude of CMV decline in all analyzed subgroups was 
similar, substantiating our conclusion on the equal efficacy of both drugs in CMV infection. 
In our study, the hematological toxicity of oral valganciclovir in alloSCT patients was similar 
as compared to ganciclovir intravenously. The slightly higher, although not statistically 
significant, percentage of patients receiving erythrocyte transfusions in the intravenous 
ganciclovir group might be the result of co-morbidity in the admitted patients treated with 
ganciclovir intravenously. Mainly owing to the retrospective nature of this study, differences 
in non-hematological toxicity, such as gastrointestinal and neurological complications, 
between the two treatment groups could not be assessed adequately and further evaluation 
in a prospective study is warranted. 
So far, no other studies have been reported on the use of valganciclovir compared to 
intravenous ganciclovir in stem cell recipients. In conclusion, based on our findings, oral 
valganciclovir (900 mg, twice daily) is equally effective and safe as intravenous ganciclovir 
(5 mg/kg, twice daily) in the pre-emptive treatment of CMV disease following alloSCT. 
There is an urgent need for an effective oral treatment for pre-emptive CMV therapy, which 
would enable prevention and treatment of CMV in an outpatient setting leading to reduced 
patient burden and health-care cost. The finding of the therapeutic equivalence of oral 
valganciclovir and intravenous ganciclovir is a confirmation of previous reports with respect 
to pre-emptive12–14, 22 and prophylactic treatment20 in solid organ transplant recipients. 
The large majority of alloSCT recipients, without any signs and symptoms of CMV disease 
when the first laboratory signs of CMV infection are detected, can benefit from treatment 
with an oral drug, without the need of hospitalization. Based on rational precautions, 
intravenously administered ganciclovir remains the first choice drug for patients with 
suspected symptomatic CMV infections, as the course of CMV disease can be serious, 
rapidly progressive and ultimately fatal. 
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Reports on infectious complications following reduced intensity conditioning (RIC) before 
allogeneic stem cell transplantation (alloSCT) are equivocal. This prospective follow-up study 
compared the impact of cytomegalovirus (CMV) infections following RIC with fludarabine, 
ATG and busulphan or conventional myeloablative conditioning (MAC). Forty-eight RIC and 
59 MAC patients were enrolled. The occurrence and severity of CMV infections within 100 
days following alloSCT were assessed, using plasma CMV DNA load kinetics. CMV DNAemia 
was observed in 21 RIC (60%) and in 19 MAC (44%) patients at risk for CMV. The mean 
CMV DNAemia free survival time was comparable following RIC and MAC: 70 days (95% 
(confidence interval) CI: 59–80 days) and 77 days (95% CI: 68–86 days), respectively (P¼0.24). 
Parameters indicative for the level of CMV reactivation, including the area under the curve of 
CMV DNA load over time as well as the onset, the peak values and duration of CMV infection 
episodes, the numbers and duration of CMV treatment episodes and recurrent infections, 
were not different in both groups. During follow-up, none of the patients developed CMV 
disease. RIC with fludarabine, ATG and busulphan demonstrated safety comparable to 
conventional MAC with regard to frequency and severity of CMV infections within 100 days 
following T cell depleted alloSCT.
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Introduction
Allogeneic stem cell transplantation (alloSCT) is increasingly used to treat hematological 
and non-hematological malignancies. Recently, conditioning regimens have been designed 
to exploit the graft-versus-tumor effects while reducing the intensity of the conditioning 
to minimize toxicities1-3. Results of studies demonstrate rapid allogeneic engraftment with 
minimal non-hematological toxicity and a significant antitumor effect. Despite the lower 
toxicity of the reduced intensity conditioning (RIC), acute and chronic graft-versus-host 
disease (GvHD) remains a significant cause of morbidity and mortality with a reported 
incidence of severe GvHD of 30–60%1. 
Recently, an in vitro T cell depleted alloSCT protocol following non-myeloablative 
conditioning with fludarabine, antithymocyte globulin (ATG), busulphan and Campath-in-
the-bag was reported as a suitable platform for subsequent cellular immunotherapy4. It was 
shown that this protocol leads to durable donor engraftment, favorable response of the 
disease and minimal GvHD. Still, infections remain a prominent cause of transplant-related 
mortality following RIC5. As in myeloablative SCT recipients, risk factors for infections include 
the degree of myeloablation, GvHD and organ toxicities. However, as the timing and types of 
infections may differ5, information regarding infectious risks and outcomes are important to 
develop preventative strategies in alloSCT recipients following RIC.
Cytomegalovirus (CMV) is one of the major causes of infectious complications following 
alloSCT6, and the strategy of viral load guided pre-emptive antiviral therapy has been shown 
to reduce the risk of CMV disease7, 8. Viral load kinetics has been reported to be predictive 
for the development of CMV disease, with the initial viral load and the initial rate of increase 
in viral load being independent risk factors9 and as such this method can also be applied to 
assess the incidence and severity of CMV reactivation following transplantation. However, 
in this context, it should be considered that an episode of CMV viremia is characterized not 
only by its level (for example, peak load), but also by its duration9, 10; as a consequence, long-
term viremia at lower levels may have the same clinical significance as shorter episodes of 
high-level viremia. A novel approach has been devised previously to assess both quantities 
(level and duration of viremia) with a single parameter, which is based on calculating the 
area under the curve (AUC) of viral load over time10. Hence, the AUC approach is a universal 
means of assessing interrelated determinants, including peak viral load, initial viral load 
and rate of increase of viral load, parameters that have been described as independent risk 
factors for CMV disease9. 
In the current prospective follow-up study, viral load kinetics were used to assess the 
incidence and the level of CMV reactivation in patients receiving in vitro T cell depleted 
alloSCT following either non-myeloablative conditioning with fludarabine, ATG and 




Forty-eight consecutive patients who received alloSCT following RIC between January 2001 
and December 2004 were analyzed for CMV reactivation. Patients eligible for alloSCT were 
selected to receive RIC either when MAC was contraindicated (due to comorbidity or age) 
or in patients with an HLA identical donor who failed to respond on conventional treatment 
for lymphoma, multiple myeloma or chronic lymphocytic leukemia, or in patients with 
solid tumors such as metastatic renal cell carcinoma or breast carcinoma. Forty-three RIC 
patients had hematological malignancies, four had renal cell carcinoma and one had breast 
carcinoma. Additionally, 59 consecutive patients who received alloSCT using conventional 
MAC regimens between August 2001 and December 2004 were included in this analysis. 
All conventional MAC patients had hematological malignancies. General institutional policy 
with respect to patients’ informed consent for inclusion into the study, approved by the 
ethical institutional board, was applied.
Transplantation
T cell depleted transplantation was performed either according to a RIC protocol or a MAC 
regimen as described previously4, 11. The RIC regimen consisted of fludarabine (30mg/m2, 
intravenously, day -10 to -6), busulphan (3.2 mg/kg, intravenously, day -6 and -5) and ATG 
(10mg/kg/day intravenously, day -4 to -1), for both sibling and matched unrelated donor 
(MUD) grafts. The MAC regimen consisted of cyclophosphamide (60mg/kg/day intravenously 
for 2 consecutive days) followed by single dose of total body irradiation (TBI, 9 Gy, day -1) in 
patients receiving sibling donor grafts. Recipients of MUD grafts, in the myeloablative regimen, 
received additional Campath-1G or -1H (day -8 and -4) and cyclosporine (3 mg/kg intravenously, 
starting on day -1) and TBI (6 Gy, day -8 and -7). The stem cell product was infused on day 0. In 
all conditioning regimens, T cell depletion of the graft was performed by in vitro incubation of 
the graft with Campath-1H (20mg). Prophylaxis for GvHD was not administered. Assessment 
of acute and chronic GvHD was performed using the Glucksberg and Shulman criteria12, 13. In 
the absence of GvHD or graft failure, patients received donor lymphocyte infusion (DLI) after 
RIC transplantation or in mixed chimerism or relapsed disease after MAC transplantation. DLI 
was never administered before 6 months following transplantation. 
CMV monitoring and pre-emptive treatment 
CMV DNA load was measured at least once a week for up to 100 days following 
transplantation. The real-time quantitative PCR for detection of CMV DNA in plasma was 
performed according to the method described previously14. The course of CMV DNA load in 
plasma was documented longitudinally for each patient during follow-up. Individual areas 
under the CMV DNAemia curve post-transplant were calculated using the trapezoidal rule 
as described previously10, 15. 
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CMV DNA load guided pre-emptive therapy was initiated according to a protocol based 
on criteria established in a previous study14. In short, CMV DNAemia episodes following 
transplantation treatment was initiated at a CMV DNA load level of >104 copies/ml or at a level 
of >103 copies/ml and more than one 10log increase as compared to previous measurement, 
without clinical symptoms of CMV disease14. Pre-emptive treatment consisted of 900 mg 
valganciclovir b.i.d. or intravenous 5 mg/kg ganciclovir b.i.d for an average duration of 2 
weeks. CMV disease would be treated with intravenous 5 mg/kg ganciclovir b.i.d. Ganciclovir 
and valganciclovir dose were adjusted to renal function as described previously16. Serum 
creatinine levels and hematological parameters (that is, hemoglobin, leucocyte and 
thrombocyte counts) were monitored throughout treatment episodes. 
Study end points and statistical analysis 
The primary end point for this study was CMV infection, defined as ‘detection of two 
consecutive positive CMV DNA loads (more than log10 2.7 (=500) copies/ml plasma) within 
100 days following alloSCT transplantation’. The level of log10 2.7 copies/ml plasma as the 
lower detection limit of the ‘real-time’ quantitative CMV DNA PCR was established by earlier 
assessments with respect to the sensitivity and reproducibility of the assay14. The number 
of two consecutive detections of log10 2.7 copies/ml as the definition of CMV infection was 
arbitrarily chosen to exclude incidental single positive findings. Secondary end points were 
CMV DNA load requiring antiviral treatment and recurrent infections. Definitions for CMV 
infection, CMV disease, CMV detection in blood and recurrent infection were adopted from 
internationally accepted criteria17. 
All database entries and statistical analyses were performed with SPSS version 12.0.1. 
Differences in age at transplantation, time to the first CMV DNA load detection, CMV DNA 
peak load, the duration of the CMV infection and the area under the DNAemia curve (AUC) 
were compared between groups using Mann–Whitney U-test and analyses of variance. For 
all measurements, the median and range or the 25th and 75th percentiles are presented. 
Differences in the distribution of CMV serostatus, underlying disease, GvHD and gender 
were tested using χ2 and Fisher exact-test statistics. Kaplan–Meier analysis was performed 
to detect differences in CMV DNAemia free survival between groups during the first 100 
days following transplantation and a Cox regression analysis was used to adjust for the 
possible confounders age and donor type. Relative risks for occurrence of CMV disease are 
presented with 95% confidence interval (95% CI).
Results
Patient characteristics
A total of 107 patients were included in this study. The demographic and disease 
characteristics for patients in both conditioning groups are shown in Table 1. Distribution of 
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the characteristics across the two groups was similar with respect to risk for CMV infections 
(based on donor and recipients CMV serostatus), underlying disease, GvHD and gender. 
However, significant differences were noted with regard to mean age at transplantation and 
donor type (Table 1). The mean age at transplantation was 54.5 years in the RIC patients 
compared with 44.0 years in the MAC patient group (P<0.01). In the reduced intensity 
group, 31 patients were transplanted with hematopoietic stem cells from an HLA identical 
donor and 17 patients had mismatched unrelated donors (in the myeloablative group, 52 
and 7, respectively) (P=0.004). Further analyses were restricted to 78 patients who were 
considered to be at risk for CMV infection/reactivation (based on donor and receptor 
serostatus: 8 D+R-, 40 D+R+ and 30 D-R+). This selection did not introduce significant change 
in the patients’ characteristics. 
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Table 1. Relevant characteristics of the study population in both conditioning groups. No significant 
differences were present between the two groups, with the exception of age and donor type. 
Systemic treatment of GvHD consisted of oral prednisone, intravenous methylprednisolone  
and/or oral cyclosporine. RIC: reduced intensity conditioning, MAC: myeloablative conditioning,  
ns: not significant. CLL: chronic lymphocytic leukaemia; CML: chronic myelogenous leukaemia;  
CMV: cytomegalovirus; GvHD: graft-versus-host disease; MAC: myeloablative conditioning;  
MM: multiple myeloma; NHL: non-Hodgkin lymphoma; NS: not significant; RIC: reduced intensity 
conditioning. 





Age (median/range) 54.5 (26-76) 44.0 (21-62) p<0.01
Male gender (%) (34) 71 (43) 73 ns
Serostatus: (%)
D+R+ 20 (42) 20 (34) ns
D+R- 4 (8) 4 (7)
D-R+ 11 (23) 19 (32)
D-R- 13 (27) 16 (27)  
Donor type (%)
Related 31 (65) 52 (88) p<0.01
Unrelated 17 (35) 7 (12)  
Underlying disease (%) ns
Acute leukemia 10 (21) 33 (56)
CML 5 (10) 10 (17)
CLL 5 (10) 1 (2)
MM 5 (10) 7 (12)
NHL 10 (21) 7 (12)
 Other 13 (27) 1 (2)  
T cell depletion (%) 48 (100) 59 (100) ns
Acute GvHD (%) p=0.07
Grade I/II 4 (8) 13 (22)
Grade III/IV 0 0
Chronic GvHD (%) 0 5 (9) p=0.07
GvHD treatment (%)  (systemic) 0 5 (8.5) ns
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Incidence of CMV DNAemia
CMV DNAemia occurred in 40 pati ents within 100 days following transplantati on, which 
accounts for 37% of all 107 pati ents and 51% of pati ents at risk for CMV (n=78). The fi rst 
signs of CMV DNAemia were observed at a median of 27 days (range: 8–81) and all fi rst 
episodes occurred within 90 days following transplantati on. None of the pati ents developed 
CMV disease during the follow-up of 100 days following alloSCT. Among the 78 pati ents at 
risk for CMV DNAemia, the highest incidence of CMV DNAemia was observed in R+ cases; 
21 (53%) D+R+ and 18 (60%) D+R+ compared with 1 (12.5%) D+R- pati ents within 100 days 
following transplantati on. Within the group of pati ents at risk for CMV (35 and 43 receiving 
RIC and MAC, respecti vely), CMV DNAemia was observed in 21 (60%) pati ents receiving RIC 
and in 19 (44%) pati ents receiving MAC. Although the mean CMV DNAemia free survival 
ti me was shorter in RIC pati ents (70 days, 95% CI: 59–80) then in MAC pati ents (77 days, 
95% CI: 68–86), this diff erence was not stati sti cally signifi cant (P=0.24; Figure 1). This was 
not diff erent when a multi variate Cox regression analysis was performed to control for the 
possible confounders age, GvHD and donor type.
Figure 1. 
Patt ern of CMV-free survival (Kaplan-Meier) during the fi rst 100 days following allo-SCT in pati ents receiving 
reduced intensity (RIC) or myeloablati ve conditi oning (MAC). CMV viraemia was observed in 21 (60%) and 19 (44%) 
of the RIC and MAC pati ents respecti vely. The mean CMV free survival ti me in RIC pati ents was 70 days, (95% CI: 
59-80 days) compared to 77 days (95% CI: 68-86 days) in MAC pati ents (p= 0.24).
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Level of CMV reactivation following RIC and MAC
To assess the level of CMV reactivation, the onset of the first positive CMV PCR following 
transplantation, the peak load of the first episodes following alloSCT and the duration of the 
first CMV DNAemia episodes were evaluated in patients receiving RIC or MAC. There was no 
difference in the onset of the first CMV DNAemia episodes following RIC or MAC; median of 
27 days (range: 8–81) and 27 days (range: 14–58) following transplant in recipients of RIC and 
MAC, respectively (P=0.36). Also the median peak loads of the first CMV episodes following 
alloSCT were comparable between the RIC and MAC patients: log10 4.7 copies/ml (range: 
log10 3.2–log10 5.6) and log10 4.7 copies/ml (range: log10 3.5–log10 6.2), respectively (P=0.74). 
The median duration of the first CMV DNAemia episode was longer in RIC patients (42 days 
(range: 7–73)) compared with MAC patients (28 days (range: 2–83)). However, this difference 
was not statistically different (P=0.72). These findings did not change after correcting for the 
possible confounders age, GvHD and donor type. Alternatively, the level of CMV reactivation 
was evaluated by calculating the time-adjusted area under the DNAemia curve (assessing 
both, the level and the duration of CMV DNAemia in mentioned time period). Although the 
median area under the DNAemia curve over time during the first 100 days following alloSCT 
was higher in RIC patients (0.61 (range: 0.08–1.68)) compared with MAC patients (0.49 
[range: 0.10–1.42]), this difference was not statistically significant (P=0.41). These findings 
did not change after correcting for differences in age, GvHD and donor type between the 
two induction groups. Another approach to assess the level of CMV reactivation in both 
groups was to evaluate CMV load episodes requiring antiviral treatment. (Val)ganciclovir 
was administered to an equal amount of RIC and MAC patients with CMV DNAemia: 17 
out of 21 (81%) and 16 out of 19 (84%), respectively (P=0.45). The total duration of CMV 
treatment was also comparable in both groups: median duration of 14 days (range: 7–53) 
in RIC patients and 14 days (range: 11–29) in MAC patients (P=0.279). Multiple treatment 
episodes (with a maximum of 2) within 100 days following alloSCT were seen in 7 patients 
(41%) following RIC and in 4 patients (25%) following MAC. This difference did not reach 
statistical significance (P=0.458), also not after correction for the possible confounders age, 
GvHD and donor type. Foscarnet was never administered within 100 days following alloSCT. 
These findings also indicate equal levels of CMV reactivation in both conditioning groups. 
Recurrent CMV infections following RIC and MAC
CMV infection recurred within 100 days following transplantation in 3 out of 21 patients 
(14.3%) receiving RIC and also in 3 out of 19 (15.8%) with MAC. None of the six patients with 
recurrent CMV infections developed more than 2 CMV DNAemia episodes within 100 days 
following transplant.
Influence of donor and recipient CMV serostatus on CMV infections
In a univariate analysis, serological status of recipient and donor appeared to be 
associated with the occurrence of CMV infection within 100 days following alloSCT, 
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when D-R- patients were included (P=0.071). Among patients at risk for CMV (donor and/
or recipient seropositive), seropositive recipients were at higher risk for CMV infections 
compared with seronegative recipients, whereas no significant difference was observed 
between seropositive and seronegative donors (Table 2). Within the high-risk CMV patients 
(seropositive recipients), the relative risk for CMV reactivation was 1.1 for D-R+ patients 
compared with D+R+ patients; this difference was not statistically significant (P=0.65; Figure 
2a). Also, the level of CMV reactivation was comparable (Figure 2b). These findings did not 
change after stratification for conditioning therapy (Figure 2c–f). Donor type and recipients’ 
age did not have significant impact on the occurrence of CMV within 100 days following 
transplantation.
Table 2. Univariate analysis of risk factors for CMV within 100 days following alloSCT in patients at 
risk for CMV infection (n=78)
Risk factors Crude RR (95% CI) P-value
Conditioning 
(RIC vs MAC) 1.50 (0.81-2.79) 0.20
Recipient age (years) 
(>45 vs <45) 1.40 (0.69-2.78) 0.35
CMV serostatus
D- vs D+ 1.40 (0.75-2.62) 0.29
R+ vs R- 6.10 (0.84-45.50) 0.07
Donor type 
unrelated vs related 1.40 (0.67-2.80) 0.39
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Figure 2. 
The probability (left  panels) and severity (right panels) of CMV infecti on in high-risk pati ents (i.e. CMV seropositi ve 
recipients) within 100 days following alloSCT, according to CMV serostatus of the donor and conditi oning regimens. 
The probability and severity of CMV infecti on were comparable between seropositi ve and seronegati ve donors 
(panels A and B). This did not change aft er strati fi cati on for inducti on therapy (C and D, and E and F). The box 
plots display the median (horizontal bars), the 25th and 75th percenti les (box), and the smallest and largest values 
(whiskers). Open circles depict the outliers (values between 1.5 and 3 box lengths from the upper or lower edge 
of the box). 
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Discussion
It has been established that allogeneic transplantation with RIC can be successfully 
performed in individuals with a wide variety of different diseases and with reduced risk 
of transplant-related mortality5, 18. Previously, an in vitro T cell depleted alloSCT protocol 
following RIC with fludarabine, ATG, busulphan and Campath-in-the-bag was reported to 
lead to durable donor engraftment and favorable response of the disease with no GvHD4. 
The current analysis demonstrates that there was no significant difference in incidence and 
severity of CMV infections within 100 days following alloSCT preceded by RIC compared to 
a conventional MAC. A limitation in the current study concerns its non-randomized nature. 
Patients were allocated to the RIC or MAC group on clinical grounds, rather than by random 
selection. Therefore the possibility of confounding by indication could not be entirely 
excluded. 
Although there was a trend towards a shorter CMV DNAemia free survival following RIC, 
this difference was not statistically significant. Furthermore, various parameters related to 
the severity of CMV infections (that is, the onset of CMV DNA detection in plasma following 
alloSCT, the duration of a CMV infection, the peak load, the area under the DNAemia curve, 
the number and duration of pre-emptive CMV treatment episodes as well as the number 
of recurrent infections within 100 days following alloSCT) were not different after RIC and 
MAC, supporting the conclusion of comparable severity of CMV infections in both groups.
In this study, both patient groups received T cell depleted grafts. By itself, T cell depletion 
of the graft is associated with an increased risk for CMV infections19, which seems to be 
reflected by the high overall incidence of CMV infections (51%) within 100 days following 
alloSCT in this study. 
Previous studies have reported variable outcomes with regard to CMV infections following 
RIC20-22. Such differences can be explained by the variable immune suppressive potentials of 
the RIC regimens investigated at different centers, presumably reflecting a balance between 
more residual immunity in the host and a higher risk for opportunistic infections either due 
to more persisting intracellular pathogens or an increased incidence of GvHD following RIC. 
A high rate of CMV infections was observed in alemtuzumab-based RIC regimen20. Recent 
reports with respect to CMV infections following fludarabine, busulphan and ATG-based RIC 
regimens compared to MAC have either reported no influence of conditioning protocols23 or 
a significant increase of CMV infection following RIC22. However, limitations in these studies 
included analysis of CMV infections mainly using CMV antigenemia detection rather than 
the more sensitive and accurate CMV DNA PCR in plasma14. Another difference is the use of 
GvHD prophylaxis in these previous studies, which may be of major importance with respect 
to CMV infections. 
The association of CMV positive serostatus of the recipients (R+) and an increased risk for 
CMV infections following alloSCT is well established24. Recently, it has been demonstrated 
that a CMV seronegative donor for a seropositive patient (D-R+) in particular was found to 
be a risk factor for CMV infections following alloSCT in an study including both reduced 
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intensity as well as MAC regimens. Although the previous report did not show a difference 
between conditioning regimens25, we observed increased frequency and severity of 
CMV infections in seropositive patients receiving a graft from seronegative donors (D-R+) 
compared to seropositive donor and recipient combination (D+R+) only following MAC, 
presumably reflecting residual immunity following RIC. However, this difference was not 
statistically significant and the clinical relevance of this observation is questionable. 
Another relevant conclusion resulting from the current study was that irrespective of the 
conditioning regimen, monitoring of CMV DNA in plasma and pre-emptive therapy proved 
highly effective in preventing CMV disease following alloSCT, as CMV disease was not seen 
in any patient. 
In conclusion, RIC with busulphan, fludarabine and ATG demonstrated comparable safety 
to conventional MAC with regard to the frequency and severity of CMV infections within 
100 days following T cell depleted alloSCT. Moreover, with RIC, pre-emptive CMV treatment 
guided by CMV DNA load monitoring in plasma is highly effective in preventing CMV disease 
following T cell depleted alloSCT.
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Abstract
Cytomegalovirus (CMV)-specific T cells are crucial to prevent CMV disease. CMV seropositive 
recipients transplanted with stem cells from a CMV seronegative allogeneic donor (R+D-) 
may be at risk for CMV disease due to absence of donor CMV-specific memory T cells in 
the graft. We analyzed the duration of CMV reactivations and the incidence of CMV disease 
in R+D- and R+D+ patients after alemtuzumab-based T cell depleted allogeneic stem cell 
transplantation (TCD alloSCT). To determine the presence of donor-derived primary CMV-
specific T cell responses we analyzed the origin of CMV-specific T cells in R+D- patients.  The 
duration of CMV reactivations (54 versus 38 days, respectively, p=0.048) and the incidence of 
CMV disease (0.14 versus 0.02, p=0.003 at 1 year after alloSCT) were higher in R+D- patients 
compared to R+D+ patients. In R+D- patients, CMV-specific CD4+ and CD8+ T cells were mainly 
of recipient origin. However, in 53% of R+D- patients donor-derived CMV-specific T cells were 
detected within the first year. In R+D- patients, immunity against CMV was predominantly 
mediated by recipient T cells. Nevertheless, donor CMV serostatus significantly influenced 
the clinical severity of CMV reactivations indicating the role of CMV-specific memory T cells 
transferred with the graft, despite the ultimate formation of primary donor-derived CMV-
specific T cell responses in R+D- patients.
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Introduction
The presence of anti-viral T cell immunity is crucial for effective and sustained protection 
against cytomegalovirus (CMV) following allogeneic stem cell transplantation (alloSCT)1.  In 
vitro and in vivo T cell depletion (TCD) via addition of the anti-CD52 monoclonal antibody 
alemtuzumab to the stem cell graft (alemtuzumab “in the bag”) is used to reduce the 
incidence of acute Graft versus Host Disease (GVHD) following alloSCT2-4. Alemtuzumab 
does not exclusively eliminate alloreactive T cells, but affects presumably all T cells, 
including donor-derived CMV-specific T cells in the graft and residual CMV-specific T cells 
of the recipient. Despite the profound TCD, protection against CMV is observed early after 
TCD alloSCT in CMV seropositive recipients (R+) transplanted with a CMV seropositive 
donor (R+D+) mediated by CMV-specific T cells that can either originate from the donor via 
transfer with the graft or from the recipient as residual memory T cells. In CMV seropositive 
recipients (R+) transplanted with a CMV seronegative donor (R+D-) donor-derived CMV-
specific memory T cells are not present in the graft and R+D- patients must therefore rely on 
residual CMV-specific T cells of recipient origin and/or a donor-derived primary CMV-specific 
T cell response to control CMV reactivations. If despite the in vivo T cell depletion mediated 
by the free alemtuzumab transferred with the graft, recipient-derived T cell immunity 
predominates in the protection against CMV, the incidence and severity of CMV reactivation 
and disease would not differ between R+D+ and R+D- patients. Because the function of the 
thymus is likely to be impaired after TCD alloSCT5, it is not known if or when to expect a 
donor-derived primary immune response after TCD alloSCT. Demonstrating donor derived 
CMV-specific T cells after transplantation with a CMV seronegative donor (R+D-) would be 
indicative of a newly developed CMV-specific primary T cell response. 
In this study we analyzed the effect of donor CMV serostatus on the incidence of CMV 
reactivation and CMV disease in R+D- patients versus R+D+ patients following TCD alloSCT 
using alemtuzumab in the bag (20 mg). Furthermore we analyzed the origin of circulating 
CMV-specific CD4+ and CD8+ T cell populations in R+D- patients by chimerism analysis to 
detect donor derived CMV-specific T cells indicative of a donor derived primary CMV-specific 
T cell response. 
Objectives
The objectives of this studies were to analyze the effect of donor CMV serostatus on the 
incidence of CMV reactivation and CMV disease following T cell depleted allogeneic stem 
cell transplantation and to detect CMV-specific primary T cell responses by demonstrating 
donor derived CMV-specific CD4+ and CD8+ T cell populations in seropositive recipients 
transplanted with stem cells from a CMV seronegative allogeneic donor.
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Material and Methods
Patients and CMV monitoring
General institutional policy with respect to patients’ informed consent for inclusion into 
the study, approved by the ethical institutional board, was applied. Consecutive patients 
transplanted in the period 2004-2010 were included. Patients with haplo-identical or cord 
blood transplantation were excluded from the analysis. We retrospectively analyzed CMV 
PCR loads, determined as part of regular post transplantation monitoring. The real-time 
quantitative PCR for detection of CMV DNA in plasma was performed according to the 
method described previously6. CMV DNA load guided pre-emptive therapy was initiated 
according to a protocol based on criteria established in a previous study7. CMV reactivation 
was defined as previously described by the detection of two consecutive positive CMV DNA 
loads (>log10 2.7 (>500)/ml copies plasma) and CMV disease was defined as previously 
published8. Post transplantation sampling for T cell analysis was scheduled every 3 months 
and continued for 1 year after alloSCT or longer if deemed necessary.
T cell depletion and transplantation 
T cell depletion of the graft was performed by in vitro incubation of the graft with 
alemtuzumab (20 mg). The stem cell product was infused on day 0. Pre-transplantation 
conditioning was performed either according to a myeloablative (MA) conditioning protocol 
or a nonmyeloablative (NMA) conditioning (RIC) protocol as described previously9, 10. 
Detection and isolation of CMV-specific CD4+ and CD8+ T cells based on CD137 expression
CMV-specific CD4+ or CD8+ T cells were detected by flow cytometric analysis of expression of 
the activation marker CD137 upon stimulation of PBMC with protein spanning overlapping 
peptide pools of the CMV-derived proteins pp65 and IE111-13. A cluster of ≥5 CD137+ events 
on FACS analysis within a total of 10.000 acquired events was considered positive based on 
the low level of background seen in CMV seronegative individuals. The isolation of CMV-
specific CD4+ or CD8+ CD137+ T cells was performed as described previously13. In short, after 
thawing, PBMCs at a concentration of 10*106/ml were stimulated with 10-6 M CMV-derived 
pp65 and IE1 protein spanning peptide pools in culture medium supplemented with 10 IU/
mL IL-2 (Chiron, Amsterdam, The Netherlands) for 24 hours at 37°C and 5% CO2.  Viability 
after thawing was consistently >75%. After stimulation the cells were stained with CD137-
allophycocyanin (APC, BD Pharmingen, Franklin Lakes, USA), fluorescein isothiocyanate-
labelled CD16 (BD, Franklin Lakes, USA), CD14 (BD Pharmingen), CD19 (BD) and TCRγδ (BD) 
(dump gate), phycoerythrin (PE labelled CD4, BD Pharmingen), Alexa fluor 700 labelled CD8+ 
(Invitrogen, Waltham, MA, USA) and PE Texas Red labelled CD3 (Invitrogen) for 30 minutes 
at 4°C. Isolation was performed by Fluorescence Activated Cell Sorting using the FACS Aria 
(BD). CD16, CD14, CD19 and TCRγδ negative and CD3/CD4/CD137 triple positive and CD3/
CD8+/CD137 triple positive cells were sorted in bulk for chimerism analysis.
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Chimerism analysis
Chimerism analysis on sorted CMV-specific CD4+ and CD8+ CD137+ T cells was performed 
as described previously14. In short, we performed PCR analysis with primers specific 
for patient and donor selected polymorphic short tandem repeats using the AmpFLSTR 
Profiler Plus ID amplification kit (Applied Biosystems, Waltham, MA, USA) and a GeneAmp 
9700 thermocycler (Applied Biosystems) using AmpliTaq Gold DNA polymerase (Applied 
Biosystems). PCR products were analyzed using the ABI PRISM 3100 Genetic Analyzer and 
Genemapper V3.5 analysis software (Applied Biosystems). Maximum sensitivity of the 
markers was set at 2% for all markers.
Statistical analysis
Analysis of CMV reactivation and CMV disease was performed using competing risk analysis 
as described earlier15.  Factors taken into account as competing risks were death, non-
engraftment, rejection, systemic immune suppression, DLI and relapse. Additional analyses 
were performed using Student T-test IBM SPSS Statistics version 22.
Results
CMV reactivation and disease in CMV seropositive patients following TCD alloSCT
From the cohort of 157 CMV seropositive patients, 51 were transplanted with a CMV 
seronegative donor (R+D-) and 106 were transplanted with a CMV seropositive donor (R+D+). 
The donor and patient demographics (age, gender, type of conditioning regimen, unrelated/
related donor) did not significantly differ between the two patient groups (table 1). The 
cumulative incidences of CMV reactivations and CMV disease were compared by separate 
competing risks analyses, taking non-engraftment, rejection, immune suppression, DLI, 
relapse and death of the patient without any of these events into account as competing 
risks. Non-engraftment did not occur and the cumulative incidence of rejection was very 
low in both groups (cumulative incidence 0.02 and 0.03 in R+D- and R+D+ respectively). The 
cumulative incidence of CMV reactivation did not differ between the R+D- cohort and the 
R+D+ cohort (0.80 versus 0.74 at 1 year after alloSCT, respectively; Gray’s test p=0.91), nor 
did the moment of onset of CMV reactivation after alloSCT (27 days versus 22 days, range 
4-129 vs. 4-271, respectively; p=0.7). In the patients who developed at least one CMV 
reactivation, the mean number of episodes of CMV reactivation was found to be similar 
in both groups (1.4 versus 1.4 CMV reactivations per patient in the R+D- (n=44) and R+D+ 
(n=84) group, respectively). However, the median duration of individual CMV reactivations 
was significantly longer in the R+D- cohort compared to the R+D+ cohort (54 versus 38 days, 
respectively, p=0.048). The cumulative incidence of CMV disease was significantly higher 
in the R+D- cohort compared to the R+D+ cohort (0.14 versus 0.02 at 1 year after alloSCT, 
respectively; Gray’s test p=0.003; table 1). The cumulative incidences of the competing 
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events non-engraftment, rejection, immune suppression, DLI, relapse and death did not 
differ significantly between the two groups. 
Table 1.  Outcome of CMV reactivation and disease in CMV seropositive recipients transplanted with 
a CMV seronegative donor (R+D-) compared to CMV seropositive recipients transplanted with a CMV 
seropositive donor (R+D+) patients up to one year after TCD alloSCT. 
 R+D- R+D+ P
Total number of patients 51 106  
Male/Female 29/22 62/44 NS
Median age (years) 52 51 NS
Myelo-ablative conditioning 25 (49%) 49 (46%) NS
Nonmyelo-ablative conditioning 26 (51%) 57 (54%) NS
Matched related donor 24 (47%) 54 (51%) NS
Matched unrelated donor 27 (53%) 52 (49%) NS
CI Relapse 0.33 0.33 NS
CI Non relapse mortality 0.33 0.18 NS
Onset CMV reactivation (days after TX, range) 27 (4-129) 22 (4-271) NS
Mean number of CMV reactivations 1.4 1.4 NS
Median days of CMV reactivation 54 38 0.048
CI CMV reactivation* 0.80 0.74 NS
CI CMV disease* 0.14 0.02 0.003
CI Systemic immune suppression 0.22 0.23 NS
CI Donor Lymphocyte Infusion 0.24 0.31 NS
* Competing risks analyses taking non-engraftment, rejection, systemic immune suppression, Donor 
Lymphocyte Infusion, relapse and death of the patient without CMV reactivation or CMV disease, 
respectively, into account as competing risks. 
CMV = cytomegalovirus; TCD = T cell depleted; alloSCT = allogeneic stem cell transplantation; NS = 
not significant; CI = cumulative incidence; NRM = non-relapse mortality; CMV reactivation = defined 
by the detection of two consecutive positive CMV DNA loads (>log10 2.7 (>500)/ml copies plasma); 
Days of CMV reactivation = number of days between first positive CMV DNA load (log10>2.7) and first 
negative CMV DNA load (log10<2.7). CMV disease = defined as previously published
8.
Origin of CMV-specific T cells in R+D- patients following TCD alloSCT
Chimerism analysis of circulating CMV-specific T cells in R+D+ patients demonstrated recipient 
and donor origin, ranging from mixed donor/recipient chimerism to full donor chimerism 
or full recipient chimerism (n=6, donor origin in 5/6, data not shown). To investigate the 
presence and origin of anti-viral immunity in R+D- patients, we performed in-depth analyses 
in the cohort of R+D- patients, allowing the discrimination of pre-existing patient-derived 
memory T cells and the possible induction of a primary CMV-directed immune response 
mediated by donor T cells. CMV-specific CD4+ or CD8+ T cells were detected by flow 
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cytometric analysis of expression of the activation marker CD137 upon stimulation of PBMC 
with protein spanning overlapping peptide pools of the CMV-derived proteins pp65 and 
IE111-13. A representative example of CD137 expression on T cells following stimulation with 
CMV-derived pp65 and IE1 protein spanning peptide pools and the corresponding negative 
control without peptide stimulation is shown in Figure 1.
Figure 1. 
Representative example for CD137 expression on unstimulated T cells and following stimulation of PBMC from 
R+D- patient with 10-6 M CMV-derived pp65 and IE1 protein spanning peptide pools for 24 hrs. Left panels show 
CD137 expression of  unstimulated T cells (CD8+ T cells on top panels) and CD4+ T cells on bottom panels) and right 
panels demonstrate CD137 expression of stimulated T cells. Additional staining allowed for a gating strategy for 
bulk sorting of CD16, CD14, CD19 and TCRγδ negative and CD3/CD4/CD137 triple positive and CD3/CD8+/CD137 
triple positive cells.
From the cohort of 51 R+D- patients, 26 patients were excluded from this analysis due to graft 
failure, early disease relapse, therapeutic use of systemic immune suppression, early death 
or lack of cryopreserved samples for analysis. Twenty-five patients were eligible for analysis 
of the presence of CMV-specific CD4+ and/or CD8+ T cells. Samples were cryopreserved as 
part of routine follow-up after alloSCT (irrespective of viral load). In 19/25 (76%) of the 
analyzed patients of the R+D- cohort, visible frequencies of CMV-specific CD4+ and/or CD8+ 
T cells were detected (median of 198 (range 85-361) days after TCD alloSCT). The median 
frequency of CD4 CMV-specific T cells in the CD4 compartment was 3.3%, (range 0.4 to 5.1%; 
n=8) and the median CD8+ CMV-specific T cells in the CD8+ compartment was 6.2 (range 0.4 
to 26.2%; n=18) (Figure 2A). To analyze the origin of these CMV-specific CD4+ and/or CD8+ 
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T cells, chimerism analysis was performed on CMV-specifi c T cells purifi ed from peripheral 
blood of the 19 pati ents with detectable frequencies of circulati ng CMV-specifi c T cells. Of 
these 19 pati ents, 17 had developed a CMV reacti vati on within the fi rst year following TCD 
alloSCT. As expected, in most pati ents the majority of these CMV-specifi c T cells were of 
recipient origin (median 95.5%,range 0-100; n=8) in CMV-specifi c CD4+ T cells versus 100% 
(range 0-100; n=18) in CMV-specifi c CD8+ T cells. However, although in varying frequencies, 
in 10/19 (53%) of pati ents in this R+D- cohort CMV-specifi c CD4 and/or CD8+ T cells of donor 
origin were detected within the fi rst year following TCD alloSCT (Figure 2B). In the 2 pati ents 
without detectable CMV reacti vati on within the fi rst year following TCD alloSCT (marked in 
green in Figure 2), unexpected high numbers of CD4+ and CD8+ CMV-specifi c T cells were 
detected (4.1% and 5.1 in CD4+ compartment and 1.3% and 5.9% in CD8+ compartment in 
both pati ents, respecti vely, analysis on day 85 and day 99). Part of these CMV-specifi c T cells 
was even found to be of donor origin in both pati ents (4% and 5% within CD4+, and 0% and 
9% in CD8+ CMV-specifi c T cells, respecti vely). 
Figure 2. 
Frequencies and origin of CMV-specifi c T cells in CMV seropositi ve pati ents aft er TCD alloSCT with a CMV 
seronegati ve donor (R+D-). (A) Frequencies of CMV-specifi c CD4+ and CD8+ T cells following TCD alloSCT were 
detected by fl ow cytometric analysis of CD137 expression upon sti mulati on with CMV-derived pp65 and IE1 
protein spanning pepti de pools in 19/25 R+D- pati ents. Frequencies of CMV-specifi c T cells in individual pati ents 
are depicted as unique symbols. The symbols in green represent 2 pati ents without detectable CMV reacti vati on 
in the fi rst year following alloSCT. (B) Chimerism analysis of isolated CMV-specifi c CD4+ CD137+ and CD8+ CD137+
T cells. Samples were cryopreserved as part of routi ne follow-up aft er alloSCT (irrespecti ve of viral load). The 
dott ed line represents the detecti on level of 2% in chimerism analysis. Donor origin of CMV-specifi c T cells in 
individual pati ents is depicted as unique symbols. The symbols in green represent 2 pati ents without detectable 
CMV reacti vati on following alloSCT. 
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Discussion
The observed effect of the donor serostatus on the course of CMV reactivations in CMV 
seropositive patients suggests that in vitro TCD by addition of 20 mg of alemtuzumab to the 
bag is not 100% effective in fully depleting grafts from T cells. This importance of donor-
derived CMV-specific memory T cells for sustained control of CMV reactivation has been 
demonstrated in previous studies5. Our clinical data on CMV reactivation are in agreement 
with these studies and suggest that donor-derived CMV-specific memory T cells are able 
to survive profound TCD and provide protective immunity. Indeed, chimerism analysis to 
assess the origin of CMV-specific T cells circulating in R+D+ patients demonstrated that CMV-
specific immunity in these patients can be mediated by CMV-specific T cells of donor origin, 
patient origin or a mixture of these. A recent study16 described loss of expression of the 
Alemtuzumab target antigen CD52 as a possible escape mechanism allowing survival of T 
cells (including virus-specific donor T cells) following alemtuzumab based TCD alloSCT.
The data in our manuscript confirm previous data on the origin of CMV-specific T cells 
following TCD alloSCT in CMV seropositive patients transplanted with a CMV seronegative 
donor (R+D-) and demonstrate that also recipient CMV-specific memory T cells are able to 
survive alemtuzumab based TCD and are the main actors supplying protective immunity to 
prevent CMV disease in these patients5, 17. However, the demonstration of donor-derived 
CMV-specific T cells, as indicator of the development of a donor-derived primary immune 
response after TCD alloSCT in R+D- patients, adds an important novel insight to the findings 
made in previous studies. It may provide a rationale for adoptive cell transfer (ACT) of CMV-
specific T cells from healthy third party donors or autologous CMV-specific T cells harvested 
prior to the transplant for bridging the period of severe T cell deficiency prior to development 
of the primary T cell response18-20. Although these strategies imply a risk of rapid rejection, 
a short-term protective effect may be sufficient to prevent CMV disease while allowing the 
development of donor-derived CMV-specific T cells.
In previous studies, analysis of CMV-specific T cells after alloSCT consistently demonstrated 
mainly cells of patient origin5, 17. A possible explanation for the better detection of donor-
derived CMV-specific T cells in our study may be the utilized methodology for detection and 
purification of virus-specific T cells. Whereas previous studies were focused only on CMV-
specific CD8+ T cells, isolated using peptide/MHC multimers, in our study we analyzed both 
CMV-specific CD4+ and CD8+ T cells, isolated based on expression of the activation marker 
CD137 upon stimulation with CMV-derived pp65 and IE1 protein spanning peptides, which 
allows the analysis of a broader repertoire of CMV-specific T cells11-13. 
In conclusion, we demonstrated a significantly increased duration of CMV reactivation and a 
significantly increased incidence of CMV disease in CMV seropositive patients transplanted 
with a CMV seronegative donor (R+D-) compared to CMV seropositive patients transplanted 
with a CMV seropositive donor (R+D+) following TCD alloSCT, illustrating that despite 
alemtuzumab-based TCD, memory T cells can be transferred from the graft to provide 
protective anti-viral immunity. Furthermore, we demonstrated that protective immunity 
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against CMV was predominantly mediated by T cells from recipient origin in patients 
transplanted with a CMV seronegative donor (R+D-) within the first year after TCD alloSCT, 
but that a primary donor-derived CMV-specific T cell response was frequently observed 
within the first year following TCD alloSCT, even as early as 3 months following TCD alloSCT. 
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Abstract
To treat patients with refractory cytomegalovirus (CMV) reactivation after allogeneic stem 
cell transplantation, a phase I/II clinical study on adoptive transfer of in vitro-generated 
donor-derived or patient-derived CMV pp65-specific CD8+ T cell lines was performed. 
Peripheral blood mononuclear cells from CMV seropositive donors or patients were 
stimulated with HLA-A*0201-restricted and/ or HLA-B*0702-restricted CMV pp65 peptides 
(NLV/TPR) and 1 day after stimulation interferon-γ)-producing cells were enriched using the 
CliniMACS Cytokine Capture System (interferon-γ), and cultured with autologous feeders 
and low-dose interleukin-2. After 7–14 days of culture, quality controls were performed 
and the CMV-specific T cell lines were administered or cryopreserved. The T cell lines 
generated contained 0.6–17 x 106 cells, comprising 54%–96% CMV pp65-specific CD8+ 
T cells, and showed CMV-specific lysis of target cells. Fifteen CMV-specific T cell lines were 
generated of which 8 were administered to patients with refractory CMV reactivation. After 
administration, no acute adverse events and no graft versus host disease were observed and 
CMV load disappeared. In several patients, a direct relation between administration of the 
T cell line and the in vivo appearance of CMV pp65-specific T cells could be documented. In 
conclusion, administration of CMV pp65-specific CD8+  T cell lines was found to be feasible 
and safe, and enduring efficacy of administered CMV pp65-specific CD8+  T cell lines could 
be demonstrated. 
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Introduction
Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for a 
variety of hematological malignancies and inherited hematopoietic disorders. A significant 
complication of alloSCT is the development of severe graft versus host disease (GvHD), 
which can be treated by immune suppression. Depletion of T cells from the stem cell graft 
can be performed to prevent the development of severe GvHD. However, T cell depletion 
and immune suppression significantly delay immune reconstitution in patients after 
alloSCT, which is associated with an increased risk of opportunistic infections including 
cytomegalovirus (CMV) infection.1-3 Reactivation of CMV can cause serious morbidity and 
mortality during the prolonged period of immune deficiency after alloSCT, which is also 
illustrated by increased CMV-related morbidity in patients receiving a graft from a CMV 
seronegative donor.4-5 The availability of antiviral agents like ganciclovir and foscarnet 
has contributed to a significant reduction of CMV-related morbidity and mortality after 
alloSCT. However, if appropriate T cell responses against CMV do not develop after alloSCT, 
subsequent viral reactivations and refractory disease are commonly observed. Reconstitution 
of the CMV-specific T cell repertoire directed against immunodominant proteins in the first 
year after alloSCT has been demonstrated to confer sustained protection from CMV disease. 
Furthermore, for the long-term protection against CMV, the development of CMV-specific 
T cell immunity has been found to be essential.6-9 Therefore, adoptive transfer of donor-
derived virus-specific T cells is an attractive strategy for treatment and prevention of viral 
disease in alloSCT recipients. Clinical studies have demonstrated that the adoptive transfer 
of donor-derived CMV-specific memory T cells can be a safe and effective treatment for 
patients with refractory CMV reactivation.10-18
In most clinical studies, CMV-specific CD8+ T cell lines were generated by repetitive 
stimulation of the T cells in vitro for several weeks to obtain highly pure T cell lines to 
minimize the risk of the induction of GvHD.11,13-18 However, isolation of CMV-specific T 
cells from peripheral blood also allows the generation of highly specific T cell lines without 
prolonged culture and repetitive stimulation. As it has been demonstrated that adoptive 
transfer of interferon-γ (IFNγ)-producing memory T cells can provide long-lived functional 
memory T cell reconstitution and that the presence of IFNγ-producing CMV-specific T cells 
is associated with protection from CMV reactivation, isolation of CMV-specific memory 
CD8+ T cells based on their IFNγ production is an attractive strategy for generating effective 
CMV-specific CD8+ T cell lines.4,6,8,9,12,13,19 Although clinical studies have shown that adoptive 
transfer of CMV-specific T cells is safe and effective, in these studies the clinical effect could 
not always be directly correlated to the infusion of CMV-specific CD8+ T cells. 
In this study, a phase I/II clinical protocol for the adoptive transfer of donor or patient-
derived CMV pp65- specific CD8+ T cell lines for patients with refractory CMV reactivation 
after alloSCT was conducted. CMV- specific T cells were isolated using an IFNγ-based isolation 
technique and cultured for 1–2 weeks. Six patients with CMV reactivation failing antiviral 
therapy were treated with these CMV pp65-specific CD8+ T cell lines. In all the 6 patients, 
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CMV DNA load turned negative and CMV- specific T cells could be detected in the peripheral 
blood. In 2 patients, a direct relation was demonstrated between the administration of 
CMV-specific T cells, the appearance of CMV-specific T cells in the peripheral blood, and the 
clearance of CMV reactivation. 
Materials and methods
Study design 
Adult and pediatric patients with refractory CMV reactivation after HLA-matched alloSCT 
were eligible. Patients were weekly monitored for CMV reactivation after receiving a stem 
cell transplant by measuring CMV DNA copy numbers with quantitative polymerase chain 
reaction. Refractory CMV reactivation was defined as persisting CMV viremia for >2 weeks 
while receiving pharmacotherapy or as early relapse (within 2 wk) after therapy. As only 
peptides binding in HLA-A*0201 or HLA-B*0702 were available for clinical use and therefore 
only T cells specific for these epitopes could be isolated, HLA-A*0201 and/or HLA-B*0702+ 
patients were eligible. In case of a CMV seropositive donor, a donor-derived T cell line 
was generated. When the donor was CMV seronegative, a patient-derived T cell line was 
generated from cryopreserved peripheral blood mononuclear cells (PBMNCs) harvested 
before transplantation. When the CMV pp65-specific T cell line met the release criteria and 
CMV was still detectable, the T cell line was administered to the patient. Antiviral treatment 
could be continued conform standard protocol. The procedure was repeated in case of stable 
or progressive CMV reactivation and no severe toxicity. Patients or their parents (in case of 
children) gave written informed consent, and the study was performed in accordance with 
the regulations of the institutional ethics committee. 
The aim of this phase I/II study was to investigate the feasibility of generating CMV-specific 
T cell lines for clinical application, of which at least half should be administrated. Endpoints 
of the study were feasibility and toxicity of the treatment. Feasibility was defined as ≥80% 
success rate in generating a T cell line and toxicity was defined as ≥30% of patients developing 
GvHD after administration of the T cell line. In addition, the efficacy of the treatment was 
analyzed; however, this was not a primary endpoint. 
Collection of peripheral blood cells 
After informed consent, at least 2 x 109 PBMNCs were harvested by leukapheresis from 
each donor or patient. Red blood cells were lysed using an NH4Cl (8.4g/L) and KHCO3 (1 
g/L) buffer (pH = 7.4) (LUMC Pharmacy, Leiden, The Netherlands). PBMNC were directly 
used or cryopreserved in the vapor phase of liquid nitrogen until further use. Cells were 
cryopreserved in IMDM (Lonza, Basel, Switzerland) containing 20 g/L human albumin (CeAlb; 
Sanquin, Amsterdam, The Netherlands) and 10% dimethyl sulphoxide (LUMC Pharmacy). 
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Generation and administration of clinical grade CMV-specific CD8+ T cell lines 
PBMNC were resuspended in culture medium consisting of IMDM supplemented with 
3mmol/L L-glutamine (Lonza) and 100 U/mL penicillin and 100 mg/mL streptomycin (Lonza) 
plus 10% heat-inactivated pooled prescreened AB serum from healthy blood bank donors 
(Sanquin). Cells were cultured at a cell concentration of 10 x 10
6 cells/mL and 1 mg/mL 
of peptide was added. Peptides used were the HLA- A*0201-binding peptide NLVPMVATV 
(NLV) and the HLA-B*0702-binding peptide TPRVTGGGAM (TPR) both purchased from 
Bachem (Bubendorf, Switzerland). 
After overnight stimulation, IFNγ-secreting cells were isolated using the CliniMACS Cytokine 
Capture System (IFNγ) (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
manufacturer’s instructions. After washing, the positive fraction was resuspended in culture 
medium containing 10 IU/mL interleukin (IL)-2 (Proleukin; Novartis Pharma B.V., Arnhem, The 
Netherlands). Cells were cultured at a 1:10 ratio with 30 Gy-irradiated feeder cells, which were 
obtained from the negative fraction after isolation. Cultures were refreshed every 3–4 days, 
and after 7–14 days the T cell lines were analyzed. Cultures were evaluated for the presence of 
CMV NLV-specific and/or TPR-specific CD8+ T cells by tetramer staining, and quality control was 
performed. Quality assurance specifications included: (1) no microbiological contamination; 
(2) confirmation of the origin of the material (donor or patient); (3) the presence of minimally 
50% of CMV-specific CD8+ T cells as measured by tetramer staining; and (4) the presence of 
maximally 10% CD19+ B cells. Functionality was tested in a 51Cr release assay and defined as 
minimally 20% lysis of positive target cells and maximally 10% lysis of negative target cells. 
When released for administration, the CMV-specific T cell lines were resuspended in 100 mL 
NaCl 0.9% (LUMC Pharmacy) supplemented with 2% human albumin (Sanquin) in a 500 mL 
cryocyte freezing container (Baxter, Deerfield, IL). 
Phenotypic analysis 
To determine the composition and phenotype of the starting material, the fractions after 
isolation, the T cell line, and the PBMC fractions from the peripheral blood cells were stained 
using fluorescein isothiocyanate-labeled TCRab, CD14, CD4, HLA-DR, CD27 (BD Biosciences, 
San Jose, CA) and CD197 (R&D systems, Minneapolis, MN) antibodies, phycoerythrin-labeled 
TCRgd, CD56, CD25 (BD) and IFNγ (Miltenyi Biotec) antibodies, PerCP-labeled CD8+, CD3 
(BD) and CD45RO (Invitrogen, Frederick, MD) antibodies, allophycocyanin (APC)-labeled 
CD19, CD33, CD45RA, CD28 (BD), and CD4 (Beckman Coulter, Fullerton, CA) antibodies, 
and PE-labeled or APC-labeled tetramers of the NLVPMVATV peptide bound to HLA-A*0201 
or the TPRVTGGGAM peptide bound to HLA-B*0702, which were prepared as described 
previously.20 After labeling, cells were analyzed on a FACSCalibur (BD). 
Cytotoxicity assay 
To determine the cytotoxicity of the T cell lines, standard 51Cr release assays were performed 
as described previously.21 Target cells (donor and patient phytohemagglutinin (PHA) blasts, 
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HLA-A*0201 and HLA-B*0702+ EBV-LCL (JY), or pp65-transduced JY (JY-pp65)22) were loaded 
with 100 mCi of Na51Cr2O4 (Amersham, Roosendaal, The Netherlands) and when necessary 
with 1mM of peptide (NLV or TPR) for 1 hour. Effector/target ratios ranged from 30:1 to 1:1 
and after 4 hours of incubation 51Cr release was determined. 
Ex vivo analysis of cytokine production of CMV-specific T cells 
After thawing, PBMNC from the patients were resuspended in culture medium and with 10-6 
M NLV or TPR peptides for 5 hours at 371C and 5% CO2. After 1 hour of peptide stimulation, 
10mg/mL of brefeldin A (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added for the 
remaining 4 hours of incubation. After stimulation, cell-surface staining with monoclonal 
antibodies was performed, followed by intracellular staining as described previously.23 Cells 
were stained using fluorescein isothiocyanate-labeled IFNγ (BD), PE-labeled tumor necrosis 
factor (TNFα) (BD), PerCP-labeled CD4 and CD8+ (BD), and APC-labeled IL-2 (BD). 
Ex vivo identification of CMV-specific CD8+ T cells 
To identify donor or recipient origin of CMV-specific T cells reconstituting in peripheral blood 
after infusion of the CMV pp65-specific CD8+ T cell lines, PBMNC from the patient were 
stained using HLA class I tetramers specific for NLV or TPR. Subsequently, the tetramer+ CD8+ 
T cells were selected by flow cytometric sorting using a FACSDiva and Cellquest software 
(BD). The DNA profile of the sorted cells was established by chimerism analysis based on 
short tandem repeats polymorphism as previously described.24
Results
Generation of clinical grade CMV-specific CD8+ T cell lines 
A total of 12 donor-derived and 3 patient-derived CMV-specific T cell lines specific for the 
HLA-A*0201-restricted NLV epitope and/or for the HLA-B*0702-restricted TPR epitope 
were generated for patients failing antiviral therapy after alloSCT. Donor-derived T cell lines 
were generated when the donor was CMV seropositive, whereas patient-derived T cell lines 
were generated when the donor was CMV seronegative and the patient CMV seropositive. 
Figure 1 shows the data of a representative donor-derived (Figs. 1A–D) and patient-derived 
(Figs. 1E–H) CMV-specific T cell line. The frequencies of the NLV-specific T cells in the PBMNC 
starting material were 0.4% in the donor (Figure 1A) and 1.45% in the patient (Figure 1E). 
After overnight stimulation with the HLA-A*0201-binding NLV peptide, IFNγ-producing cells 
were isolated using the CliniMACS Cytokine Capture System (IFNγ). The positive fraction 
contained between 20% and 25% IFNγ
+ CD8
+ T cells within the lymphocyte gate (Figure 1B, 
F), other T cells present in the positive fraction were CD4+ T cells and IFNγ-negative CD8+ 
T cells. After 10 days and 7 days of culture, respectively (Figs. 1C, G), specific proliferation 
of the NLV-specific CD8+ T cells resulted in a donor-derived T cell line containing 83% NLV-
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specific CD8+ T cells and in a patient-derived T cell line containing 66% NLV-specific CD8+ 
T cells. Less than 1% of CD19+ B cells were detected in the T cell lines (data not shown). 
As is shown in Figures 1D, H both T cell lines showed reactivity against NLV-loaded target 
cells and no reactivity against donor or patient cells. Furthermore, both T cell lines also 
showed recognition of endogenous presented antigen using CMV pp65-transduced EBV-LCL 
(JY-pp65). 
Table 1 shows the results of all the CMV-specific T cell lines generated. Frequencies of NLV-
specific and/or TPR- specific CD8+ T cells in the donor or patient starting material used for 
the generation of the T cell lines ranged from 0.02% to 1.45% of total PBMNC. Cell numbers 
obtained directly after isolation ranged from 0.25 to 14.4 x 106 cells and contained between 
3% and 45% IFNγ+ CD8+ T cells within the lymphocyte gate. Total cell numbers obtained after 
culture ranged from 0.6–17.1 x 106 cells. During culture, no increase in total cell numbers 
was observed, but further enrichment of CMV-specific T cells was observed resulting in 
T cell lines containing 54%–96% NLV-specific and/or TPR-specific T cells. 
All donor-derived and patient-derived CMV-specific T cell lines generated met the quality 
control criteria. No microbiological contamination was detected in any of the T cell lines, and 
chimerism analysis showed the correct origin of the material. As is shown in Table 1, all T cell 
lines contained >50% of NLV-specific and/or TPR-specific T cells and showed recognition of 




Compositi on and functi onality of donor-derived (A-D) and pati ent-derived (E-H) CMV-specifi c T cell lines. (A, E) the 
percentage of CMV NLV (A) and CMV TPR (E) -specifi c T cells in the starti ng material (day 0); (B, F) the percentage 
of IFN positi ve cells in the positi ve fracti on direct aft er isolati on; (C, G) the percentage of CMV NLV (C) or CMV TPR 
(G) in the T cell line aft er culture (day 7); (D, H) functi onality of the T cell lines in a 51Cr release assay. Dot plots are 
shown and events shown are gated on the lymphocyte gate and PI-negati ve gate. Percentage lysis aft er 4 hours in a 
51Cr release assay at an E:T rati o of 3:1 is depicted. JY = EBV-LCL; JY-pp65 = CMV pp65 transduced JY.













































































































































































































































































































































































































































































































































Administration of CMV-specific CD8+ T cell lines 
In a phase I/II clinical study, the toxicity and the potential antiviral effect of treatment with 
CMV pp65- specific T cell lines for refractory CMV reactivation after alloSCT was investigated. 
Eight of the 15 T cell lines generated were administrated. Six patients with refractory CMV 
reactivation after alloSCT received donor-derived CMV pp65-specific T cell line(s). Four 
patients (patient 2, 3, 4, and 14) received 1 CMV pp65-specific T cell line and 2 patients 
(patient 1 and 9) received 2 CMV pp65-specific T cell lines. The other T cell lines generated 
were not administrated, as patients were CMV load negative (n = 4), had relapsing malignant 
disease (n = 1), or deceased because of CMV disease (n = 2) at the time the production of the 
CMV pp65-specific T cell line was completed. 
Despite prior treatment with antiviral agents, all 6 patients who received a CMV pp65-
specific T cell line had ongoing positive CMV DNA loads (log 2.5–log 3.2) at the time of 
administration of the CMV-specific T cell lines. The patients received a total cell dose ranging 
from 0.6 to 7.5 x 106 cells (analogous to 0.9 x 104–3.1 x 105 T cells/kg), corresponding to 
0.4–6.1 x 106 NLV-specific and/or TPR- specific T cells. In 5 out of 6 patients, antiviral therapy 
was discontinued before infusion of the CMV-specific T cell line. Patient 9 was treated until 2 
weeks after infusion of the second CMV-specific T cell line. None of the 6 patients developed 
GvHD or any other complications during infusion of the T cell lines, and all patients cleared 
CMV reactivation within weeks after administration of the CMV pp65-specific T cell line. 
Reconstitution of CMV-specific T cells after administration of the CMV-specific CD8+ T cell 
lines 
In all patients CMV-specific, NLV-specific, and/or TPR-specific CD8+ T cells could be detected 
after administration of the T cell lines. To determine a possible correlation between the 
infusion of the CMV-specific T cell lines and the appearance of CMV-specific T cells in 
peripheral blood of the patients, the presence of CMV- specific T cells was analyzed at 
different time points before and after administration of the T cell lines. Before infusion of 
the CMV-specific T cell lines in 4 of the 6 patients, CMV pp65-specific T cells with the same 
specificity as the T cell line could already be detected in the peripheral blood. In 3 of these 
patients, a rise in CMV-specific T cells in the peripheral blood was observed after infusion 
of the T cell line. In the other patient, the numbers of CMV-specific T cells was stably high 
after infusion. In 2 of the 6 patients (patient 4 and 9), no CMV-specific T cells were detected 
before infusion of the T cell line, and a direct relation was observed between infusion of the 
CMV pp65-specific T cell line, the appearance of CMV pp65-specific T cells in the peripheral 
blood. 
From 3 patients showing CMV-specific T cells already before infusion, we compared the 
phenotype and functionality of the CMV-specific T cells in peripheral blood before and after 
infusion. As illustrated in Figure 2A, both before and after infusion the CMV-specific T cells 
in peripheral blood of the patients predominantly produced IFNγ and TNFα after antigenic 
stimulation; only a minority produced IL-2 after restimulation with the specific peptide. Both 
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eff ector memory (CD45RO+, CD45RA-, CD27-, CD28-) and eff ector (CD45RO-, CD45RA+, CD27-, 
CD28-) CMV-specifi c T cells were similarly found before and aft er infusion (data not shown). 
In additi on, the tetramer-binding capacity of the CMV pp65 NLV-specifi c and/or TPR-specifi c 
T cells was not diff erent before and aft er adopti ve transfer, as is shown in Figure 2B. Thus, 
the contributi on of the infused CMV-specifi c T cells to the clearance of CMV could not be 
determined in these pati ents. 
Figure 2. 
A, Cytokine producti on aft er anti gen-specifi c resti mulati on of cytomegalovirus (CMV)-specifi c T cells in PBMNC 
from pati ent 1 to 3 obtained prior and at diff erent ti me points aft er infusion of the CMV-specifi c T cell line (depicted 
on the x-ax). The percentage of positi ve cells within the peripheral blood mononuclear cells (PBMNC) populati on 
is shown. Black bars represent tetramer positi ve cells; dashed bars represent interferon (IFN)γ-producing T cells; 
white bars represent TNFα-producing T cells; and gray bars represent interleukin-2- producing T cells. B, Tetramer-
binding capacity of CMV TPR-specifi c T cells of pati ents 1, 2, and 3 in the peripheral blood before and aft er infusion 
of the CMV-specifi c T cell line. The mean fl uorescence intensity of the tetramer staining and the diluti on of the 
tetramer is depicted. Solid lines are before infusion and the broken lines are aft er infusion of the T cell lines; n, fi rst 
infusion; , second infusion. 
Pati ent 4 developed CMV reacti vati on within the fi rst month aft er alloSCT, which was 
treated with anti viral drugs (Figure 3). The rise in CMV load coincided with a rise in CMV 
TPR-specifi c T cells. Four months aft er alloSCT, the pati ent received unmanipulated donor 
lymphocyte infusion for the treatment of progressive disease, and 6 months aft er alloSCT 
the pati ent developed GvHD for which he was treated. The CMV-specifi c T cells disappeared, 
and the pati ent developed refractory CMV reacti vati on. A CMV TPR-specifi c T cell line was 
administered 8 months aft er alloSCT (7.6 x 104 T cells/kg) and within 2 weeks CMV TPR-
specifi c CD8
+ 
T cells appeared in peripheral blood, and the CMV load turned negati ve and 
remained negati ve (follow-up >4 y). To asses why no persistence of the CMV TPR-specifi c 
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T cells from the fi rst peak response was observed and to determine whether the CMV TPR-
specifi c T cells appearing in the second peak response were the same as the T cells in the 
fi rst peak response, the pati ent or donor origin of the CMV-specifi c T cells from both peak 
responses (day 33 and day 289 aft er alloSCT, respecti vely) was determined. The CMV TPR-
specifi c T cells were isolated from both peak responses by fl uorescence-acti vated cell sorti ng, 
and DNA profi ling showed that the CMV-specifi c T cells during the fi rst response (day 33) 
were of pati ent origin, and that the CMV-specifi c T cells that appeared aft er administrati on 
of the T cell line (day 289) were completely donor-derived, illustrati ng the correlati on 
between the infusion of the CMV TPR-specifi c T cell line and the in vivo appearance of the 
donor-derived CMV TPR-specifi c T cells. Ex vivo sti mulati on of PBMNC isolated from the 
pati ent aft er adopti ve transfer of the T cell line with the specifi c CMV pepti de illustrated 
high IFNγ and TNFα producti on by the CMV-specifi c T cells. 
Figure 3 
CMV pp65-specifi c T cells in peripheral blood from pati ent 4 in relati on to the CMV DNA load in peripheral blood. 
CMV-specifi c T cells (CD8+/tetramer+) are expressed as absolute numbers per liter in peripheral blood (left  axis). p, 
CMV TPR-specifi c T cells; ¿, CMV NLV-specifi c T cells; l, CMV RPH-specifi c T cells. CMV DNA load (n) is depicted 
as log CMV DNA load in peripheral blood (right axis).The lower level of detecti on is log 2.5. GCV = ganciclovir; GvHD 
= graft  versus host disease.
Pati ent 9 developed refractory CMV reacti vati on post- alloSCT in the absence of CMV-
specifi c T cells (Figure 4). A CMV NLV-specifi c T cell line was administrated at day 72 (1 x 
105 T cells/kg), but no CMV NLV-specifi c T cells appeared in peripheral blood and the CMV 
load remained positi ve. The quality of the T cells in this T cell line was poor because of 
poor quality, as refl ected by the low cell viability, of the starti ng material, explaining the 
absence of in vivo persistence of the infused T cells. A second CMV NLV-specifi c T cell line 
was generated from new starti ng material, which was administered at day 116 aft er alloSCT 
(3.1 x 105 T cells/kg). Aft er 2 weeks, CMV NLV-specifi c T cells appeared in peripheral blood, 
which was coincided with a disappearance of CMV DNA load (follow-up >2 y). 
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Figure 4. 
CMV pp65 (NLV)-specifi c T cells in peripheral blood from pati ent 9 in relati on to the CMV DNA load in peripheral 
blood. CMV-specifi c T cells (p, CD8+/CMV NLV-tetramer+) are expressed as absolute numbers per liter in peripheral 
blood (left  axis) and CMV DNA load (n) is depicted as log CMV DNA load in peripheral blood (right axis). The lower 
level of detecti on is log 2.5. 
Discussion 
In this study, a phase I/II clinical protocol for the adopti ve transfer of donor-derived or 
pati ent-derived CMV pp65-specifi c CD8+ T cell lines for pati ents with refractory CMV 
reacti vati on aft er alloSCT was conducted. No toxicity was observed aft er administrati on 
of the T cell lines, and all pati ents who received a CMV-specifi c T cell line cleared CMV 
reacti vati on. A direct relati on between administrati on of donor-derived CMV pp65-specifi c 
T cell lines and clinical eff ect could be demonstrated in 2 pati ents. Limited culture ti me in 
vitro using low doses of IL-2 apparently does not impair the ability of T cells to expand in 
vivo and to be eff ecti ve. This study illustrates that clinical effi  cacy of adopti vely transferred 
T cells can be achieved with low cell numbers. 
Both donor-derived and pati ent-derived CMV pp65-specifi c CD8+ T cell lines could be 
reproducibly generated, even when frequencies of CMV pp65-specifi c CD8+ T cells were 
very low (< 0.01%). Directly aft er isolati on, the purity of the positi ve fracti on (percentage 
CD8+ / IFNγ+ T cells) appeared to be low for some isolati on, which was also observed in 
other studies using the IFNγ-based isolati on method.12,26 This can be due to nonspecifi c co-
isolati on of other cells, what preponderates especially in those cases where the starti ng 
frequency of CMV-specifi c T cells is very low. Preferenti al expansion of the CMV-specifi c 
CD8+ T cells during the subsequent culture period led to T cell lines with a high purity of 
CMV-specifi c CD8+ T cells, reducing the risk of the inducti on of GvHD aft er administrati on. 
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In the current study, 6 patients with refractory CMV reactivation received 1 or 2 donor-
derived CMV-specific CD8+ T cell line(s). Administration was safe, no toxicity was observed 
after infusion, and all patients cleared CMV reactivation after treatment with the CMV-
specific CD8+ T cell lines. In 4 patients, T cells with the same reactivity as the T cell line 
could already be detected in peripheral blood of the patients before administration of the 
T cell lines. Although it is likely that the infused T cells contributed to the clearance of CMV 
reactivation in these patients, direct evidence for this cannot be provided. No differences 
in the phenotype, cytokine profile, or tetramer-binding capacity of the NLV-specific or 
TPR-specific T cells in the peripheral blood before and after adoptive transfer could be 
determined. 
However, in 2 of the 6 patients a direct time correlation between the administration of 
donor-derived CMV pp65-specific T cell lines, the appearance of CMV-specific CD8+ T cells, 
and clearance of CMV reactivation was demonstrated. In these patients, no CMV-specific 
T cells were present before the administration of the T cell lines, and within 2 weeks after 
administration of the T cell line increasing numbers of CMV NLV-specific or CMV TPR- specific 
CD8+ T cells could be detected in peripheral blood of the patients, illustrating persistence 
and in vivo proliferation of the infused T cells. The appearance of the CMV-specific CD8+ T 
cells coincided with the clearance of CMV reactivation. Although CMV-specific CD8+ T cells 
have been detected in peripheral blood after the adoptive transfer of CD8+ T cell lines in 
previous studies, this study shows a direct correlation between the administration of a CD8+ 
T cell line and the clinical effect.10,11,13-18
Two patients eligible for the study deceased because of CMV disease. CMV-specific T cell 
lines could be generated for these patients, however, both patients deceased before the 
T cell line could be administered. Decreasing the time interval between the appearance of 
the clinical need and administration of the T cell product by direct administration of the 
isolated CMV pp65-specific T cells may improve the efficacy, although in vivo proliferation is 
also likely to be necessary in these patients to allow a clinical effect. It has been shown that 
direct administration of CMV-specific T cells isolated based on their IFNγ production can be 
effective and does not lead to GvHD induction12
In the current protocol, T cell lines could only be generated for patients who were HLA-A*0201 
and HLA- B*0702+. To increase the potential clinical use of CMV- specific T cells, a CMV pp65 
whole protein overlapping 15-mer (11-mer overlapping) peptide pool may be used for the 
generation of CMV pp65-specific T cell lines. It has been shown by us and others that using 
this peptide pool CMV pp65-specific T cells can be isolated irrespective of HLA restriction of 
the donor and patient.23,27-29 Furthermore, using these peptide pools also CMV-specific CD4+ 
T cells will be isolated and studies have indicated that adoptively transferred CMV-specific 
CD4+ T cells may promote development of a CMV-specific CD8+ T cell response in vivo and 
that adoptively transferred CMV-specific CD8+ T cells may show better persistence in the 
presence of CMV-specific CD4+T cells.12,13,15-18,27 
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In conclusion, we have shown that the clinical grade generation of donor-derived and 
patient-derived CMV pp65-specific CD8+ T cell lines is feasible, and that administration of 
CMV-specific T cell lines to patients with refractory CMV reactivation after alloSCT was safe. 
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Abstract
To study the role of CD8+ T cells in the control of varicella zoster virus (VZV) reactivation, we 
developed multimeric major histocompatibility complexes to identify VZV-specific CD8+ T 
cells. Potential HLA-A2 binding peptides from the putative immediate-early 62 protein (IE62) 
of VZV were tested for binding, and peptides with sufficient binding capacity were used 
to generate pentamers. Patients with VZV reactivation following stem cell transplantation 
were screened with these pentamers, leading to the identification of the first validated class 
I-restricted epitope of VZV. In 42% of HLA-A2 patients following VZV reactivation, these 
IE62-ALW-A2 T cells could be detected ex vivo. 
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Varicella zoster virus (VZV) infects about 95% of the population, persists throughout life, 
and may lead to herpes zoster when the virus reactivates. After T cell depleted allogeneic 
stem cell transplantation (TCD alloSCT), reactivation of the virus leads to considerable 
morbidity10. Primary infection elicits both humoral and cellular responses, but cellular 
immunity is essential for preventing herpes zoster. The VZV genome comprises more than 
70 unique open reading frames that encode proteins that are coordinately expressed during 
replication. The product of open reading frame 62, the immediate-early 62 (IE62) protein, 
is required for the initiation of VZV replication9 and is expressed at high levels before viral 
replication has occurred8. Previous research has demonstrated that IE62-specific T cells 
were detected after primary VZV infection and in immune subjects2, 4. In addition, T cells 
recognizing various other IE proteins and glycoproteins of VZV, as demonstrated by gamma 
interferon (IFN-γ) production upon stimulation with peptides or lysate derived from these 
proteins, have been described1, 6, 13. The VZV- specific memory T cells found in these studies 
were predominantly CD4 T cells, while no VZV-specific CD8+ T cells were demonstrated 
without prior in vitro expansion, possibly due to the low frequency of VZV-specific CD8+ 
T cells or to the low sensitivity of the screening methods used to detect CD8+ T cells by 
IFN- γ production upon stimulation. Frey et al. described CD8+ epitopes of IE62 detected 
following in vitro restimulation. However, the HLA restriction and specificity of these T cells 
were not confirmed4. Due to the lack of validated VZV-derived immunodominant peptides 
for major histocompatibility complex (MHC) class I, the analysis of VZV-specific CD8+ T cell 
responses is hampered14. To be able to analyze the role of CD8+ T cells in VZV reactivation, 
we therefore set out to identify epitopes for VZV by using VZV-IE62-specific MHC class I 
peptide complexes. 
The predictive algorithms BIMAS11 and SYFPEITHI12 were used to select potential HLA-A2 
binding peptides from the IE62 protein. Peptides with a score of ≥ 3 (BIMAS) or ≥ 20 
(SYFPEITHI) were considered to have potentially significant binding affinity. The 81 resulting 
9-mer peptides were synthesized and tested for binding affinity with the REVEAL MHC-
peptide binding assay (ProImmune, Oxford, United Kingdom). HLA-A2 binding affinity was 
determined by the ability of the peptides to stabilize the HLA-peptide complex. Based on 
the binding affinity measurements, 34 high- to medium-affinity HLA-A2 binding peptides 
were selected and used to generate ProVE MHC pentamers (ProImmune, Ox- ford, United 
Kingdom). 
To enable screening of this large number of pentamers, the pentamers were divided into 
five pools, each containing six or seven pentamers. In the initial screening with pooled 
pentamers, four HLA-A2-positive patients were screened after a clinical diagnosis of VZV 
reactivation after TCD alloSCT. The presence of viral DNA in plasma at the time of clinical 
observations of VZV reactivation was confirmed by real-time PCR on plasma samples as 
previously described7. After informed consent was obtained, peripheral blood mononuclear 
cells (PBMCs) were cryopreserved and thawed and 0.5 x 106 cells were incubated with 
pentamers at a concentration of 0.03 mg/ml for 10 min at room temperature in RPMI 
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medium supplemented with 2% fetal bovine serum. After the cells were washed twice, 8 
μl of FluoroTag-phycoerythrin (PE) was added for 20 min of incubation at 4°C and the cells 
were counterstained with CD4, CD40, and CD19- fluorescein isothiocyanate (FITC). Flow 
cytometric analysis was performed on a FACScalibur fluorescence-activated cell sorter (FACS; 
Becton-Dickinson [BD], San Jose, CA). In one of four patients, pentamer pool 6, containing 
pentamers 61, 62, 64, 65, 66, and 67, was positive (0.06% of CD8+ T cells); no other positive 
signals were observed. Staining with the individual pentamers revealed that pentamer 66, 
containing the epitope ALWALPHAA derived from the IE62 protein of VZV (IE62-ALW-A2) 
was responsible for the positive signal (0.06% of CD8+ T cells, Figure 1B). 
To confirm the specificity of the IE62-ALW-A2-specific T cells, the pentamer-positive T cells 
were sorted into a single cell per well with a FACSDiva (BD) and expanded as previously 
described5. The expanded T cell clones were labeled specifically with the IE62-ALW-A2 PE-
conjugated tetramer that was constructed as previously described3 (Figure 1D), and Vβ 
analysis with the T cell receptor Vβ repertoire kit (BD) showed that at least two different 
T cell clones were isolated, demonstrating the oligoclonal origin of IE62-ALW-A2-positive 
T cells (Figure 1E and F). 
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Figure 1.Screening with Pentamers containing VZV derived immunogenic epitopes. 
PBMCs of a patient after VZV reactivation following a TCD alloSCT were incubated with Pentamers and then stained 
with Fluorotag-PE to detect the Pentamer positive cells (A and B), and counterstained with CD4-, CD40- and 
CD19FITC. Pentamer staining is shown of the CD4, CD40, CD19 negative cells. (A) PBMCs stained with Pentamer 67 
containing the epitope ALPHAAAAV, showing no specific staining. (B) PBMCs stained with Pentamer 66 containing 
the epitope ALWALPHAA, showing specific staining. IE62-ALW-A2-specific T cell clones were sorted single cell per 
well and expanded non-specifically. The clones were stained with an irrelevant tetramer (C) and the IE62-ALW-A2 
tetramer (D) in combination with CD8+ FITC. Clones 1 and 2 were stained with Vbeta kit (BD) to demonstrate that 
clone 1 (E) and clone 2 (F) express different TCR. The results demonstrate that we have isolated different T cell 
clones that specifically stain with the IE62-ALW-A2 tetramer. 
To assess the cytolytic capacity of IE62-ALW-A2 T cells, chromium release assays were 
performed as described earlier5. 51Cr-labeled Epstein-Barr virus (EBV) lymphoblastoid cell 
lines (LCLs) loaded with the IE62-ALW peptide were incubated with IE62-ALW-A2 T cells for 
4 h. As demonstrated in Figure 2A, HLA-A2-positive EBV LCLs loaded with the IE62-ALW-A2 
peptide were lysed by both T cell clones, whereas unloaded EBV LCLs were not lysed. To 
determine the avidity of the T cell clones, the IE62- ALW-A2 peptide was titrated on EBV 
LCLs, and after 24 h of coculture, supernatants were harvested and used to determine the 
IFN-γ production of the stimulated T cells by standard enzyme-linked immunosorbent assay. 
Half-maximum IFN-γ production of the T cell clones was observed when the stimulator 
cells were loaded with 10 ng/ml peptide, indicative of high-avidity T cell clones (Figure 2B). 
To determine whether the T cells recognized cells endogenously expressing the IE-62- 
encoding gene, COS-A2 cells were transfected with Lipofectamine (Invitrogen, Carlsbad, 
CA) by using pcDNA vectors coding for different VZV genes, which were kindly provided 
by E. Wiertz (Department of Medical Microbiology, Leiden University Medical Center, 
Leiden, The Netherlands). The transfected COS-A2 cells were used 24 h after transfection 
90 CHAPTER 6
as stimulator cells in this assay. After 24 h of coculture, supernatants were harvested and 
used to determine the IFN-γ production of the stimulated T cells. IE62-ALW-A2 T cell clones 
produced IFN-γ in response to COS-A2 cells endogenously expressing the IE62 protein, as 
well as COS-A2 cells pulsed with the IE62-ALW-A2 peptide. No IFN-γ was produced when 
the COS-A2 cells were transfected with the IE63-encoding gene of VZV or pulsed with an 
irrelevant peptide (Figure 2C). 
To determine whether IE62-ALW-A2-specific T cells were present in healthy individuals, 
cryopreserved PBMCs from 18 healthy, VZV-seropositive, HLA-A2-positive individuals 
were screened with the PE-conjugated VZV tetramer. PBMCs were labeled with tetramers 
for 15 min at 37°C in RPMI medium without phenol supplemented with 2% fetal bovine 
serum, washed, and analyzed with a FACScalibur. In 3 of these 18 serologically VZV-positive 
individuals, IE62-ALW-A2 tetramer-positive T cells could be detected (range, 0.01 to 
0.02% of CD8+ T cells). These data demonstrate that IE62-ALW-A2- specific T cells can be 
observed and that the frequency of these T cells is low under steady-state conditions in 
immunocompetent persons. 
To assess the frequency of IE62-ALW-A2-specific T cells in a cohort of patient who suffered from 
VZV reactivation following TCD alloSCT, 19 HLA-A2-positive patients after VZV reactivation 
following TCD alloSCT were screened by using the IE62-ALW-A2 tetramer. We screened 
these patients at a median of 47 days after the clinical diagnosis of VZV reactivation. In 8 
of these 19 patients, IE62-ALW-A2-specific T cells could be directly detected ex vivo (mean, 
0.04% [range, 0.01 to 0.11%] of CD8+ T cells), indicating that this epitope is recognized in 
42% of the HLA-A2-positive patients during VZV reactivation (Table 1). In VZV-seronegative 
patients (six screened), no IE62-ALW-A2 tetramer-positive cells could be detected. 
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Figure 2. IE62-ALW-A2 T cells recognize IE62-ALW-A2 peptide loaded target cells and target cells endogenously 
expressing IE62.
(A) Cytolytic activity of the IE62-ALW-A2 positive T cell clones 1 and 2 was analyzed using the 51Cr release assay. T 
cells were incubated for 4 h with IE62-ALW-A2 peptide loaded or unloaded HLA-A2 positive EBV-LCLs at an effector 
to target ratio of 10:1. (B) IE62-ALW-A2 T cell clone 1 was stimulated with HLA-A2 positive EBV-LCLs loaded with 
different concentrations of the IE62-ALW-A2 peptide. Release of IFN-g (pg/ml) after 24 hours of stimulation is 
shown. (C) IE62-ALW-A2 T cell clones 1 and 2 were stimulated with HLA-A2 positive COS-A2 cells, untreated, or 
loaded with the IE62-ALW-A2 peptide or with the IE4-ALR-B8 peptide as an irrelevant peptide or transfected with 
the IE63 gene (COS-A2-IE63) or the IE62 gene (COS-A2-IE62). Release of IFN-g (pg/ml) after 24 hours of stimulation 
is shown. 
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Table 1. The presence of IE62-ALW-A2-specific T cells in HLA-A2 patients after VZV reactivation 
following TCD alloSCT




1 180 46 neg 0.22 (0.15)
2 190 38 0.03 (0.01) 0.51 (0.21)
3 545 31 neg neg
4 294 52 neg 0.12 (0.06)
5 82 38 neg neg
6 183 16 neg 0.01 (0.01)
7 176 81 0.02 (0.01) 0.44 (0.06)
8 99 35 0.11 (0.02) 0.22 (0.04)
9 601 88 neg 0.01 (0.01)
10 95 63 neg neg
11 90 83 neg neg
12 179 48 neg neg
13 1224 62 neg neg
14 173 20 0.03 (0.01) 0.22 (0.12) 
15 514 21 0.03 (0.01) nd$
16 635 40 0.02 (0.01) nd
17 161 8 neg neg
18 174 48 0.01 (0.00) 0.02 (0.01)
19 92 49 0.04 (0.01) 0.06 (0.02)
*Mean percentages of IE62-ALW-A2 tetramer positive cells of CD8+ T cells of 3 tetramer stainings 
performed on different days are indicated.  #PBMCs were in vitro stimulated (IVS) for 7 days with 
IE62-ALW-A2 peptide, the mean percentages of tetramer positive cells of 3 to 6 stimulations are 
indicated. A negative result was determined as < 0.01% of CD8+ T cells. $No PBMCs were available to 
do the analysis.
To verify the presence of the IE62-ALW-A2-specific T cells in the patient and donor cohort 
and to investigate whether individuals negative for IE62-ALW-A2-specific T cells were unable 
to mount a response against the epitope or whether the frequency of IE62-ALW-A2-specific 
T cells was too low to detect by FACS, the presence of these T cells was further measured 
after in vitro stimulation. PBMCs were cultured at a concentration of 1 x 10
6
/ml in 24-well 
plates in Iscove’s modified Dulbecco’s medium supplemented with 10% human serum in the 
presence of IE62-ALW peptide (1 μg/ml), interleukin-2 (IL-2; 50 IU/ml), and IL-15 (10 ng/ml). 
After stimulation for 7 days, the presence of IE62-ALW-A2-specific T cells was reassessed 
by tetramer labeling. These in vitro stimulations demonstrated that IE62-ALW-A2 CD8+ 
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T cells were detectable in another four patients and confirmed the presence of IE62-ALW-
A2-specific T cells in eight patients and three healthy, VZV-seropositive individuals with ex 
vivo-detectable IE62-ALW-A2-specific T cells (Table 1; Figure 3A to D). Thus, in 12 (63%) of 
19 patients, IE62- ALW-A2 CD8+ T cells could be detected either by direct tetramer labeling 
or after in vitro expansion, indicating that this HLA-A2-restricted epitope is commonly used 
in HLA- A2-positive individuals. 
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Figure 3. Detection and kinetics of IE62-ALW-A2-specific T cells. 
PBMCs with detectable IE62-ALW-A2 T cells (A, left figure), low (B, left figure), or without detectable tetramer 
positive cells (C and D, left figures) were in-vitro stimulated (IVS) for 7 days with IE62-ALW-A2 peptide (I mg/ml), 
in the presence of IL-2 and IL-15 (A, B, C, D right figures). Cells were stained with CD4 FITC, CD40 FITC and IE62-
ALW-A2 tetramer, and percentages IE62-ALW-A2 tetramer positive cells of CD8+ T cells are indicated. CD8+ T cells 
are defined as CD4- CD40- lymphocytes. E) PBMCs of a patient during the course of a VZV reactivation following 
TCD alloSCT were stained with the IE62-ALW-A2 tetramer in combination with CD8+ FITC. The percentages IE62-
ALW-A2-specific CD8+ T cells before, during and after VZV reactivation are shown. In the box, the presence of viral 
DNA in peripheral blood is shown as measured by real time PCR at various time points. The bold line illustrates the 
use of valaciclovir for treatment of the VZV reactivation.
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To study whether the immune response against the IE62- ALW-A2 epitope correlated with 
clinical reactivation, the percentage of IE62-ALW-A2-positive T cells was analyzed during the 
course of VZV reactivation in one patient. To determine the presence of viral DNA in plasma 
before and during the course of VZV reactivation, real-time PCR was performed on plasma 
samples derived at different time points. Six days prior to clinical signs of VZV reactivation, 
only 0.03% of the CD8+ T cells were IE62-ALW-A2-specific. At 42 days after the onset of VZV 
reactivation, 0.23% of the CD8+ T cells were IE62- ALW-A2-specific. After the VZV infection 
resolved, the percentage of IE62-ALW-A2-specific CD8+ T cells declined to 0.09% at day 49 
and 0.03% at day 145 after reactivation (Figure 3D). The T cells present at the peak of the 
response were predominantly HLA-DR positive, CD45RA negative, CCR7 negative, CD28 
negative, and CD27 positive, consistent with an activated effector memory phenotype. 
In this study, we demonstrate that CD8+ T cells specific for VZV are detectable without prior 
in vitro stimulation in patients with VZV reactivation following TCD alloSCT. We identified 
the ALWALPHAA peptide derived from the IE62- encoding gene of VZV as the first validated 
VZV-specific HLA class I-restricted immunogenic epitope by a pentamer- based epitope 
discovery method. The detection of the IE62-ALW peptide as an immunogenic peptide for 
VZV-specific CD8+ T cells demonstrates the usefulness of this procedure for discovering new 
immunogenic virus- or tumor-specific epitopes. We demonstrated that, despite the low 
frequency, it is possible to detect VZV-specific CD8+ T cells, allowing ex vivo analysis of the 
immune response to VZV infection, reactivation, and possibly VZV vaccination. 
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Abstract
Recipients of allogeneic stem cell transplantation (alloSCT) are at risk for reactivation of 
endogenous herpesviruses due to profound and prolonged T cell deficiency following 
conditions such as GVHD, immunosuppression and/or T cell depletion. Reactivation of 
endogenous CMV is the most frequently occurring herpesvirus reactivation following 
alloSCT. Antiviral medication is often used in pre-emptive treatment strategies initiated 
when increases in CMV viral loads are detected as a result of active reactivation of the virus. 
Despite pre-emptive antiviral treatment, the incidence of CMV disease in CMV seropositive 
alloSCT patients is still 10% at 1 year following alloSCT. This illustrates the necessity for 
adequate CMV-specific T cell immunity for long-term control of CMV and prevention of CMV 
disease. In this review, we analyzed the available studies on the influence of donor CMV 
status on CMV-specific T cell reconstitution and CMV disease. Furthermore, we reviewed 
the available studies on the safety and efficacy of adoptive transfer of donor CMV-specific 
T cells for the prevention and treatment of CMV disease following alloSCT, including studies 
on adoptive transfer of third-party CMV-specific T cells as a possible alternative when donor 
T cells are not available.  
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Introduction
Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for various 
hematological diseases1. Following alloSCT, patients experience a period of profound and 
prolonged T cell deficiency in which they are at risk for developing infectious complications, 
including reactivations of endogenous herpesviruses like cytomegalovirus (CMV)2, Epstein-
Barr virus (EBV)3 and varicella zoster virus (VZV)4. Infections with herpesviruses usually occur 
during childhood, and are controlled via the development of virus-specific T cell responses 
and ultimate formation of immunological memory. Despite virus-specific T cells control, 
herpesviruses are not completely cleared resulting in latent infections with equilibrium 
between the viruses and the virus-specific T cells. The frequencies of circulating memory 
T cells directed against these latent viruses are relatively high in immune competent, CMV 
or EBV infected hosts and can comprise up to 40% of the complete T cell repertoire5, 6. These 
high frequencies are presumably the result of repeated stimulation by frequent reactivations 
of CMV or EBV during life. Reactivation of endogenous CMV is the most frequently occurring 
herpes virus reactivation following alloSCT. In Western Europe and the United states 45-
60% of alloSCT recipients is seropositive for CMV and therefore at risk for endogenous 
reactivation of latent CMV infection7, 8. 
CMV-specific T cells are essential for long-term control of CMV reactivation following 
alloSCT9-11. Failing CMV-specific T cell immunity, either quantitatively due to eradication 
by the conditioning regimen or qualitatively due to immune suppression or exhaustion 
by chronic antigen stimulation12, 13 leads to impaired control of CMV reactivation, and 
may result in CMV disease, such as CMV pneumonitis, CMV colitis or CMV encephalitis14. 
Antiviral medication used in a pre-emptive treatment strategy can prevent CMV disease 
during this period of impaired CMV-specific T cell immunity. In a pre-emptive treatment 
strategy, viral load is routinely monitored using quantitative PCR and antiviral therapy is 
initiated when the viral load is above a predetermined PCR threshold. Multiple trials have 
demonstrated the safety and efficacy of pre-emptive strategies using oral valganciclovir15. 
However, despite the use of a pre-emptive strategy, the incidence of CMV disease is still 
10% at 1 year following alloSCT in CMV seropositive patients16, 17, illustrating the need for 
effective CMV-specific T cell immunity. 
Several circumstances can increase the risk for CMV disease despite pre-emptive antiviral 
treatment (table 1). Graft versus Host Disease (GVHD) is associated with an increased 
risk of CMV disease despite pre-emptive antiviral treatment18-22. The use of an unrelated 
or HLA mismatched donor also implies an increased risk of developing CMV disease20-22. 
This may be caused by a higher risk of GVHD due to HLA mismatches requiring prolonged 
systemic immune suppression for prevention or treatment. Donor derived alloreactive 
T cells cause GVHD by targeting non-hematopoietic cells in the tissues and organs of 
the patient. Treatment of GVHD with systemic immune suppression not only suppresses 
alloreactive T cells responsible for the GVHD but also CMV-specific T cells. The increased 
risk of developing CMV disease in the presence of GVHD can also be caused by eradication 
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of recipient derived CMV-specific memory T cells by the profound alloreactive donor T cell 
response mediating the GVHD23, 24. If adequate reconstitution of donor-derived CMV-specific 
T cells is not yet sufficiently in place, these patients suffer from impaired anti-viral immune 
control. 
GVHD can be prevented by immunosuppression after alloSCT or by T cell depleted (TCD) 
alloSCT25-27. In TCD alloSCT strategies, mature donor T cells are depleted from the stem cell 
graft. Various methods are used to deplete T cells from the graft resulting in different levels of 
TCD  including CD34+ selection resulting in almost complete T cell depletion or lymphocyte-
depleting antibodies such as anti-thymocyte globulin (ATG)28 or alemtuzumab29, 30. Although 
TCD strategies are effective in preventing GVHD and long-term post-transplant immune 
suppression is rarely needed, TCD also contributes to T cell impairment. Several studies 
demonstrate a higher incidence of CMV reactivation following TCD alloSCT. However, with 
the exception of CD34+ selection, the incidence of CMV disease is not increased compared 
to non-TCD alloSCT18, 19, 21, 31, 32. The avoidance of immunosuppression after TCD alloSCT 
strategies, may allow even small numbers of CMV-specific T cells to reconstitute effective 
CMV-specific T cell immunity controlling CMV reactivation. This is confirmed by the finding 
that the high incidences of CMV disease after CD34+ selected alloSCT can be reduced by 
adding back small numbers of T cells to the CD34+ selected stem cell graft33, 34. This positive 
effect of even minimal numbers of donor T cells in the graft on the prevention of CMV 
disease  leads to a preference of selecting a CMV seropositive donor for a CMV seropositive 
recipient. 
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Table 1. Overview of evidence for factors potentially associated with increased risk for CMV disease 
after allogeneic stem cell transplantation
Factor Number of patients Outcome on CMV Disease Reference
GVHD 117 R+ and R-
Increased incidence CMV disease at day 
100 in grade II–IV acute GVHD vs grade 
0–I acute GVHD (17.1% vs 1.3%)
18
162 R+or D+ Increased risk for CMV disease in acute GVHD (OR 9.7) 19
1571 R+ Increased risk for CMV disease in acute 
or chronic GVHD (Adjusted HR 4.1) 20
186 R+or D+ 
Increased risk for CMV disease in steroid 
therapy for moderate- to-severe GVHD 
(HR 4.7)
21
488 recipients with CMV 
reactivation after alloSCT
Increased risk for refractory CMV 





Increased risk for CMV disease with 
unrelated or HLA mismatched donor 
(Adjusted HR 2.1)
20
186 R+or D+ Increased risk for CMV disease with non-HLA-identical donors (HR 2.7) 21
488 recipients with CMV 
reactivation after alloSCT
Increased risk for refractory CMV 




+ and R- (15 (12.8%) 
received ATG for TCD)
No difference in CMV disease in 
conventional and ATG based TCD 18
162 R+or D+
No difference in CMV disease in patients 
treated with ATG and not treated with 
ATG
19
186 R+ and R- (23 
alemtuzumab/ATG  
for T cell depletion)
No difference in CMV disease following 
RIC in conventional and alemtuzumab/
ATG based TCD
21
73 R+ and R- No CMV disease following Alemtuzumab 
based TCD; all matched related donor 31
107 R+ and R-
No CMV disease within 100 days 
following Alemtuzumab based TCD, 
additional ATG in transplantation 
unrelated donor
32
Abbreviations: CMV = cytomegalovirus; R+ = recipient CMV seropositive; R- = recipient CMV 
seronegative; D+  = Donor CMV seropositive; GVHD = graft vs host disease; OR = odds ratio; HR = 
hazard ratio; HLA = human leucocyte antigen; ATG = antithymocyte globulin; TCD = T cell depletion
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Influence of donor CMV serostatus on CMV specific T cell reconstitution and CMV 
disease 
Donor CMV serostatus and the associated presence or absence of donor CMV-specific 
memory T cells in the graft impact on the incidence of CMV related complications especially 
in CMV seropositive recipients undergoing alloSCT. In different studies the incidence of CMV 
related complications in CMV seropositive recipients transplanted with a CMV seropositive 
donor (R+D+) versus CMV seropositive recipients transplanted with a CMV seronegative 
donor (R+D-) has been investigated for TCD and non-TCD alloSCT programs (table 2). These 
studies demonstrate better CMV-specific T cell reconstitution35-37 and less CMV related 
complications and deaths in R+D+ patients compared to R+D- patients19, 36-41. 
In R+D- patients CMV-specific memory T cells are not present in the graft and as a result the 
short term anti-viral immunity depends on residual recipient-derived CMV-specific memory 
T cells42 and/or on the ultimate formation of a donor-derived primary CMV-specific T cell 
response. Recipient-derived T cells may be affected by the conditioning regimen prior to 
the alloSCT.  Furthermore, all residual recipient derived lymphopoietic cells, including the 
T cells, may be attacked after the alloSCT by an alloreactive T cell response mounted by 
donor T cells. This is demonstrated by a study in which absence of CMV-specific T cells and 
CMV disease was seen in R+D- patients following T cell replete and not in T cell depleted 
alloSCT, indicating the eradication of residual CMV-specific T cells due to an alloreactive 
T cell response43. Consequently, adequate development of a donor derived primary T cell 
response is warranted for long-term anti-viral immune protection. Donor derived primary 
T cells  can originate post transplant from donor stem cells via thymic development or from 
mature naive T cells present in the graft. Because the function of the thymus is anticipated 
to be greatly impaired in mature recipients following alloSCT, a primary T cell response 
derived from donor stem cells via thymic development cannot be expected shortly after 
alloSCT43, 44. High numbers of naive mature donor T cells present in the graft as seen in 
umbilical cord blood transplantation (UCBSCT) could hypothetically prevent CMV disease via 
the development of a primary CMV-specific immune response. However, despite the high 
number of naive T cells in the graft, delayed immune reconstitution and a high incidence of 
CMV disease is observed following UCBSCT45-47. 
Although it may take a period of 6 months to even several years, eventually most R+D- patients 
develop CMV-specific immunity. If time is allowed for successful immune reconstitution and 
primary CMV-specific T cell responses develop, CMV reactivation is controlled and CMV 
disease is prevented. This paves the way for strategies to bridge the period of impaired 
immunity via adoptive T cell transfer (ACT) to prevent CMV disease.
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Table 2. Effect of donor CMV serology on survival, clinical endpoints and CMV-specific T cell 
reconstitution in CMV positive recipients 
Endpoint No of CMV
+ recipients 
(R+D+ vs R+D-) Outcome Reference
Survival 298; TCD in all patients (177 vs 121)
Lower mortality in R+D+ (42% versus 
56%) 36
531; TCD in all patients 
(331 vs 200)
Lower mortality in R+D+; even in R+D+ 
unrelated donor vs R+D- sibling donor 38
29349 (19385 vs 9964) Superior overall survival R
+D+ in MAC, 
not in RIC 39
10638 (7008 vs 3630) Superior overall survival R
+D+ in MAC 
and RIC 40
CMV disease  
or treatment 298 (177 vs 121)
Lower incidence of CMV disease (3% 
versus 13%) in R+D+ 36
178; T cell repletion (128 
vs 50)
More recurrent need for antiviral 
therapy in R+D- (16% vs 0.8) 37




69 (55 vs 14)
More CMV-specific T cell responses 
detectable at day 100 in R+D+ compared 
to R+D- (82% vs 42%)
35
298; TCD in all patients 
(177 vs 121)
CMV-specific CD4+ and CD8+ T cell 
counts higher in R+D+ 36
178; T cell repletion (128 
vs 50)
CMV-specific CD8+ T cell counts higher in 
R+D+ compared to R+D- 37
Abbreviations: CMV = cytomegalovirus; R+ = recipient CMV seropositive; D+ = donor CMV seropositive; 
D- = donor CMV seronegative; TCD = T cell depletion; MAC = myeloablative conditioning; RIC = 
reduced intensity conditioning
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Adoptive cell transfer for prevention and treatment of CMV disease following alloSCT
Several trials have been performed using ACT of purified populations of CMV-specific T cells 
isolated via different in-vitro strategies (table 3)48-59. ACT in these trials was either prophylactic 
or pre-emptive or intended for treatment of persistent CMV reactivation or CMV disease. All 
trials published thus far are phase-1/2 trials with relatively small numbers of patients.  These 
studies suggest safety, proof of concept, and an association between ACT and viral clearance, 
but no formal phase-3 efficacy trials have been performed yet. Restoration of anti-viral 
immunity after CMV-specific ACT was demonstrated, however it remained unclear whether all 
immune responses seen following ACT were causally related to the ACT or that CMV-specific 
T cell responses developed irrespective of the ACT. 
In general, 2 different approaches are used to produce CMV-specific T cell products for 
adoptive transfer. CMV-specific T cell products can consist of in vitro selected and expanded 
CMV-specific T cell lines or non-expanded CMV-specific T cells. T cell lines consisting of 
expanded CMV-specific T cells can be produced by repeated stimulation of peripheral blood 
derived mononuclear cells (PBMCs) with CMV derived antigens. After repeated stimulation 
in the course of several weeks, T cells specific for the antigens used for stimulation will be 
the main component of the cultures due to preferential outgrowth. The advantage of this 
technique is than combined CD4+ and CD8+ T cell lines are usually generated, depending on the 
antigens used for stimulation. The antigens used for stimulation also determine the broadness 
of specificity of the T cells lines, ranging from specificity to a single peptide to protein spanning 
peptide pools or viral proteins. Although expansion techniques will lead to large numbers of 
CMV-specific T cells, the down side is that repeated stimulation may lead to exhaustion of 
the expanded T cells leading to reduced persistence following ACT54, 60. However, if the goal of 
ACT is to temporarily overcome persistent CMV reactivation or CMV disease, transfusing large 
numbers of CMV-specific effector T cells may be sufficient to bridge and allow CMV-specific 
T cell reconstitution to develop. 
CMV-specific T cell lines can also be generated from isolated CMV-specific T cells without 
or after only minimal expansion, aiming to prevent T cell exhaustion. In vivo, naive T cells 
differentiate to effector T cells upon first activation by antigen encounter and into memory 
T cells, which can mount another response after re-exposure to the antigen. Memory T cells 
can either be less differentiated central memory T cells or more differentiated effector 
memory T cells61. Stem cell characteristics such as multi-potency and self-renewal capacity 
have been demonstrated within the less differentiated central memory T cell compartment 
62. Experimental studies demonstrated the capacity of a single naive CD8+ T cells to repopulate 
and develop into various memory and effector subsets and transferring even very low numbers 
of less differentiated T cells may be effective for successful T cell reconstitution63-65. Therefore, 
adoptively transferring less differentiated CMV-specific T cells may lead to more effective 
CMV-specific T cell reconstitution and persistence than transferring in vitro expanded effector 
T cells. CMV-specific T cell products generated with no or very limited expansion can be made 
by selection of T cells producing interferon gamma (IFNγ) upon in-vitro stimulation with 
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CMV derived antigens using the cytokine capture assay and a magnetic bead isolation system 
(MACS)66, 67. Using stimulation with CMV antigens as basis for isolation allows isolation of both 
CD4+ and CD8+ CMV-specific T cells. Another method is the highly specific isolation based on 
interaction of the T cell receptor with CMV peptide-HLA-multimer complexes (e.g. tetramers 
and streptamers) loaded on isolation beads68, 69. In this technique however, isolation is only 
possibly for CD8+ T cells, specific for the peptide used and with known HLA restriction pattern. 
In non-expansion techniques the number of CMV-specific T cells generated is lower compared 
to techniques based on T cell expansion, however with lower risk of culture-induced T cell 
exhaustion and better proliferative capacity and persistence. If time for in vivo proliferation is 
granted, i.e. in the absence of persistent CMV viremia or CMV disease as in prophylactic ACT 
and in the absence of immunosuppression or GVHD, using non-expanded CMV-specific T cell 
lines may be best suited for reconstituting CMV-specific T cell immunity. 
A major limitation for interpreting the clinical relevance of ACT following alloSCT has been 
the exclusion of active GVHD treated with systemic immune suppression in all trials. However, 
GVHD and treatment with systemic immune suppression are major risk factors for CMV disease 
and these patients may benefit the most from CMV-specific ACT. Considering the body of 
evidence that ACT with in-vitro selected CMV-specific T cells is safe with minimal risk of inducing 
concurrent GVHD, future trials may consider including patients with active GVHD, especially 
when using ACT products with high purity. In case of ongoing immune suppressive therapy 
the numbers of CMV-specific T cells used for ACT may need to be higher to overcome the 
immune suppression, e.g. derived from an expansion-based approach to generate sufficient 
number of CMV-specific T cells.  A potential future approach for patients with uncontrolled 
CMV viremia and active GVHD may be treatment with CMV-specific T cells rendered resistant 
to corticosteroids by gene editing techniques70. In this approach the glucocorticoid receptor 
gene of CMV-specific T cells is disrupted leading to corticosteroid resistance. Adoptively 
transferring these cells for ACT may be effective in treating CMV disease during corticosteroid 
treatment for GVHD. This technique is still in a preclinical stage, and safety and efficacy have to 
be determined in clinical trials.  
A major limitation of clinical applicability of CMV-specific ACT is that isolation of CMV-specific 
memory T cells from the donor is restricted to CMV seropositive donors. However, especially 
CMV seropositive patients transplanted with a graft from a CMV seronegative donor (R+D-) 
are at greatest risk of developing CMV disease, due to delayed reconstitution of virus-specific 
immunity. In theory, CMV-specific T cells from the CMV seropositive recipient harvested 
prior to the alloSCT procedure (autologous CMV-specific T cells) could be used for ACT post-
transplant for prevention or treatment of CMV disease in R+D- patients. However, transfusing 
autologous CMV-specific T cells poses a risk of inducing graft rejection and would be eradicated 
by alloreactive donor T cells in case of GVHD. Autologous CMV-specific ACT has not yet been 
studied in a clinical trial. A different solution for R+D- patients may be the use of CMV-specific 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adoptive cell transfer using third-party CMV specific T cells 
Using CMV-specific T cells from third-party donors (TPD) allows the formation of a bank of 
stored T cell lines from CMV seropositive donors with different HLA types. TPD CMV-specific 
T cell lines can be used  “off the shelf” for treating persistent CMV viremia or CMV disease 
which eliminates  delays caused by obtaining fresh cells from the donor, T cell isolation, 
processing and quality control. The potential efficacy as well as the potential toxicity of 
this approach is likely to be associated with the level of HLA matching between the third 
party donor and the respective patient and stem cell donor. Potential toxicity risks include 
the risk for graft rejection by an alloreactive response to donor hematopoietic cells or 
induction of GVHD by an alloreactive response to recipient tissue antigens by the adoptively 
transferred TPD T cells. It has been demonstrated that T cells, including CMV-specific T cells, 
harbor the capacity to cross-react to one or more allo-HLA molecules, thereby potentially 
inducing GVHD71. Vice versa, rejection of the adoptively transferred TPD T cells by anti-HLA/
alloreactive donor derived T cells may also occur, consequently hampering efficacy.
In one recent multicenter trial 50 patients with severe refractory CMV, EBV or adenovirus 
infections were treated with banked TPD virus-specific T cells72. The cell lines used for 
adoptive transfer in this trial were generated by expansion, generating large numbers of 
CMV-specific T cells. The cumulative rate of complete responses (decrease of viral load 
below limit of detection and resolution of symptoms) or partial responses (decrease 
of viral load of at least 50% and alleviation of symptoms) was 74%. Development of de 
novo GVHD was seen in only 2/50 patients. Another recent study described ACT with TPD 
CMV-specific T cells in 8 R+D- patients with persistent CMV reactivation and no visible 
frequencies of circulating CMV-specific T cells73.  The cell products used in this trial were 
generated without expansion, resulting in low numbers of CMV-specific T cells. In all but 
one patient survival/persistence of TPD CMV-specific T cells could not be demonstrated in 
peripheral blood of the patients after infusion. In one patient TPD T cells were found back 
at detectable frequencies after the adoptive transfer. In contrast to the other patients in this 
study, in this single case there was a complete HLA match between the patient, the stem cell 
donor and the TPD T cells. 
These trials indicate that ACT with TPD virus-specific T cells is feasible, probably safe and 
may be effective in treating persistent CMV reactivation and CMV disease. However, long-
term persistence of these T cells is unlikely. The level of HLA matching between the TPD 
and the respective patient and stem cell donor most likely impacts on the rejection of 
the adoptively transferred virus-specific T cells. However, the induction of an alloreactive 
response to reject the TPD takes time to develop and will depend on a functional T cell 
compartment in the patient. Therefore, the use of a third party T cell product with confers 
immediate protection is probably preferred over a product in which the T cells depend on 
profound in vivo proliferation  for protection because by the time the third party T cells may 
have sufficiently proliferated, these cells may be  eradicated by a developing alloreactive 
response by patient T cells. Thus, for immediate short-term protection in R+D- patients 
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with refractory CMV viremia or CMV disease, large numbers of TPD CMV-specific T cells 
produced by expansion techniques may be more effective than non-expanded T cells. A 
short-term effect as demonstrated in the recent clinical trials may be sufficient for bridging a 
period of severe CMV-specific T cell deficiency, thereby preventing or treating CMV disease 
and allowing for the development of subsequent CMV-specific immunity from the stem cell 
donor T cell repertoire for long-term control of CMV viremia. 
Although the clinical results so far suggest that ACT with TPD CMV-specific T cells is safe, 
the induction of GVHD is still a major concern when using partially HLA matched TPD T cells 
and may correlate with in vivo persistence of the TPD T cells. The low incidence of GVHD 
after TPD ACT observed in the clinical studies may at least in part be explained by the rapid 
rejection and/or limited persistence of TPD T cells. If TPD were to persist and proliferate, 
GVHD may manifest as collateral damage.
A potential future alternative to TPD T cells is CMV-specific T cell Receptor (TCR) transfer 
to T cells from the CMV negative donor74.  If stem cell donor derived T cells will be used, 
they will be  likely to persist and expand after infusion. However, a potential danger is still 
the induction of GVHD due to a co-expressed endogenous alloreactive TCR. A clinical trial is 
currently undertaken to determine to the incidence of GVHD and the efficacy to generate 
CMV-specific T cells responses by infusing CMV TCR transduced T cells (ClinicalTrials.gov 
NCT02988258). Another potential future approach for R+D- patients is adoptively transferring 
CMV-specific T cells developed from the naive repertoire of the CMV seronegative donor. 
Although the procedure is experimental and the procedure is time-consuming, two studies 
demonstrated proof of principle that generation of CMV-specific T cells from a naive T cell 
repertoire is possible75, 76.  
Conclusion
Despite the use of pre-emptive strategies to control CMV viremia, CMV disease is not 
prevented in all patients. Patients with impaired CMV-specific T cell immunity due to GVHD, 
systemic immune suppression or absence of CMV-specific memory T cells in the graft have 
the greatest risk of developing CMV disease. The selection of a CMV seropositive donor 
for a CMV seropositive patient will potentiate efficient CMV-specific T cell reconstitution 
and significantly reduces the incidence of CMV disease. Multiple trials demonstrated that 
ACT with CMV-specific donor T cells is feasible and safe. However, the ultimate proof of 
efficacy of these strategies must come from future placebo controlled phase-3 clinical trials 
with significant patient numbers. In patients with GVHD treated with immune suppression, 
larger numbers of T cells may be required for ACT to overcome the effect of the immune 
suppression. ACT using third-party off the shelf donor derived CMV-specific T cell lines 
may be applied to provide short-term protection and temporary control of persistent CMV 
reactivation and disease in alloSCT patients. However, no long-term survival/persistence of 
partially HLA matched third-party donor derived CMV-specific T cells is likely to occur. The use 
of larger numbers of third-party CMV-specific T cells may be effective in bridging the period 
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of impaired immunity, despite the eradication by an alloreactive response. The execution 
of a large trial  evaluating the effect of third party T cell products on CMV reactivation and 
-disease, the relevance of HLA-matching between third party donor and recipient, and the 
persistence of third party donor T cells in relation to the occurrence of GVHD would greatly 
enhance our knowledge to prevent and treat CMV disease in immunocompromised patients.
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Following allogeneic stem cell transplantation (alloSCT), most patients experience a 
period of profound and prolonged T cell deficiency due to the immune suppression and/
or T cell depletion (TCD). In this period the patients are at risk for developing infectious 
complications by reactivation of endogenous herpes like viruses cytomegalovirus (CMV), 
Epstein-Barr virus (EBV) and varicella zoster virus (VZV). Reactivation of endogenous CMV 
is the most frequently occurring herpes virus reactivation following alloSCT. Approximately 
60% of alloSCT recipients are seropositive for CMV and are therefore at risk for endogenous 
reactivation of latent CMV. CMV reactivation can lead to potentially fatal CMV disease, 
comprising CMV pneumonitis, CMV colitis or CMV encephalitis. The aim of this thesis was to 
evaluate factors that influence the incidence of CMV disease after TCD alloSCT. These factors 
include the conditioning regimen, serostatus of the donor, pharmacological intervention 
following alloSCT and adoptive T cell transfer for treatment of refractory CMV reactivation 
or CMV disease.
CMV disease can be prevented by pre-emptively treating CMV reactivation using ganciclovir 
intravenously. In a pre-emptive treatment strategy, antiviral therapy is initiated when the 
viral load is above a predetermined PCR threshold. An effective oral treatment for pre-
emptive CMV therapy would enable prevention and treatment of CMV in an outpatient 
setting and would lead to reduced patient burden and health-care costs. In chapter 2 
we demonstrate that pre-emptive treatment with oral valganciclovir is equally effective 
in reducing CMV DNA load in allogeneic stem cell recipients compared to intravenous 
ganciclovir. Severe adverse effects were not observed and CMV disease did not occur. 
The percentage of patients receiving erythrocyte transfusions was higher in the group of 
patients receiving ganciclovir, which is possibly the result of co-morbidity in the admitted 
patients treated with ganciclovir intravenously. Pre-emptive treatment of CMV viremia 
episodes in allogeneic stem cell recipients with either valganciclovir or ganciclovir led to 
a similar median CMV DNA load reduction in plasma of approximately 0.1 log10 copies/ml/
day. We concluded that oral valganciclovir (900 mg, twice daily) is equally effective and 
safe as intravenous ganciclovir (5 mg/kg, twice daily) in the treatment of CMV reactivation 
aiming to prevent CMV disease following alloSCT. The vast majority of alloSCT recipients, 
without any clinical signs and symptoms of CMV disease when the first laboratory signs of 
CMV infection are detected, can benefit from treatment with an oral drug, without the need 
for hospitalization. For patients with suspected symptomatic CMV infections intravenously 
administered ganciclovir remains the first choice drug, as the course of CMV disease can be 
rapidly progressive and ultimately fatal. 
It has been established that alloSCT with reduced intensity conditioning (RIC) can be 
successfully performed in individuals with a wide variety of different diseases and results 
in reduced risk of transplant-related mortality. Durable donor engraftment and favorable 
response of the disease with no graft versus host disease (GVHD) was reported for the 
in vitro TCD alloSCT protocol using RIC with fludarabine, anti-thymocyte globulin (ATG), 
busulphan and Campath-in-the-bag. It can be hypothesized that following RIC more residual 
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recipient T cells survive the conditioning regimen and can confer protective immunity 
following alloSCT. In chapter 3 we demonstrate that there was no significant difference in 
incidence and severity of CMV infections within 100 days following alloSCT preceded by RIC 
compared to a conventional MAC. The onset of CMV DNA detection in plasma following 
alloSCT, the duration of a CMV infection, the peak load, the area under the DNAemia curve, 
the number and duration of pre-emptive CMV treatment episodes, as well as the number 
of recurrent infections within 100 days following alloSCT were comparable after RIC and 
MAC. This comparable severity after RIC and MAC may be explained by TCD as both patient 
groups received TCD grafts. By itself, TCD of the graft is associated with an increased risk of 
CMV infections, which seems to be reflected by the high overall incidence of CMV infections 
(51%) within 100 days following alloSCT in this study. As RIC relatively spares recipient 
hematopoietic cells, recipients who depend on recipient CMV-specific T cells were expected 
to benefit most from RIC in control of CMV reactivation. CMV seropositive recipients 
(R+) transplanted with a CMV seronegative donor (R+D-) depend on residual recipient 
CMV-specific T cells, as the graft of the donor does not contain memory CMV-specific T cells. 
In this study no statistical difference in frequency and severity of CMV reactivation was 
present R+D- patients compared to CMV seropositive recipients transplanted with a CMV 
seropositive donor (R+D+).  However, a non-significant increase of frequency and severity 
of CMV reactivation was observed in R+D- patients compared to R+D+ and as expected this 
difference was more pronounced in MAC compared to RIC. This difference did not reach 
statistical significance presumably due to small numbers of patients and a short follow-up 
of 100 days following alloSCT. 
In chapter 4 we specifically investigated the effect of donor CMV serostatus on the 
incidence of CMV disease after TCD alloSCT in a larger cohort of CMV seropositive patients. 
CMV-specific T cells may be transferred with the graft from CMV seropositive donors and 
provide protection against CMV disease. However, profound T cell depletion may eradicate 
these CMV-specific T cells. To determine the effect of donor CMV serostatus, we analyzed 
the incidence of CMV disease after TCD alloSCT in 157 CMV seropositive recipients, 
comprising 51 R+D- patients and 106 R+D+ patients. Furthermore, we determined the origin 
of CMV-specific T cells in a selection of 25 R+D- patients to determine whether primary 
donor-derived CMV-specific T cell responses could be demonstrated. The duration of CMV 
reactivations and the incidence of CMV disease were higher in R+D- patients compared to 
R+D+ patients. In R+D- patients, CMV-specific CD4+ and CD8+ T cells were mainly of recipient 
origin. However, in 53% of R+D- patients donor-derived CMV-specific T cells were detected 
within the first year, even as early as 3 months following TCD alloSCT. We conclude that 
donor CMV serostatus significantly influenced the clinical severity of CMV reactivations 
indicating the role of CMV-specific memory T cells transferred with the graft, despite the 
ultimate formation of primary donor-derived CMV-specific T cell responses in R+D- patients.
Considering the pivotal role of CMV-specific T cells in preventing CMV disease, improving 
CMV-specific T cell reconstitution in patients by adoptive transfer of CMV-specific T cells 
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can be an attractive treatment modality. However, the use of adoptive T cell transfer is not 
commonplace, as questions regarding safety and efficacy still need answering. In chapter 
5 we analyzed the safety and efficacy of adoptive transfer of CMV pp65-specific CD8+ T cell 
lines to restore CMV-specific T cell immunity by performing a phase I/II clinical study on 
adoptive transfer of in vitro-generated donor-derived or patient-derived CMV pp65-specific 
CD8
+ T cell lines. Peripheral blood mononuclear cells from CMV seropositive donors or 
patients were stimulated with HLA-A*0201-restricted and/ or HLA-B*0702-restricted CMV 
pp65 peptides (NLV/TPR) and 1 day after stimulation interferon-gamma producing T cells 
were enriched using the CliniMACS Cytokine Capture System, and cultured with autologous 
feeders and low-dose interleukin-2. After 7–14 days of culture, quality controls were 
performed and the CMV-specific T cell lines were administered or cryopreserved. The T cell 
lines generated contained 0.6–17 x 106 cells, comprising 54%–96% CMV pp65-specific CD8+ 
T cells, and showed CMV-specific lysis of target cells. Fifteen CMV-specific T cell lines were 
generated, of which 8 were administered to patients with refractory CMV reactivation. 
Seven cell lines were generated but not administered because patients had cleared the CMV 
reactivation by the time the cell line was generated (n=4), due to a relapse of the malignant 
disease (n=1), or patients died due to the progressive CMV disease before infusion of the 
CMV-specific T cells (n=2). After administration, no acute adverse events and no graft versus 
host disease were observed and CMV loads disappeared. In several patients, a direct relation 
between administration of the T cell line and the in vivo appearance of CMV pp65-specific 
T cells could be documented. In conclusion, administration of CMV pp65-specific CD8+ T cell 
lines was found to be feasible and safe.
In contrast to CMV, little is known about VZV-specific CD8+ T cell immunity because validated 
VZV-derived immunodominant peptides for Human Leucocyte Antigen (HLA) class I are 
lacking. Because of this lack of validated VZV-derived immunodominant peptides for HLA 
class I, the analysis of VZV-specific CD8+ T cell responses is hampered. To be able to analyze 
the role of CD8+ T cells in VZV reactivation, we set out to identify epitopes for VZV by a 
new pentamer-based epitope discovery method. In chapter 6 we describe our search for 
immunogenic antigens for VZV to develop VZV-specific pentamers and the development of 
multimeric HLA complexes to identify VZV-specific CD8+ T cells. Potential HLA-A2 binding 
peptides from the putative immediate-early (IE) 62 protein of VZV were tested for binding, 
and peptides with sufficient binding capacity were used to generate pentamers. Patients 
with VZV reactivation following TCD alloSCT were screened with these pentamers, leading 
to the identification of the first validated HLA class I-restricted epitope of VZV. In 42% of 
HLA-A2 positive patients following VZV reactivation, these IE62-ALW-HLA-A2-specific T cells 
could be detected ex vivo. We demonstrated that despite the low frequencies, it is possible 
to detect VZV-specific CD8+ T cells, allowing ex vivo analysis of immune responses to VZV 
infection, reactivation, and possibly VZV vaccination. 
Despite pre-emptive antiviral treatment the incidence of CMV disease in CMV seropositive 
alloSCT patients is still 10% at 1 year following alloSCT. This illustrates the necessity for 
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adequate CMV-specific T cell immunity for long-term control of CMV and prevention of 
CMV disease. In chapter 7 we provide an overview of factors relevant for prevention of 
CMV disease after alloSCT. GVHD and the use of an unrelated or HLA mismatched donor 
was found to be associated with an increased risk of developing CMV disease despite pre-
emptive antiviral treatment, either due to systemic immune suppression needed to prevent 
or treat GVHD or due to eradication of recipient derived CMV-specific memory T cells by 
the alloreactive donor T cell response mediating GVHD. T cell depletion was found to be 
associated with an increased risk for CMV reactivation but not with an increased risk for 
CMV disease. It can be hypothesized that because immune suppression is in general not 
needed after TCD alloSCT, CMV-specific T cells are not hampered by immune suppression to 
provide protective immunity in case of CMV reactivation. Donor CMV serostatus significantly 
appears to influence CMV-specific T cell reconstitution and the risk of developing CMV 
disease. The incidence of CMV related complications and mortality is lower in R+D+ patients 
compared to R+D- patients. In R+D- patients memory CMV-specific T cells are not present 
in the donor graft and recipient-derived virus-specific T cells can be (partially) eradicated 
by the conditioning regimen and/or by an alloreactive T cell response mounted by donor 
T cells. Finally, we reviewed the available studies on the safety and efficacy of adoptive 
transfer of donor CMV-specific T cells for the prevention and treatment of CMV disease 
following alloSCT. All trials published thus far are phase-1/2 trials, demonstrating safety, 
proof of concept and association between adoptive T cell therapy (ACT) and viral clearance. 
A major limitation for ACT following alloSCT is that treatment of active GVHD with systemic 
immune suppression was an exclusion criterion for administration of CMV-specific ACT in all 
trials. Another major limitation of clinical applicability of CMV-specific ACT is that isolation 
of CMV-specific memory T cells from the donor is restricted to CMV seropositive donors. 
Adoptive transfer of T cells isolated from healthy third-party donors may be a solution for 
R+D- patients as donor CMV-specific T cells are not readily available for these patients. Trials 
demonstrate that ACT with third-party donor derived virus-specific T cells is feasible, safe 
and may be effective in treating persistent CMV reactivation and CMV disease. However 
long-term persistence of these T cells is uncertain. 
In conclusion, the aim of this thesis was to evaluate the factors that influence the incidence 
of CMV disease after TCD alloSCT. We determined that prevention of CMV disease is safe 
and feasible using pre-emptive treatment with oral valganciclovir. We did not demonstrate 
a reduced risk for CMV reactivation or disease in patients treated with a RIC regimen and 
TCD alloSCT. GVHD and the use of immune suppression following alloSCT were found to be 
important risk factors for the development of CMV disease. T cell reconstitution was found 
to be improved in CMV seropositive patients transplanted with a CMV seropositive donor, 
which leads to a decreased risk of developing CMV disease. Donor derived CMV-specific 






Developments in CMV-specific antiviral medication
We investigated the safety and efficacy of pre-emptive therapy using (val)ganciclovir 
following TCD alloSCT and demonstrated that valganciclovir was equally effective to 
ganciclovir in preventing CMV disease1. In our study of 107 patients following TCD alloSCT, 
CMV disease did not occur following pre-emptive therapy with (val)ganciclovir. Based on 
results obtained by us and others2-4, pre-emptive strategies using valganciclovir are now 
the golden standard for prevention of CMV disease following alloSCT despite considerable 
side effects such as myelotoxicity and nephrotoxicity5. Although in our study on the safety 
and efficacy of pre-emptive therapy using (val)ganciclovir no CMV disease was observed, 13 
patients had no or only moderate response to (val)ganciclovir. Larger studies demonstrate 
that despite a pre-emptive therapy strategy, the incidence of CMV disease is still 10% 
at 1 year following alloSCT6, 7. Our study was not designed to identify factors associated 
with an increased risk of treatment failure. In the review of literature that we performed, 
it is demonstrated that GVHD and the use of an unrelated or HLA-mismatched donor are 
important risk factors for developing CMV disease despite pre-emptive therapy8. In these 
patients prolonged use or prophylactic use of antiviral medication may be beneficial to 
allow more time for CMV-specific T cell reconstitution to develop while suppressing CMV 
reactivation and preventing CMV disease. However, due to the side effects, prolonged 
treatment with ganciclovir or valganciclovir as prophylaxis is not feasible9-12. Foscarnet and 
cidofovir are alternatives to (val)ganciclovir, but are also not suitable for prophylaxis due to 
considerable side effects. 
Maribavir, brincidofovir and letermovir have been described as promising new anti-CMV 
drugs13, possibly suitable for prophylaxis. Maribavir was not beneficial over placebo in a 
phase II trial14 and is therefore not recommended for CMV prophylaxis after alloSCT. Phase 
III trials with maribavir are ongoing (NCT02927067 and NCT02931539) but for pre-emptive 
treatment of CMV reactivation rather than prophylaxis. Brincidofovir (also known as 
CMX001) was effective in decreasing the incidence of CMV reactivation in a phase II study 
as prophylaxis following alloSCT. However, efficacy to prevent CMV reactivation was only 
achieved in a dosage which was associated with increased gastrointestinal symptoms15. A 
phase III trial was performed (SUPPRESS, NCT01769170) and although the results of this 
trial have not yet been published, a manufacturer statement reported that prophylaxis with 
brincidofovir did not prevent CMV reactivation. In contrast to maribavir and brincidofovir, 
prophylaxis with Letermovir was demonstrated to be safe and effective to prevent CMV 
disease in a double blinded randomized control trial in CMV seropositive patients following 
alloSCT16. However, after cessation of the prophylaxis (predetermined at 100 days after 
alloSCT), the incidence of clinically significant CMV reactivation increased. The incidence of 
CMV disease was low in the letermovir group and in the placebo group, 1.5% and 1.8% at 24 
weeks after alloSCT. The incidence and frequency of side effects was comparable to placebo 
with, most notably no increase in myelotoxic or nephrotoxic evens in the letermovir group. 
With the FDA approval based on this phase III trial, it can be concluded that prophylaxis for 
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CMV reactivation after alloSCT is possible using letermovir as an alternative for pre-emptive 
treatment with (val)ganciclovir. 
Although Letermovir for CMV prophylaxis appears promising, trials directly comparing 
letermovir prophylaxes to pre-emptive therapy with (val)ganciclovir to prevent CMV disease 
following alloSCT have not been performed. Thus far no clinical superiority in efficacy of 
letermovir has been demonstrated compared to pre-emptive (val)ganciclovir. Besides efficacy, 
additional questions remain to be answered before CMV prophylaxis with Letermovir can be 
recommended over pre-emptive therapy with (val)ganciclovir. First, in order to prevent CMV 
disease, letermovir should provide protection during the period in which CMV-specific T cell 
immunity reconstitutes. It may take longer than the 100 days used in the trial to bridge this 
period especially in high-risk populations such as CMV seropositive recipients transplanted 
with CMV seronegative donors or during GHVD and treatment with immune suppression. 
However, prolonged use (i.e. longer than 14 weeks) of letermovir may eventually induce 
letermovir resistance. Second, it is not known whether CMV-specific T cell reconstitution is 
effective during letermovir prophylaxis, as Letermovir suppresses CMV viremia completely17, 
18. By completely suppressing CMV reactivation, CMV-specific antigen presentation may 
also be suppressed, possibly hampering CMV-specific T cell reconstitution.  Future studies 
should focus on development of  Letermovir resistance and on the influence of letermovir 
use of T cell reconstitution before the place of letermovir prophylaxis for prevention of CMV 
disease following alloSCT is determined. 
CMV-specific vaccination after alloSCT
Since CMV-specific T cells are essential for long-term control of CMV reactivation, 
interventions to accelerate CMV-specific T cell reconstitution may significantly contribute to 
the prevention of CMV disease. Traditionally, T cell immunity can be boosted by vaccination, 
an intervention in which antigen is presented in conjunction with a stimulatory adjuvant. 
A beneficial effect of CMV vaccination on CMV-specific T cell reconstitution may overcome 
the aforementioned possibly impaired CMV-specific antigen presentation when Letermovir 
prophylaxis is applied. It is not clear what the nature of the CMV-specific T cell reconstitution 
would be following vaccination, whether recipient or donor memory CMV-specific T cells 
are expanding on a recall response or whether naïve donor CMV-specific T cells develop 
into effector T cells by a primary immune response. We have demonstrated that a primary 
CMV-specific T cell response is possible shortly after alloSCT. However, the majority of 
patients depend on recipient CMV-specific T cells during the first year after alloSCT19. It can 
therefore be anticipated that CMV-specific vaccination early after alloSCT will primarily lead 
to a boosting of CMV-specific memory T cells. In CMV seropositive patients transplanted 
with a CMV seronegative donor (R+D-), no CMV-specific memory T cells of donor origin are 
present and CMV vaccination early after transplantation will boost memory CMV-specific 
T cell response from recipient origin. However, recipient CMV-specific memory T cells are 
at risk of being eradicated when an alloreactive immune response eradicates the recipient 
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hematopoietic cells. When this alloreactive immune response eradicates the boosted 
recipient CMV-specific memory T cells, the effect of vaccination will be abrogated. In that 
case, vaccination can be only effective when it induces a primary immune response from 
donor origin. 
A commercially available CMV-specific vaccine has not yet been developed. Several phase 
I/II trials demonstrated that CMV-specific vaccination can boost pre-existing memory 
T cells20-23. Two randomized controlled trials have been performed to determine the clinical 
benefit of CMV-specific vaccination after alloSCT. The first trial was a randomized, double 
blind, placebo-controlled trial that investigated safety and efficacy of a CMV DNA vaccine 
(TransVax) in 108 patients following alloSCT24. Although the frequency of CMV reactivation 
did not differ between the vaccine recipients and the controls, the combined endpoint of 
clinically significant CMV viremia and initiation of antiviral therapy was significantly reduced 
in vaccine recipients. Despite this significant effect on the combined endpoint, no difference 
in occurrence of CMV disease and CMV-specific T cell reconstitution could be demonstrated. 
The second randomized trial investigated the safety and efficacy of a chimeric peptide 
vaccine containing a CMV pp65 derived CD8+ T cell epitope combined with a tetanus T 
helper epitope (CMVPepVax) in 36 patients following alloSCT25. This study demonstrated a 
significant effect after CMVPepVax vaccination with a significant rise in pp65-specific CD8+ T 
cells, reduced incidence of CMV reactivation and usage of antiviral treatment, and increased 
relapse free survival compared to patients with observation only. This trial provides proof 
of principle that vaccination can improve CMV-specific T cell reconstitution after alloSCT. 
However, in this trial only HLA-A2 positive patients could be vaccinated due to the HLA 
restriction of the peptide in the CMVPepVax vaccine. Vaccination of non-HLA-A2 patients 
would require multiple vaccines with different CMV peptides or a single vaccine with multiple 
CMV peptides. Currently, a clinical trial (#NCT02506933) is being performed to determine 
the efficacy to prevent CMV disease after alloSCT with an attenuated poxvirus Modified 
Vaccine Ankara (MVA) containing 3 immunodominant CMV antigens (pp65, IE1 and IE2, 
Triplex). This vaccine was demonstrated to be safe and effective in inducing CMV-specific 
T cell responses in CMV seronegative and CMV seropositive healthy adults26. The results of 
this phase 2 trial must be awaited. 
It has thus far not been demonstrated that CMV-specific vaccination can induce primary 
immune responses from donor origin. The efficacy of vaccination after alloSCT to induce 
a primary immune response depends on the immune status of the alloSCT recipient. This 
immune status is influenced by T cell reconstitution, occurrence of GVHD and use of immune 
suppression27. The optimal timing of vaccination after alloSCT to induce primary T cell 
responses is not clear. In our study on the origin of CMV-specific T cells early after alloSCT, the 
majority of the analyzed R+D- patients developed a CMV-specific primary immune response 
within the first year after TCD alloSCT, some patients even as early as 3 months after TCD 
alloSCT19. In a T cell depended pneumococcal vaccination it was demonstrated that the 
primary immune response rate increased from 54% at 3 months to 94% at 9 months after 
GENERAL DISCUSSION 131
9
alloSCT, demonstrating a time dependent effect probably due to T cell reconstitution28.  To 
induce a primary immune response, presentation of the antigen by antigen presenting cells 
is mandatory. Dendritic cells (DC) are professional antigen presenting cells, which can be 
pulsed with antigen and used for vaccination after alloSCT (DC vaccination). In DC vaccination, 
donor derived DC are pulsed with pathogen specific peptides and transferred to the patient 
29. This approach, although time consuming and laborious, may be more effective to induce 
a primary CMV-specific T cell response and prevent CMV disease compared to peptide only 
vaccination in R+D- patients20, 30. Analysis of efficacy of CMV-specific vaccination to induce 
a primary immune response should include chimerism analysis to determine the origin 
of the induced CMV-specific immunity to exclude the effect of boosting residual recipient 
CMV-specific T cells after vaccination. 
Due to the increased risk for CMV disease in R+D- patients, accelerating CMV-specific T cell 
reconstitution is especially important for these patients to prevent CMV disease. Because 
vaccination after transplantation does not yet reliably induce primary CMV-specific immune 
responses, vaccinating the CMV seronegative donor prior to harvesting the stem cell graft 
may be an effective approach to avoid the R+D- serostatus combination. Thus far, CMV 
vaccination of the donor prior to transplantation was attempted in one trial, but was not 
feasible because the time between donor identification and transplantation was not enough 
to perform adequate vaccination24. CMV vaccination of CMV seronegative donor prior to 
alloSCT to avoid the R+D- combination has never been studied.
VZV-specific T cell reconstitution after alloSCT
Cellular immunity is essential for preventing reactivation of VZV leading to the clinical 
syndrome of herpes zoster.  Ex vivo analysis of VZV-specific T cell reconstitution after TCD is 
hampered by the lack of clinically validated immunodominant peptides needed for artificial 
HLA class I constructs (tetramers or pentamers). Therefore, we developed and validated the 
first VZV-specific pentamer (IE62-ALW-A2) by determining immunogenic antigens for VZV 
using a pentamer-based epitope discovery method31. 
Using this VZV-specific pentamer it was possible to detect VZV-specific CD8+ T cells upon 
VZV reactivation after TCD alloSCT in 63% of HLA-A2 patients after TCD alloSCT. Compared 
to CMV-specific T cells, the frequency of IE62-ALW-CD8+ T cells in ex vivo analysis was low 
(mean 0.04%, range 0.01%-0.11%). This lower frequency may be explained by differences in 
viral tropism and replication between CMV and VZV. Whereas CMV resides and reactivates 
regularly in monocytes and vascular endothelial cells, VZV resides in neurons, which are 
immune privileged sites, and reactivates only sporadically. We also demonstrated that 
antigenic stimulation by VZV reactivation following alloSCT leads to an increase in IE62-ALW-
A2-specific T cells. It is demonstrated that introduction of VZV antigens to T cells in this 
situation leads to a boost in VZV-specific memory T cells, providing protection when VZV 
reactivates32. VZV-specific vaccination provides antigenic stimulation to boost T cell immunity 
to prevent VZV reactivation. As discussed earlier, the efficacy of vaccination after alloSCT is 
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determined by the immune competence of the patient after alloSCT, which is influenced by 
factors like the occurrence of GVHD and/or treatment with immune suppression affecting 
T cell reconstitution. The efficacy of vaccination in general is defined by a predefined rise 
in antibody titer with at least partially recovered B and T cell immunity.  However, a recent 
study in VZV vaccination in alloSCT recipients demonstrated VZV vaccination induced T cell 
responses in the absence of a B cell antibody response33. Therefore, to determine vaccination 
efficacy after alloSCT additional immunological assays are necessary34. The IE62-ALW-A2 
pentamer can potentially be used for ex vivo analysis of efficacy of VZV vaccination of HLA 
A2 positive patients after TCD alloSCT. Future directions on vaccination after alloSCT should 
focus on determining the individual immune competence to allow for optimal vaccination 
and protection from preventable diseases such as herpes zoster. 
Origin of CMV-specific T cells
Understanding the mechanisms leading to successful CMV-specific T cell reconstitution is 
important for future attempts to improve CMV-specific T cell reconstitution and prevent CMV 
disease after alloSCT. We demonstrated that in CMV positive recipients (R+) transplanted 
with a CMV seronegative donor (R+D-) CMV-specific T cells are mainly of recipient origin 
and that in time primary CMV-specific T cell responses can develop from donor origin19. 
Selecting a CMV negative donor will exclude the possibility of donor derived CMV-specific 
memory T cells to provide protection in the first months following alloSCT. Protection in that 
period depends solely on residual recipient CMV-specific T cells until the development of a 
primary CMV-specific T cell response of donor origin. 
As discussed earlier, residual recipient CMV-specific T cells may be the target of an alloreactive 
response and may therefore be eradicated. It can therefore be hypothesized that prevention 
of an alloreactive T cell response can help to preserve recipient CMV-specific T cells. T cell 
depletion is used to prevent GVHD after alloSCT by preventing alloreactive T cell responses. 
T cell repletion by adding back small numbers of T cells to the graft is performed with the 
intent to induce an alloreactive T cell response to eradicate the residual malignant cells (GVL) 
with lower risk of inducing GVHD. In a study by Chalandon the origin of CMV-specific T cells 
was compared after T cell replete and T cell depleted alloSCT35. CMV-specific T cells could 
be demonstrated in only 1/6 R+D- patients following T cell replete alloSCT compared to 2/2 
R+D- patients following T cell depleted alloSCT. In the R+D- patients following T cell depleted 
alloSCT, the CMV-specific T cells were of recipient origin. This study demonstrates that 
lowering the chance to induce an alloreactive T cell response by TCD may allow persistence 
of residual CMV-specific T cells providing long-term control of CMV reactivation.
Donor Lymphocyte Infusion is used to induce an alloreactive immune response targeting 
minimal residual disease (MRD) and residual hematopoietic cells, aiming at conversion to full 
donor chimerism. It could be hypothesized that the application of DLI poses a potential risk of 
developing CMV disease in R+D- patients because of the eradication of recipient CMV-specific 
T cells by the induced alloreactive immune response. However, apart from developing CMV 
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disease in the setting of acute GVHD and subsequent treatment with immune suppression 
following DLI, it is unclear whether the incidence of CMV disease is increased after DLI in 
R+D- patients. It has been demonstrated that following DLI in R+D- patients, the recipient T 
cells were indeed eradicated. However, these cells were directly replaced by donor derived 
CMV-specific T cells, indicating a donor derived primary T cell response36. 
Whether or not recipient CMV-specific T cells are present in the patient following TCD 
alloSCT presumably also depends on the conditioning strategy used prior to alloSCT. In the 
study by Grimaldi and Sellars, demonstrating persistence of recipient CMV-specific T cells, 
patients received reduced intensity conditioning (RIC). In RIC a less toxic condition regimen 
is used with relative sparing of recipient hematopoietic cells including recipient CMV-specific 
T cells. In our study, the incidence and severity of CMV reactivation following alloSCT was 
comparable after RIC and myeloablative condition (MAC)37. This may be explained by 
the additional Anti Thymocyte Globulin (ATG) used in RIC conditioning in our study. This 
additional T cell depletion, used to avoid graft rejection by recipient T cells may not only 
eradicate alloreactive T cells from recipient origin, but also residual CMV-specific T cells. 
Also in our study the observation period was short, only 100 days following alloSCT. 
Monitoring MRD by measuring total leucocyte chimerism (TLC) is important to predict 
relapse of the malignant disease for which alloSCT was indicated. Upon a rise of recipient TLC, 
interventions such as DLI are performed. However, It has been shown that following CMV 
reactivation the TLC demonstrated more recipient origin, especially in R+D- patients36, 38.  A 
recent trial of 45 recipient of TCD alloSCT for severe aplastic anemia confirmed this positive 
correlation between recipient chimerism and CMV reactivation39. CMV reactivation caused a 
massive expansion of CMV-specific T cells from recipient, thereby influencing the TLC. Unlike 
following TCD alloSCT for hematologic malignancies, full donor chimerism was not promoted 
in these patients and mixed chimerism was not treated with DLI. This state of mixed T cell 
chimerism persisted for years even after stopping immune suppression, indicating a state 
of mutual tolerance of donor and recipient T cells. In this case TLC may not be a marker of 
minimal residual disease and DLI should not be performed to achieve full donor chimerism. 
Adoptive cell transfer for prevention and treatment of CMV disease following alloSCT
Although it may take a period of several months to even years, eventually most R+D- patients 
develop CMV-specific immunity. If time is allowed for successful immune reconstitution and 
primary CMV-specific T cell responses develop, CMV reactivation will be controlled and CMV 
disease will be prevented. This paves the way for strategies to bridge the period of impaired 
immunity via adoptive T cell transfer (ACT) to prevent CMV disease. Although the rationale 
for ACT is clear, thus far no evidence for efficacy has been demonstrated in formal phase 3 
trials. As discussed in our review on prevention of CMV disease following alloSCT, all trials 
published thus far are phase-1/2 trials with relatively small numbers of patients8. These 
trials suggest safety, proof of concept, and an association between ACT and viral clearance. 
Although restoration of anti-viral immunity after CMV-specific ACT was demonstrated, it 
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remains unclear whether all immune responses seen following ACT were causally related to 
the ACT, or that CMV-specific T cell responses developed irrespective of the ACT. This should 
be the focus of a formal randomized controlled clinical trial. 
The purpose of ACT can be prophylactic (e.g. early administration to prevent CMV related 
complications) or therapeutic when administered in case of persistent CMV reactivation or 
overt CMV disease. The purpose of ACT may affect the choice of the techniques used for 
generating the T cell. In general, 2 different approaches are used to produce CMV-specific 
T cell products for adoptive transfer. Techniques without expansion or only minimal expansion 
generate less differentiated CMV-specific T cells. Stem cell characteristics such as multi-
potency and self-renewal capacity have been demonstrated within these less differentiated 
T cells40. Adoptive transfer of these cells may lead to more effective CMV-specific T cell 
reconstitution and persistence than transfer of in vitro expanded effector T cells. If time for 
in vivo proliferation is granted, i.e. in the absence of persistent CMV reactivation or CMV 
disease as in prophylactic ACT and in the absence of immunosuppression or GVHD, the use of 
non-expanded CMV-specific T cell lines may be best suited for reconstitution of CMV-specific 
T cell immunity. Techniques using expansion by repeated stimulation generate large numbers 
of more differentiated CMV-specific effector T cells. However, repeated stimulation may lead 
to exhaustion and reduced persistence following ACT41, 42. If the goal of ACT is to temporarily 
overcome persistent CMV reactivation or CMV disease, transfusing large numbers of 
CMV-specific effector T cells may be sufficient to bridge and allow CMV-specific T cell 
reconstitution to develop. Future research to demonstrate efficacy of ACT should tailor the 
technique for isolating CMV-specific T cells and generating the T cell lines to the purpose of 
ACT.
Two factors hamper proper assessment of the clinical relevance of ACT following alloSCT, the 
exclusion of patients with active GVHD treated with systemic immune suppression and the 
exclusion of R+D- patients. GVHD and treatment with systemic immune suppression are major 
risk factors for CMV disease and these patients may benefit the most from CMV-specific 
ACT. Considering the body of evidence that ACT with in-vitro selected CMV-specific T cells 
is safe with minimal risk of inducing concurrent GVHD, future trials may consider including 
patients with active GVHD, especially when using cell products with high purity. In case of 
ongoing immune suppressive therapy the numbers of CMV-specific T cells used for ACT may 
need to be higher to overcome the immune suppression. R+D- patients are at greatest risk of 
developing CMV disease, due to delayed reconstitution of virus-specific immunity and may 
benefit greatly from CMV-specific ACT. However, most trials thus far isolate CMV-specific 
T cells from CMV seropositive donors. In theory, CMV-specific T cells from the CMV 
seropositive recipient harvested prior to the alloSCT procedure (autologous CMV-specific 
T cells) could be used for ACT in R+D- patients. Autologous CMV-specific ACT has not been 
extensively studied in a clinical trial. Successful treatment of CMV disease in one R+D- patient 
with ACT using autologous CMV-specific T cells is described in one case report43. In our study 
on CMV-specific ACT, autologous CMV-specific T cell lines were generated for 3 R+D- patients, 
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but these cell lines were never administered44. One patient died due to CMV disease 
during the cell production period and two patients cleared the CMV reactivation before 
the CMV-specific T cell product could be administered. In theory, transfusing autologous 
CMV-specific T cells could pose a risk for inducing graft rejection. In addition, the infused 
recipient CMV-specific T cells could be eradicated by alloreactive donor T cells in case of an 
alloreactive response from donor T cells, either as part of the desired GVL effect or as part 
of GVHD. Despite these considerations, the use of autologous CMV-specific ACT should be 
studied, as the treatment options for R+D- patients with CMV disease are limited. 
A different solution for R+D- patients may be the use of CMV-specific T cells isolated from CMV 
seropositive third-party donors (TPD). Using TPD CMV-specific T cells allows the formation 
of a bank of stored T cell lines from CMV seropositive donors. In such a bank CMV-specific 
T cell lines from donors partially HLA matched with the ACT recipient can be stored, for 
example an HLA–A2 restricted CMV-specific T cell line for HLA-A2 positive alloSCT recipients. 
TPD CMV-specific T cell lines can be used  “off the shelf” for the treatment of persistent 
CMV viremia or CMV disease which eliminates delays caused by obtaining fresh cells from 
the donor, T cell isolation, processing and quality control. It has been demonstrated that all 
T cells have the potential to cross-react to allo-HLA molecules, thereby inducing GVHD45. 
Therefore, potential toxicity risks include the risk for graft rejection by an alloreactive 
response to donor hematopoietic cells or induction of GVHD by an alloreactive response 
to recipient tissue antigens by the adoptively transferred TPD T cells. Trials indicate that 
ACT with TPD virus-specific T cells is feasible, probably safe and may be effective in treating 
persistent CMV reactivation and CMV disease46, 47. However, long-term persistence of these 
T cells is unlikely. The level of HLA matching between the TPD and the respective patient 
and stem cell donor impacts on the persistence of the adoptively transferred virus-specific 
T cells. Despite the concerns regarding the persistence of TPD T cells, a short-term effect as 
demonstrated in the recent clinical trials may be sufficient for bridging a period of severe 
CMV-specific T cell deficiency, thereby preventing or treating CMV disease and allowing 
for the development of subsequent CMV-specific immunity from the stem cell donor T cell 
repertoire for long-term control of CMV viremia. 
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De cellulaire componenten die samen het bloed vormen (erytrocyten, leukocyten en 
trombocyten) ontwikkelen zich uit stamcellen, een proces dat hematopoïese wordt genoemd. 
Bij verschillende kwaadaardige en niet-kwaadaardige hematologische aandoeningen is een 
hematopoïetische stamceltransplantatie dan ook een potentieel curatieve behandeling. 
Een hematopoïetische stamceltransplantatie kan worden verricht met lichaamseigen 
stamcellen (autologe stamceltransplantatie) of met lichaamsvreemde stamcellen (allogene 
stamceltransplantatie). In het geval van autologe stamceltransplantatie worden eigen 
stamcellen geoogst en gebruikt om te kunnen herstellen na intensieve chemotherapie. Het 
doel van allogene stamceltransplantatie (alloSCT) is om hematopoïetische cellen van de 
patiënt inclusief de cellen die de ziekte dragen, te vervangen door hematopoïetische cellen 
van een gezonde donor. 
Een alloSCT voor maligne hematologische aandoeningen kan worden overwogen indien de 
ziekte met chemotherapie onder controle is gebracht. Vervolgens moet er een geschikte 
donor gezocht worden. Om na alloSCT afstoting van het donor transplantaat te voorkomen is 
het van belang dat het Human Leucocyte Antigen (HLA) van donor en ontvanger voldoende 
overeenkomen. Een donor kan verwant of onverwant zijn aan de patiënt maar bij voorkeur 
zoveel mogelijk HLA gematcht. Om het aanslaan (engraftment) van donor stamcellen na 
alloSCT mogelijk te maken, is conditionering van de ontvanger met immuunsuppressiva 
en eventueel bestraling voorafgaand aan de alloSCT noodzakelijk. Deze conditionering 
leidt tot een periode van diepe beenmergdepressie met een hoge infectiegevoeligheid en 
transfusiebehoefte tot gevolg. 
Hoewel de conditionering de hematopoïetische cellen van de ontvanger door chemotherapie 
en/of bestraling zoveel mogelijk verwijdert en onderdrukt om engraftment te faciliteren, is 
dit onvoldoende om een recidief van de ziekte na transplantatie te voorkomen. Dit blijkt 
uit het hoge risico op een recidief na autologe stamceltransplantatie bij acute leukemie. 
Genezing van de ziekte kan worden bereikt door een immunologische respons door 
alloreactieve T cellen van de donor. Deze alloreactieve T cellen kunnen resterende maligne 
cellen uitroeien wanneer de respons gericht is tegen hematopoïetische cellen van de 
ontvanger (graft versus leukemia, GVL). Echter wanneer de respons ook gericht is tegen 
niet-hematopoïetische cellen in weefsels en organen, kan potentieel fatale graft-versus-host 
ziekte (GVHD) ontstaan. GVL en GVHD worden beide veroorzaakt door alloreactieve T cel 
responsen. Deze alloreactiviteit kan ontstaan door verschillen tussen donor en ontvanger 
in  HLA-moleculen maar ook door genetische verschillen die leiden tot andere presentatie 
van delen van eiwitten in HLA-moleculen. Indien een donor en ontvanger geheel genetisch 
identiek zijn, zoals bij HLA-identieke tweelingen, is er geen risico op GVHD maar kan er ook 




Preventie van GVHD door T cel depletie
GVHD is de belangrijkste complicatie na alloSCT en kan leiden tot aanzienlijke morbiditeit 
en mortaliteit na alloSCT. De frequentie en ernst van GVHD kan worden verminderd door 
het gebruik van immuunsuppressiva of door het verwijderen van donor T cellen uit het 
transplantaat (T cel depletie). Zonder T cel depletie (TCD) moeten ontvangers langdurig 
behandeld worden met immuunsuppressie om GVHD te voorkomen. Immuunsuppressie is 
ook niet selectief en onderdrukt niet alleen de alloreactieve immuunresponsen die GVHD 
veroorzaken, maar ook potentieel gunstige immuunreacties zoals GVL of immuunreacties 
die nodig zijn voor bescherming tegen infecties. 
Bij T cel depletie worden donor T cellen, waaronder alloreactieve T cellen verantwoordelijk 
voor het ontstaan van GVHD uit het transplantaat verwijderd. T cel depletie is effectief in het 
voorkomen van GVHD waardoor GVHD profylaxe met immuunsuppressie veelal niet nodig 
is. Het voorkomen van GVHD door TCD gaat echter gepaard met een verminderde kans op 
het ontstaan van een GVL respons. Om toch een GVL respons te ontwikkelen worden, in een 
later stadium, donor T cellen toegediend. Deze uitgestelde donor lymfocyten infusie (DLI) 
kan leiden tot controle van de ziekte met een kleiner risico op het ontstaan van GVHD. 
TCD kan op verschillende manieren bereikt worden en de volledigheid van de depletie hangt 
af van de gekozen techniek. Bij CD34+ selectie worden alleen stamcellen geselecteerd, leidend 
tot diepe T cel depletie. TCD kan ook verricht worden door depleterende antistoffen aan 
het transplantaat toe te voegen. Alemtuzumab (Campath) is een monoclonaal antilichaam 
gericht tegen CD52, een marker die tot expressie komt op lymfocyten. Het toedienen van 
alemtuzumab aan het transplantaat dat daarna direct aan de patiënt toegediend wordt 
(“campath in de zak”) is een goed toepasbare en tijdbesparende methode om TCD uit te 
voeren met een aangetoond laag risico op het ontwikkelen van GVHD. Hoewel TCD effectief 
is in het voorkomen van GVHD en langdurige immuunsuppressie na transplantatie over het 
algemeen niet nodig is, leidt TCD tot een periode van diepe en langdurige T cel deficiëntie. 
Gedurende deze periode lopen patiënten risico op het ontwikkelen van infectieuze 
complicaties, vooral door reactivaties van eerder doorgemaakte endogene herpesvirussen. 
Deze virussen worden in de normale situatie na infectie voortdurend onderdrukt door T cel 
immuniteit maar kunnen leiden tot klinische problemen bij reactivatie door het wegvallen 
van T cel controle door immuunsuppressie of TCD.
T cel immuniteit
T cel immuniteit ontstaat door de ontwikkeling van antigeen-specifieke memory T cellen, 
die zich na een primaire immuunrespons ontwikkelen vanuit naïeve T cellen. T cellen 
worden onderverdeeld in CD4+ en CD8+ T cellen, waarbij CD4+ T cellen belangrijk zijn voor 
het ontwikkelen en reguleren van immuunresponsen en CD8+ T cellen belangrijk zijn in het 
elimineren van de pathogenen. CD4+ T cellen herkennen delen van eiwitten (peptiden) 
gepresenteerd in HLA klasse II moleculen, die voornamelijk tot expressie worden gebracht 
door Antigeen Presenterende Cellen (APC), terwijl CD8+ T cellen peptiden herkennen die 
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worden gepresenteerd in HLA klasse I moleculen welke tot expressie worden gebracht in 
alle weefsels. De inductie van een primaire T cel reactie leidt tot een snelle toename van 
effector CD4+ en CD8+ T cellen en de vorming van memory CD4+ en CD8+ T cellen die direct 
kunnen reageren op een nieuwe blootstelling aan het pathogeen. Voor het ontwikkelen 
van naïeve T cellen uit hematopoïetische stamcellen is de functie van de thymus van groot 
belang. Na de kindertijd raakt de thymus echter in regressie en neemt de functie sterk af. 
Het is niet duidelijk in welke mate na alloSCT de functie van de thymus noodzakelijk is om T 
cel immuniteit te herstellen.
Antigeen-specifieke T cellen kunnen op verschillende manieren geanalyseerd worden. CD8+ 
T cellen specifiek voor een bepaald antigeen kunnen direct gevisualiseerd worden door 
binding met een kunstmatig HLA klasse I/peptide complex. Deze HLA/peptide complexen 
(tetrameren of pentameren, afhankelijk van het aantal gebruikte HLA moleculen) zijn voorzien 
van een fluorescerend label wat met flowcytometrie te detecteren is. T cellen kunnen ook 
geanalyseerd worden op basis van activatie. Na herkenning van een specifiek antigeen, 
produceren T cellen cytokinen, zoals interferon-gamma of interleukinen. De productie van 
deze cytokinen kan gemeten worden of direct gevisualiseerd worden. Functionele assays 
zijn geschikt om CD4+ en CD8+ T cellen te detecteren na antigene stimulatie. Deze antigene 
stimulatie kan een enkel peptide zijn, maar ook een combinatie van peptiden. Op deze 
manier kan een brede T cel respons tegen antigenen zoals virussen geanalyseerd worden. 
Herpesvirus reactivaties na alloSCT
T cel immuniteit is cruciaal om reactivatie van herpesvirussen zoals cytomegalovirus 
(CMV), Epstein-Barr-virus (EBV) en varicella-zoster-virus (VZV) te controleren. Infecties 
met herpesvirussen komen veel voor in de algemene bevolking. Primaire infecties treden 
meestal op in de kindertijd en klinische symptomen zijn vaak mild of zelfs afwezig. Hoewel 
virus-specifieke T cellen massale replicatie kunnen voorkomen, worden herpesvirussen niet 
volledig geklaard en leiden ze tot latente infecties in hun gastheer. Deze latentie is het gevolg 
van een evenwicht tussen het virus en de virus-specifieke T cellen. In immuuncompetente 
individuen zonder klinische symptomen kan het percentage van herpesvirus-specifieke T 
cellen oplopen tot wel 40% van het totaal aantal T cellen in het bloed. Dit hoge percentage 
ontstaat waarschijnlijk door recidiverende stimulatie van memory T cellen door subklinische 
reactivaties van het virus. Diepe en langdurige T cel deficiëntie na TCD alloSCT of 
immuunsuppressie verstoort de balans tussen T cel immuniteit en de herpes virussen en 
kan leiden tot mogelijk fatale CMV ziekte in geval van CMV reactivatie, Post Transplantatie 
Lymfoproliferatieve ziekte (PTLD) na EBV reactivatie of gedissemineerde herpes zoster bij 
VZV reactivatie. 
Cytomegalovirus
Ongeveer 60% van de westerse bevolking is geïnfecteerd met het cytomegalovirus. De 
infectie vindt meestal plaats in de kinderjaren. Het klinische beloop van CMV-infectie bij 
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immuuncompetente personen is mild en soms zelf geheel asymptomatisch. Een uitzondering 
is een primaire CMV infectie bij een zwangere vrouw waarbij de infectie tot neurologische 
afwijkingen bij het kind kan leiden. Na de primaire infectie persisteert CMV latent met name 
in monocyten en endotheelcellen. Bij immuungecompromitteerde patiënten kan door het 
ontbreken of disfunctioneren van CMV-specifieke T cellen de CMV reactivatie leiden tot 
mogelijk fatale CMV-ziekte, zoals CMV pneumonitis, CMV colitis of CMV encefalitis. 
Reactivatie van CMV is de meest voorkomende reactivatie van herpesvirussen na alloSCT met 
een incidentie van 80% bij CMV seropositieve ontvangers. Primaire CMV infectie van een CMV 
seronegatieve ontvanger via een stamceltransplantaat van een CMV seropositieve donor is 
mogelijk maar in mindere mate (slechts 10% van de CMV seronegatieve ontvangers ontwikkelt 
een CMV infectie middels een stamceltransplantaat van een CMV seropositieve donor).  Dit 
komt waarschijnlijk omdat met name endotheelcellen, de belangrijkste cellen voor CMV 
latentie en persistentie, niet in grote getalen in het stamceltransplantaat aanwezig zijn. 
Met PCR technieken is virale replicatie van CMV aan te tonen en te kwantificeren tijdens 
primaire infectie en reactivatie. Dit maakt het mogelijk om het beloop in de hoeveelheid 
CMV (viral load) te analyseren en te relateren aan de respons van de CMV-specifieke T 
cellen. Deze analyses hebben aangetoond dat CMV-specifieke T cel immuniteit essentieel is 
om CMV reactivatie te controleren en om CMV ziekte te voorkomen. 
Epstein-Barr Virus
Epstein-Barr Virus  is een herpesvirus dat meer dan 90% van de westerse bevolking 
infecteert. Na primaire infectie, die kan leiden tot het klinische syndroom van infectieuze 
mononucleose, verblijft het virus latent in B cellen. Infectieuze mononucleose wordt 
veroorzaakt door een massale expansie van EBV-specifieke T cellen na herkenning van een 
deel van een EBV eiwit met als doel de EBV infectie te beheersen. 
Na alloSCT kan reactivatie van EBV plaatsvinden door afwezigheid van voldoende EBV-
specifieke T cellen. Met falende T cel controle kan het aantal EBV geïnfecteerde B cellen 
enorm toenemen, wat kan leiden tot potentieel fatale PTLD. Hoewel de incidentie van 
EBV-geassocieerde PTLD laag is na alloSCT (4%), correleert het risico met het niveau van 
TCD. Bij strategieën die alleen T cellen verwijderen neemt het risico toe omdat B cellen, 
de belangrijkste plaats voor EBV-latentie, niet zijn verwijderd. In TCD door middel van 
antilichamen die zich richten op het verwijderen van zowel T als B cellen, zoals alemtuzumab, 
is het risico op PTLD laag. 
Varicella zoster virus
Varicella zoster virus (VZV) is een herpesvirus dat ongeveer 95% van de bevolking infecteert. 
De primaire infectie met VZV leidt tot varicella (waterpokken). Na de primaire infectie 
verblijft VZV latent in neuronen en reactivatie leidt tot herpes zoster (gordelroos). Doordat 
zenuwcellen minder blootgesteld worden aan het immuunsysteem dan andere weefsels 
in het lichaam en omdat VZV minder frequent reactiveert vergeleken met CMV en EBV 
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worden VZV-specifieke memory T cellen niet herhaaldelijk gestimuleerd. Hierdoor neemt 
de frequentie van circulerende VZV-specifieke memory T cellen langzaam af in de loop der 
tijd. De afname van VZV-specifieke memory T cellen wordt versneld door de conditionering 
en/of TCD in het kader van alloSCT. 
Na alloSCT veroorzaakt reactivatie van het virus aanzienlijke morbiditeit en is mogelijk fataal 
bij gedissemineerde ziekte. Meest voorkomende complicaties zijn postherpetische neuralgie 
en perifere neuropathie. Net als bij CMV en EBV is cellulaire immuniteit essentieel voor het 
controleren van een reactivatie van VZV. In tegenstelling tot CMV en EBV is er weinig bekend 
over VZV-specifieke CD8+ T cel immuniteit omdat er voor VZV geen immunodominante HLA 
klasse I peptiden bekend zijn en daardoor HLA constructen voor analyse niet beschikbaar 
zijn. Eerdere studies met functionele assays tonen wel VZV-specifieke memory CD4+ T cellen 
aan, maar VZV-specifieke CD8+ T cellen zijn alleen aantoonbaar na kweken. Het onvermogen 
om VZV-specifieke CD8+ T cellen direct ex vivo te detecteren, kan het gevolg zijn van de 
lage frequenties van VZV-specifieke CD8+ T cellen of van de lage gevoeligheid van de 
screeningsmethoden die worden gebruikt om CD8+ T cellen te detecteren. 
Preventie van CMV ziekte door antivirale medicatie
Om CMV ziekte te voorkomen, moet een periode van ernstige T cel deficiëntie na (TCD) 
alloSCT worden overbrugd tot CMV-specifieke T cel immuniteit hersteld is. Tijdens een 
CMV reactivatie, voorafgaand aan de ontwikkeling van CMV ziekte en wanneer patiënten 
nog asymptomatisch zijn, is CMV-DNA aantoonbaar in het bloed. Door deze viral load 
routinematig na alloSCT te vervolgen middels kwantitatieve PCR technieken, is preventie 
van CMV ziekte met preëmptieve behandeling mogelijk. Hierbij wordt antivirale therapie 
gestart wanneer de viral load boven een vooraf bepaalde drempel komt. 
Ganciclovir is een synthetisch nucleoside dat DNA-virussen remt, zoals herpesvirussen 
en in het bijzonder CMV. Ganciclovir is de gouden standaard voor de behandeling 
van CMV gerelateerde complicaties, maar heeft aanzienlijke bijwerkingen, waarvan 
beenmergdepressie de belangrijkste is. Bovendien heeft ganciclovir een slechte biologische 
beschikbaarheid, waardoor orale toediening niet mogelijk is en ziekenhuisopname vaak 
vereist is. Deze factoren maken het profylactisch gebruik van ganciclovir om CMV ziekte 
te voorkomen niet haalbaar. Valganciclovir is afgeleid van ganciclovir en kan wel oraal 
toegediend worden en is daarom geschikt voor preëmptieve poliklinische behandeling om 
CMV ziekte te voorkomen. Langdurig gebruik van valganciclovir is echter, net als ganciclovir 
geassocieerd met ernstige bijwerkingen en het ontwikkelen van resistentie.
CMV-specifieke T cel reconstitutie
Ondanks preëmptieve antivirale medicatie is herstel van T cel immuniteit en reconstitutie 
van CMV-specifieke T cellen vereist voor de lange termijn controle van CMV reactivatie 
en preventie van CMV ziekte. Reconstitutie van CMV-specifieke T cellen kan het resultaat 
zijn van expansie van memory T cellen van de ontvanger die het conditioneringsregime 
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overleven of van donor memory T cellen die met het transplantaat worden overgedragen. 
Daarnaast kunnen CMV-specifieke T cellen ook ontstaan uit een primaire respons vanuit 
naïeve donor T cellen. Het is echter onduidelijk of deze naïeve donor T cellen direct uit 
het transplantaat komen of ontstaan uit hematopoïetische stamcellen gevolgd door verdere 
ontwikkeling in de thymus.
Verschillende factoren kunnen CMV-specifieke T cel reconstitutie beïnvloeden. 
Immuunsuppressie voor de preventie of behandeling van GVHD na transplantatie kan de 
T cel reconstitutie nadelig beïnvloeden. CMV-specifieke T cel reconstitutie kan ook worden 
verstoord door eradicatie van T cellen van ontvanger door intensieve conditioneringsregimes 
voorafgaand aan alloSCT. Hiernaast speelt de CMV serostatus van de donor mogelijk ook 
een rol in CMV-specifieke T cel reconstitutie. Als CMV-specifieke T cellen van een CMV 
seropositieve donor de TCD kunnen overleven, zouden deze na transplantatie kunnen 
reconstitueren en bescherming tegen CMV ziekte kunnen bieden. Het transplantaat van 
een CMV seronegatieve donor bevat geen CMV-specifieke memory T cellen. Hierdoor zou 
de bescherming tegen CMV ziekte na TCD alloSCT dus door residuale CMV-specifieke T 
cellen van ontvanger moeten komen. Deze overgebleven CMV-specifieke T cellen van de 
ontvanger lopen echter het risico om verwijderd te worden door alloreactieve donor T 
cellen na alloSCT en/of DLI, waarna de patiënt mogelijk het risico loopt om CMV ziekte te 
ontwikkelen. 
Het toedienen van ongeselecteerde donor T cellen kan een strategie zijn om T cel reconstitutie 
na alloSCT te verbeteren. Hoewel deze benadering effectief kan zijn bij het herstellen van 
antivirale T cel immuniteit, kan deze mogelijk fatale GVHD veroorzaken. Om het risico op het 
induceren van GVHD te minimaliseren en om gericht de CMV-specifieke T cel reconstitutie 
te verbeteren, kunnen CMV-specifieke T-cellen uit bloed van de donor worden geïsoleerd 
en overgedragen naar de ontvanger na alloSCT (CMV-specifieke Adoptive Cell Transfer, ACT). 
CMV-specifieke ACT kan worden gebruikt als een profylactische of preventieve behandeling 
om CMV ziekte te voorkomen of als behandeling voor CMV ziekte. ACT is het meest effectief 
in afwezigheid van immuunsuppressie, zoals het geval is bij TCD alloSCT. ACT wordt nog niet 
standaard toegepast omdat er op dit moment nog onvoldoende gegevens beschikbaar zijn 
met betrekking op de veiligheid en de effectiviteit van deze behandeling.
Dit Proefschrift
Ernstige T cel deficiëntie kan leiden tot reactivatie van endogene herpesvirussen na TCD 
alloSCT. Onvoldoende controle van deze virussen door virus-specifieke T cellen kan tot 
aanzienlijke complicaties leiden. Immuniteit op lange termijn hangt af van virus-specifieke T 
cel reconstitutie. Reactivatie van CMV is de meest voorkomende herpesvirus reactivatie na 
alloSCT. Ongeveer 60% van alloSCT-ontvangers zijn seropositief voor CMV en lopen daarom 
risico op endogene reactivatie van latente CMV. CMV reactivatie kan leiden tot mogelijk fatale 
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CMV ziekte, bestaande uit CMV pneumonitis, CMV colitis of CMV encefalitis. Het doel van 
dit proefschrift is om factoren te evalueren die de incidentie van CMV ziekte na TCD alloSCT 
beïnvloeden. Deze factoren omvatten het conditioneringsregime, CMV serostatus van de 
donor, farmacologische interventie na alloSCT en ACT voor behandeling van refractaire CMV 
reactivatie of CMV ziekte. 
CMV ziekte kan worden voorkomen door het preëmptief behandelen van CMV reactivatie 
met behulp van intraveneus ganciclovir. In een preëmptieve behandelingsstrategie wordt 
met antivirale therapie begonnen wanneer de viral load boven een vooraf bepaalde PCR 
drempelwaarde ligt. Een effectieve orale behandeling voor preëmptieve CMV therapie zou 
de preventie en behandeling van CMV poliklinisch mogelijk maken en zou leiden tot een 
lagere belasting voor de patiënt en lagere kosten voor de gezondheidszorg. In hoofdstuk 2 
laten we zien dat preëmptieve behandeling met oraal valganciclovir even effectief is bij het 
verminderen van de hoeveelheid circulerend virus (CMV viral load) na alloSCT in vergelijking 
met intraveneus ganciclovir. Ernstige bijwerkingen werden niet waargenomen en CMV ziekte 
trad niet op. Het percentage patiënten dat erytrocytentransfusies ontving, was hoger in de 
groep patiënten die ganciclovir kregen. Mogelijk was dit het resultaat van co-morbiditeit bij 
de opgenomen patiënten die intraveneus met ganciclovir werden behandeld. Preëmptieve 
behandeling van CMV reactivaties in allogene stamcelontvangers met valganciclovir of 
ganciclovir leidde tot een vergelijkbare mediane reductie van het CMV DNA in plasma van 
ongeveer 0,1 log10 kopieën / ml / dag. We concludeerden dat oraal valganciclovir (900 mg, 
tweemaal daags) even effectief en veilig is als intraveneus ganciclovir (5 mg / kg, tweemaal 
daags) bij de behandeling van CMV reactivatie gericht op het voorkomen van CMV-ziekte 
na alloSCT. De overgrote meerderheid van alloSCT-ontvangers zonder symptomen van CMV 
ziekte wanneer de CMV reactivatie wordt gedetecteerd, heeft baat bij behandeling met een 
oraal geneesmiddel, zonder dat opname in het ziekenhuis noodzakelijk is. Voor patiënten 
met verdenking op symptomatische CMV reactivatie blijft intraveneus toegediend ganciclovir 
het eerste keuzegeneesmiddel, omdat het beloop van de CMV ziekte snel progressief en 
uiteindelijk fataal kan zijn.
Het is vastgesteld dat alloSCT met verminderde intensiteitsconditionering (Reduced 
Intensity Conditioning, RIC) met succes kan worden uitgevoerd bij individuen met een grote 
verscheidenheid aan hematologische ziekten en kan leiden tot een verminderd risico op 
transplantatie gerelateerde sterfte. Duurzame donor engraftment en gunstige respons van 
de ziekte zonder graft-versus-host ziekte (Graft versus Host Disease, GVHD) werd gemeld 
voor het in vitro TCD RIC alloSCT-protocol met fludarabine, anti-thymocyten globuline (ATG), 
busulphan en “Campath in de zak”. Er kan worden verondersteld dat na RIC meer resterende 
T cellen van ontvanger het conditioneringsregime overleven en beschermende immuniteit 
na alloSCT kunnen verlenen. In hoofdstuk 3 laten we zien dat er geen significant verschil was 
in incidentie en ernst van CMV reactivaties binnen 100 dagen na alloSCT voorafgegaan door 
RIC in vergelijking met een conventionele conditionering (myeloablatieve conditionering, 
MAC). Het begin van detectie van CMV DNA in plasma na alloSCT, de duur van een CMV 
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reactivatie, de DNA piek load, het gebied onder de DNAemia-curve, het aantal en de duur 
van pre-emotieve CMV behandelingsperioden, evenals het aantal recidiverende infecties 
binnen 100 dagen na alloSCT waren vergelijkbaar na RIC en MAC. Deze vergelijkbare ernst 
van CMV reactivaties na RIC en MAC kan worden verklaard door de TCD aangezien dit in beide 
patiëntengroepen toegepast werd. Op zichzelf is TCD van het transplantaat geassocieerd 
met een verhoogd risico op CMV reactivaties, wat lijkt te worden weerspiegeld door de 
hoge incidentie van CMV reactivaties (51%) binnen 100 dagen na alloSCT in dit onderzoek. 
Omdat RIC de hematopoïetische cellen van de ontvanger relatief spaart, kan verwacht 
worden dat ontvangers die afhankelijk zijn van ontvanger CMV-specifieke T cellen het meeste 
baat hebben bij RIC in de controle van CMV reactivatie. CMV seropositieve ontvangers (R+) 
die getransplanteerd zijn met een CMV seronegatieve donor (R+D-) zijn afhankelijk van 
resterende CMV-specifieke T cellen van de ontvanger, omdat het transplantaat van de 
donor geen memory CMV-specifieke T cellen bevat. In deze studie was er geen statistisch 
verschil in frequentie en ernst van CMV reactivatie aanwezig in R+D- patiënten in vergelijking 
met CMV seropositieve ontvangers getransplanteerd met een CMV seropositieve donor 
(R+D+). Een niet-significante toename in frequentie en ernst van CMV reactivatie werd 
echter waargenomen bij R+D- patiënten in vergelijking met R+D+ en zoals verwacht was dit 
verschil meer uitgesproken in MAC in vergelijking met RIC. Dit verschil bereikte echter geen 
statistische significantie vermoedelijk als gevolg van het kleine aantal patiënten en een korte 
follow-up van 100 dagen na alloSCT.
In hoofdstuk 4 hebben we het effect onderzocht van de CMV serostatus van de donor op 
de incidentie van CMV ziekte na TCD alloSCT in een groter cohort van CMV seropositieve 
patiënten. CMV-specifieke T cellen kunnen met het transplantaat van CMV seropositieve 
donoren worden overgedragen en op die manier bescherming bieden tegen CMV ziekte. 
T cel depletie kan echter deze CMV-specifieke T cellen elimineren. Om het effect van CMV 
serostatus bij TCD alloSCT te bepalen, analyseerden we de incidentie van CMV ziekte bij 
157 CMV seropositieve ontvangers, bestaande uit 51 R+D- en 106 R+D+ patiënten. Daarnaast 
bepaalden we de oorsprong van CMV-specifieke T cellen in een selectie van 25 R+D- patiënten 
om te bepalen of primaire CMV-specifieke T cel responsen konden worden aangetoond. De 
duur van CMV reactivaties en de incidentie van CMV ziekte waren hoger bij R+D- patiënten 
in vergelijking met R+D+ patiënten. Bij R+D- patiënten waren CMV-specifieke CD4+ en CD8+ 
T cellen voornamelijk van ontvanger origine. Daar staat tegenover dat in 53% van de R+D- 
patiënten in het eerste jaar CMV-specifieke T cellen van donor origine werden gedetecteerd, 
zelfs al na 3 maanden na TCD alloSCT. We concluderen dat CMV serostatus de klinische 
ernst van CMV reactivaties significant beïnvloedde, wat de rol van CMV-specifieke memory 
T cellen die met het transplantaat werden overgedragen aangeeft, ondanks de uiteindelijke 
vorming van primaire CMV-specifieke T cel responsen bij R+D- patiënten.
Gezien de cruciale rol van CMV-specifieke T cellen bij het voorkomen van CMV ziekte, 
kan het verbeteren van CMV-specifieke T cel reconstitutie bij patiënten door ACT van 
CMV-specifieke T cellen een aantrekkelijke behandelingsmodaliteit zijn. Echter, vragen 
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met betrekking tot veiligheid en effectiviteit van het gebruik van ACT moeten nog steeds 
beantwoord worden. In hoofdstuk 5 hebben we de veiligheid en effectiviteit van ACT 
om CMV-specifieke T cel immuniteit te herstellen geanalyseerd door een fase I/II klinisch 
onderzoek uit te voeren naar ACT van in vitro-gegenereerde CMV pp65-specifieke CD8+ T 
cellijnen. Deze cellijnen werden gegenereerd door perifere mononucleaire cellen van CMV 
seropositieve donoren of patiënten te stimuleren met HLA-A*0201 en/of HLA-B*0702 
gerestricteerde CMV-pp65 peptiden (NLV / TPR). Op dag 1 na stimulatie werd verrijkt door 
interferon-gamma producerende T cellen te isoleren met het CliniMACS Cytokine Capture 
System en te kweken met autologe feeders en lage dosis interleukine-2. Na 7-14 dagen 
kweken werden kwaliteitscontroles uitgevoerd en werden de CMV-specifieke T cellijnen 
toegediend of ingevroren. Vijftien CMV-specifieke T cellijnen werden gegenereerd, waarvan 
er 8 werden toegediend aan patiënten met refractaire CMV reactivatie. Zeven cellijnen 
werden gegenereerd maar niet toegediend omdat patiënten de CMV reactivatie inmiddels 
hadden geklaard tegen de tijd dat de cellijn geschikt was voor infusie (n = 4) of patiënten 
overleden waren door een recidief van de kwaadaardige ziekte (n = 1) of als gevolg van de 
progressieve CMV ziekte vóór infusie van de CMV-specifieke T cellen (n = 2). Na toediening 
werden geen acute bijwerkingen en geen GVHD waargenomen en daalden de CMV PCR 
loads. Bij verschillende patiënten was er een directe relatie tussen toediening van de T cellijn 
en het in vivo voorkomen van CMV-pp65-specifieke T cellen. Concluderend werd gevonden 
dat toediening van CMV-pp65-specifieke CD8+ T cellijnen mogelijk en veilig was.
In tegenstelling tot CMV is er weinig bekend over VZV-specifieke CD8+ T cel immuniteit. Dit 
komt omdat er, anders dan bij CMV, geen gevalideerde van VZV afgeleide immunodominante 
peptiden voor HLA klasse I bekend zijn. Hierdoor wordt de analyse van VZV-specifieke CD8+ T 
cel responsen belemmerd. In hoofdstuk 6 beschrijven we onze zoektocht naar immunogene 
antigenen voor VZV om VZV-specifieke pentameren te ontwikkelen om VZV-specifieke CD8+ 
T cellen te identificeren. Potentiële HLA-A2 bindende peptiden van het Immediate Early 
(IE)-62 eiwit van VZV werden getest op binding met HLA-A2 en peptiden met voldoende 
bindingscapaciteit werden gebruikt voor het genereren van pentameren. Patiënten met 
VZV-reactivatie na TCD alloSCT werden gescreend met deze pentameren, wat leidde tot de 
identificatie van het eerste gevalideerde HLA klasse I gerestricteerde epitoop van VZV. Bij 
42% van de HLA-A2 positieve patiënten na VZV reactivatie konden deze IE62-ALW-HLA-A2-
specifieke T cellen ex vivo worden gedetecteerd. We hebben aangetoond dat het ondanks 
de lage frequenties mogelijk is om VZV-specifieke CD8+ T cellen te detecteren, waardoor ex 
vivo analyse van T cel responsen op VZV infectie en reactivatie en wellicht VZV vaccinatie 
mogelijk wordt.
Ondanks preëmptieve antivirale behandeling is de incidentie van CMV ziekte bij CMV 
seropositieve alloSCT patiënten nog steeds 10% 1 jaar na alloSCT. Dit illustreert de 
noodzaak van adequate CMV-specifieke T cel immuniteit voor langdurige controle van 
CMV en preventie van CMV ziekte. In hoofdstuk 7 geven we een overzicht van factoren die 
relevant zijn voor de preventie van CMV ziekte na alloSCT. GVHD en het gebruik van een 
NEDERLANDSE SAMENVATTING 153
10
onverwante of mismatch HLA donor bleken geassocieerd te zijn met een verhoogd risico 
op het ontwikkelen van CMV ziekte ondanks pre-emotieve antivirale behandeling, hetzij 
als gevolg van systemische immuunsuppressie die nodig is om GVHD te voorkomen of te 
behandelen of als gevolg van eradicatie van memory CMV-specifieke T cellen van patiënt 
origine door de alloreactieve T cel respons van donor. T cel depletie bleek geassocieerd te 
zijn met een verhoogd risico op CMV reactivatie, maar niet met een verhoogd risico op CMV 
ziekte. Er kan worden verondersteld dat omdat immuunsuppressie over het algemeen niet 
nodig is na TCD alloSCT, CMV-specifieke T cellen niet worden belemmerd om beschermende 
immuniteit te bieden in het geval van CMV-reactivatie. De CMV serostatus van de donor 
beïnvloedt de CMV-specifieke T cel reconstitutie en het risico op het ontwikkelen van CMV 
ziekte significant. De incidentie van aan CMV gerelateerde complicaties en mortaliteit is 
lager bij R+D+ patiënten in vergelijking met R+D- patiënten. Bij R+D- patiënten zijn memory 
CMV-specifieke T cellen niet aanwezig in het donortransplantaat en de van ontvanger 
afkomstige virus-specifieke T cellen kunnen (gedeeltelijk) worden verwijderd door het 
conditioneringsregime en/of door een alloreactieve donor T cel reactie. Ten slotte hebben we 
de beschikbare onderzoeken naar de veiligheid en werkzaamheid van ACT van donor CMV-
specifieke T cellen voor de preventie en behandeling van CMV ziekte na alloSCT onderzocht. 
Alle tot nu toe gepubliceerde trials zijn fase 1/2 trials, waarbij veiligheid, proof of concept 
en een associatie tussen ACT en klaring van CMV worden aangetoond. Een belangrijke 
beperking voor ACT na alloSCT is dat de behandeling van actieve GVHD met systemische 
immuunsuppressie een uitsluitingscriterium was voor toediening van CMV-specifieke ACT in 
alle onderzoeken. Een andere belangrijke beperking van klinische toepasbaarheid van CMV-
specifieke ACT is dat isolatie van CMV-specifieke memory T cellen van de donor beperkt is 
tot CMV seropositieve donoren. ACT van T cellen geïsoleerd van een andere donor dan de 
stamceldonor (third-party donor) kan een oplossing zijn voor R+D- patiënten. Trials tonen 
aan dat ACT met van een third-party donor afkomstige virus-specifieke T cellen mogelijk, 
veilig en effectief kan zijn bij de behandeling van persistente CMV-reactivatie en CMV-ziekte. 
Het persisteren van deze T cellen is echter onzeker.
Het doel van dit proefschrift was om factoren te evalueren die de incidentie van CMV ziekte 
na TCD alloSCT beïnvloeden. We hebben vastgesteld dat preventie van CMV ziekte veilig is 
met behulp van een preëmptieve behandeling met oraal valganciclovir. We hebben geen 
effect op het risico aangetoond voor CMV reactivatie of CMV ziekte bij patiënten die werden 
behandeld met een RIC-regime en TCD alloSCT. GVHD en het gebruik van immuunsuppressie 
na alloSCT bleken belangrijke risicofactoren te zijn voor de ontwikkeling van CMV ziekte. 
CMV specifieke T cel reconstitutie was efficiënter bij R+D+ patiënten, wat leidt tot een 
verlaagd risico op het ontwikkelen van CMV ziekte. Van donor afkomstige CMV-specifieke 
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